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ABSTRACT 
 
Epithelial ovarian cancer is the commonest cause of death from gynaecological 
malignancy.  Platinum based chemotherapy remains the cornerstone of first-line 
therapy for ovarian cancer, however relapse is common and acquired resistance is 
frequently observed on subsequent lines of platinum based treatment.  Because 
activation of the PI3K/AKT pathway has been shown to play a role in acquired 
platinum resistance phenotype of ovarian cancer, combination of platinum with AKT 
pathway inhibitors holds promise for resensitising tumours to platinum.  
 
The aims of this thesis were i) to evaluate the effect of pharmacological AKT 
inhibitors AKT on the resensitisation of clinically-derived platinum resistant ovarian 
cancer cells to platinum, and ii) establish molecular imaging approaches for 
monitoring resensitisation to platinum in vivo combined with biochemical profiling 
of pathway activity.   
Treatment of platinum sensitive PEO1 ovarian cancer cells with cisplatin induced 
growth inhibition and apoptosis.  The AKT inhibitor, API-2, resensitised paired 
platinum resistant PEO4 cells to cisplatin.  These in vitro studies established 1h 
pre-treatment time point with API-2 followed by cisplatin as the most appropriate 
schedule for further studies.  Resensitisation to platinum appeared to be a pathway 
effect rather than a specific effect of API-2.  In order to establish the utility of PET 
imaging for therapy response, a bilateral tumour xenograft model comprising of 
platinum sensitive PEO1 and the platinum resistant cell line PEO4 was developed. 
Both [18F]fluorothymidine ([18F]FLT)-PET, which measures proliferation, and 
[18F]fluorodeoxyglucose ([18F]FDG)-PET, which measures glucose metabolism 
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detected responses to cisplatin alone in PEO1 tumours and the combination of 
cisplatin and API-2 in both PEO1 and PEO4 tumours.  Correlative reduction in 
phosphorylated PRAS40, a direct downstream marker of AKT activity indicated that 
in vivo changes in imaging variables of the combination treatment resulted from 
AKT inhibition.  The imaging changes were also linked to histological reductions in 
Ki67 labelling index. 
AKT Biochemical profiling of tumours obtained after imaging confirmed that the 
changes in tumour [18F]FDG and [18F]FLT uptake were due, at least in part, to 
reductions in the expression of glucose transporter Glut-1 and hexokinase activity, 
as well as decreases in TK1 expression, respectively. 
These studies demonstrated that [18F]FDG-and [18F]FLT-PET hold promise for 
clinical evaluation of platinum resensitisation in patients with platinum resistant 
ovarian cancer. 
Given also that combination treatment with cisplatin and API-2 induced apoptosis 
in PEO4 cells in vitro, further studies were conducted with the aim of establishing 
[18F]ICMT11 PET, a specific cleaved caspase-3/7 radiotracer, for monitoring re-
sensitisation to platinum in PEO4 tumours.  [18F]ICMT11 uptake detected by PET 
increased after combination treatment but not with cisplatin alone.  Parallel 
increases in TUNEL and cleaved caspase-3 staining by immunohistochemistry were 
observed consistent with the PET outcome.  Thus, [18F]ICMT11 PET could also find 
utility in monitoring early responses to platinum therapy in combination with AKT 
inhibition.  In addition to the 3 imaging agents described above, analysis of 
baseline levels of integrin αvβ3/5 expression, an index of angiogenesis, as well as 
myo-inositol uptake were investigated as potential discriminators of platinum 
resistant phenotype.  These preliminary experiments were inconclusive.  
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In summary PET imaging of proliferation, glucose metabolism and apoptosis were 
shown to be promising techniques for early detection of resensitisation to platinum 
therapy in platinum resistant ovarian cancer and warrant further investigation. 
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Glut1 = glucose transporter 1 
 
Glut3 = glucose transporter 3 
 
HMG = high-mobility group proteins 
 
HMGB1 = High-mobility group protein 1 
 
HIF-1α = hypoxia-inducible factor-1α 
 
HE = haematoxylin-eosin 
 
IHC = immunohistochemistry 
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IRS-1 = insulin receptor substrate 1 
 
K-RAS = V-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue 
 
     MT= metallothioneins 
MMR = mismatch repair proteins 
 
MAPK = mitogen-activated protein kinase 
 
mTORC2 = rapamycin (mTOR) –containing protein complex 2 
 
     NHEJ= Non-Homologous End-joining 
 
NER = Nucleotide Excision Repair 
 
Pt-based compounds= oxaliplatin, carboplatin and cisplatin 
 
PARP-1 = Poly (ADP-ribose) polymerase 1 
 
PCNA = proliferating cell nuclear antigen 
 
RTK = receptor tyrosine kinases 
 
PI3K = phosphatidylinositol 3-kinase 
 
PKC = protein kinase C 
 
PtdIns = phosphatidylinositols 
 
PI[4,5]P2 = phosphatidylinositol 4,5-bisphosphate 
 
PIP3 = phosphatidyl 3,4,5-triphosphate 
 
PI3K = phosphoinositide 3-kinase 
 
PH-domain = pleckstrin-homology-domain 
 
PTEN = phosphatase and tensin homologue 
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PDK1 = phosphoinositide-dependent kinase 1 
 
p70S6K = 70kDa S6 kinase 
 
P27kip1 = 27kDa protein/kinase inhibitor protein1 
 
PRAS40 = proline-rich AKT substrate of 40 kDa 
 
PBS=phosphate-buffered saline 
 
PET = positron emission tomography 
 
RR = recombinational repair 
 
RFC = replication factor C 
 
S6 = ribosomal S6 protein 
 
SDS-PAGE = sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
 
TP53 = tumour protein 53 
 
     TCR = transcription-coupled repair 
  
     TLS = translesion synthesis 
 
TSC1 = tuberous sclerosis complex 1 
 
TSC2 = tuberous sclerosis complex 2 
 
TCN = triciribine 
 
TCN-P = triciribine phosphate 
 
TUNEL = terminal deoxynucleotidyltransferase mediated deoxyuridine 5-
triphosphate nick-end labelling 
 
TK1 = thymidine kinase 1 
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VEGF = vascular endothelial growth factor 
 
    XIAP = X-linked inhibitor of apoptosis protein     
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1.0 Introduction 
 
1.1 Ovarian Cancer 
Ovarian cancer is an insidious disease, where tumours have a tendency to spread 
within the abdominal cavity by seeding and this represents a great clinical challenge 
in gynaecologic oncology.  Since most patients are asymptomatic until the disease 
has metastasized, two-thirds are diagnosed with advanced stage disease [2]. 
For the same reason, ovarian cancer has the highest fatality-to-case ratio of all 
gynaecologic malignancies [3] and despite clinical advances and improved surgical 
techniques, it remains the deadliest form of gynaecologic malignancy.  Ovarian 
cancer has a distinctive biology and behaviour at the clinical, cellular and molecular 
levels.  Clinically, ovarian cancers often present as a complex cystic mass in the 
pelvis [4].  Although ovarian cancer has been termed the 'silent killer', more than 
80% of patients have symptoms, even when the disease is still limited to the 
ovaries, however these symptoms  have not yet proved useful for early diagnosis [5]  
Ovarian cancer varies widely in frequency among different geographic regions and 
ethnic groups, with a high incidence in Northern Europe and the United States, and 
a low incidence in Japan [6].  The majority of cases are sporadic, and only 5% to 10% 
of ovarian cancers are familial.  The aetiology of ovarian cancer is poorly 
understood.  It is the fifth most common cause of death from cancer in women 
after lung, breast, colon, and pancreatic cancer[2].  
Ovarian cancer is one of the few malignancies in which cytoreductive surgery is 
carried out to remove the bulk of the tumour, even when complete resection is 
impossible.  Primary treatment relies on surgical tumour debulking and platinum-
based chemotherapy [7].  At least 70% of ovarian cancers will respond to a 
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combination of platinum- and taxane-based chemotherapy administered after 
surgery.  In at least one-half of these patients, residual cancer cannot be detected 
using imaging studies and serum markers after 5 months of treatment [4].  
However, despite improvements in surgical techniques and advancement in 
chemotherapy, the 5-year survival rate for stage III/IV ovarian cancer patients 
remains < 25% [8].  However, the majority of patients relapse, and few, if any, 
achieve a cure.  Future advancement in treatment should aim at targeting the 
biology of the disease, specifically mechanisms critical to tumour initiation and 
progression.  Several Phase I and II clinical trials have identified novel opportunities 
for therapy [9].  The most promising venues appear to be the antiangiogenic agents 
and the inhibitors of intracellular signalling.  Although devoid of the common side 
effects associated with chemotherapy, the use of targeted agents is associated with 
specific toxicities, related to the biological processes they block.  
Cisplatin and its analogues have been most frequently used for treatment of human 
cancer, including ovarian cancer.  While adjuvant chemotherapy with paclitaxel and 
cisplatin or carboplatin achieves clinical response in approximately 80% of patients, 
the tumour recurs in most patients within 3 years following treatment[10].  The 
overall 5-year survival rate for advanced ovarian cancer patients is still low (20–
30%) and is due to chemoresistance in the primary or recurrent tumours, thus 
resulting in treatment failure.  Similarly, although ovarian cancer patients show high 
response rates to initial chemotherapy after cytoreductive surgery, most patients 
also develop resistance to chemotherapy during treatment.  Overcoming drug 
resistance is the key to successful treatment of ovarian cancer [11]. 
 
While the clinical and histological prognostic factors (e.g. surgical stage and tumour 
grade) are well understood, less is known about the biological process leading to 
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uncontrolled cellular growth.  It is now widely accepted that tissue growth is not 
only dependent on cell proliferation, but also on the rate of apoptosis.  Imbalance 
between these processes leads to uncontrolled tissue growth [12-13]. 
The molecular mechanism of chemoresistance in ovarian cancer is multifactorial 
and poorly understood.  Chemoresistance may generally be classified into acquired 
and de novo forms and has traditionally been thought of in terms of altered drug 
transport and gene expression (e.g. multi-drug resistance gene), modified drug 
target, increased rate of DNA repair or decreased rate of drug-induced DNA or 
macromolecule damage [13].  A growing body of evidence indicates that defects in 
the intra- and extra-cellular apoptotic pathways are an important cause of 
resistance to cytotoxic agents [14].  
The homeostasis of human ovarian surface epithelial cells is maintained by a 
delicate balance in the expression and actions of tumour suppressors (e.g. p53) and 
cell survival factors (e.g. intermediates of the PI3K/AKT cell survival pathway).  The 
intermediates of the PI3K/AKT survival pathway are frequently altered in human 
ovarian cancer [15-17].  AKT2, a putative oncogene encoding a member of a novel 
subfamily of serine-threonine protein kinases is amplified in human ovarian 
carcinoma [15-16].  Elevated levels of PI3K and AKTs were shown to be associated 
with poor prognosis and chemoresistance in this malignancy [16, 18]. 
The molecular events leading to the development of ovarian cancer are unknown.  
Mutations and/or overexpression of the oncogenes HER2, C-MYC, K-RAS, AKT, and 
of the tumour suppressor gene p53 have been observed in sporadic ovarian cancer, 
but their contribution to pathogenesis is not well defined [19-20].  Inactivation of 
the tumour suppressor genes PTEN and p16 may also occur.  Epigenetic 
phenomenon also play a role in tumourigenesis [21].The molecular pathways 
underlying ovarian cancer progression are poorly understood, however.  Although 
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germline mutations in BRCA1, BRCA2, and other genes have been implicated in a 
small fraction of cases, epidemiologic and experimental evidence suggest that 
ovarian carcinogenesis is predominantly driven by factors associated with 
reproduction and ovulation [22-23].  In addition, mucinous and nonmucinous 
ovarian tumours may have different causal mechanisms related to ovulatory life 
[24].   
 
1.1.1 Epidemiology and Risk Factors 
The pathogenesis of ovarian cancer is multifactorial, with genetic, environmental, 
and endocrinological factors directly or indirectly related to carcinogenesis.  Based 
on epidemiologic and pathophysiologic studies, there are several theories regarding 
the aetiology of ovarian cancer, which are not mutually exclusive [6].  
The incidence of ovarian cancer increases with age and is most prevalent in the 
eighth decade of life, with a rate of 57 per 100,000 women.  The median age at 
diagnosis is 63 years, and 70% of patients present with advanced disease [25].  
Epidemiologic and molecular-genetic studies identify numerous risk and protective 
factors for ovarian cancer.  A 30% to 60% decreased risk of cancer is associated with 
younger age at pregnancy and first birth (≤ 25 years), the use of oral 
contraceptives, or breast-feeding [25].  Conversely, nulliparity or older age at first 
birth (> 35 years) confers an increased risk of cancer. Recent data suggest that 
hormone therapy may increase the risk of ovarian cancer [26].  
 
1.1.2 Models of Ovarian Cancer  
About 90% of total cases of ovarian cancer are sporadic and occur in a 
predominantly older, postmenopausal population.  One theoretical model of ovarian 
carcinogenesis set forth is the theory of ‗incessant ovulation‘, in which a person's 
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age at ovulation, i.e., lifetime number of ovulatory cycles, is an index of her ovarian 
cancer risk [27].  The hypothesis suggests that ovulation causes repeated minor 
trauma and cellular repair of the surface epithelium, which predisposes it to 
neoplasia.  Nulliparity, early menarche, and late menopause are all identified as risk 
factors for ovarian cancer.  Excessive gonadotropin and androgen stimulation of the 
ovary have been postulated as contributing factors.  Exposure of the ovaries to 
pelvic contaminants and carcinogens may play a role in the pathogenesis of ovarian 
cancer [28].   
Conversely, protective factors include multiparity, late menarche, early menopause, 
use of oral contraceptives and tubal ligation or hysterectomy and all are associated 
with reduced risk [6].  With five years of oral contraceptive use, women can cut their 
risk of ovarian cancer approximately in half; this also holds true for individuals with 
a family history. 
 
The most significant risk factor is a family history of the disease in which a genetic 
cause is often implicated.  Hereditary causes account for 5-10 % of the total cases.  
Patients with hereditary ovarian tumours generally are younger, with most being 
premenopausal at presentation [2].  The most common of hereditary diseases is the 
breast–ovarian cancer syndrome, and recent advances in molecular genetics have 
found mutations in the BRCA1 and BRCA2 tumour suppressor genes responsible for 
the majority of hereditary ovarian cancer [6, 29-30]. 
  
Stage at diagnosis, maximum residual disease following cytoreductive surgery, and 
performance status are the three major prognostic factors.  Using a multimodality 
approach to treatment, including aggressive cytoreductive surgery and combination 
chemotherapy, five-year survival rates are as follows: Stage I (93%), Stage II (70%), 
Stage III (37%), and Stage IV (25%). 
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1.1.3 Staging System 
Tumour stage is a major risk factor in patient prognosis [28].  Although the overall 
5-year survival rate improved from 37% in 1974 to 53% in 1998, there is a large 
variability depending on the tumour stage at presentation [31].  The 5 year survival 
rate is 80% for stage I disease, 50% for stage II, 30% for stage III, and a dismal 8% 
for stage IV [32].  Multiple other factors that affect prognosis have also been 
identified, including histologic type, tumour grade, amount of residual disease after 
the initial cytoreductive surgery (debulking), and patient characteristics (age, 
performance status). 
 
Two staging systems exist: the TNM (tumour, node, metastasis) system and the 
more commonly used, surgically based system put forth by the International 
Federation of Obstetrics and Gynaecology (FIGO) [33].  The FIGO staging system is 
shown in Table. 1. 
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 Table. 1                    FIGO staging of Ovarian Carcinoma 
 
Stage                                           Findings 
Stage I Tumour limited to the ovaries 
Stage IA Tumour limited to one ovary, no malignant ascites 
Stage IB Tumour limited to both ovaries, no malignant 
ascites 
 Stage IC Stage IA or IB with malignant ascites 
Stage II  Tumour involves one or both ovaries with pelvic extension 
 Stage IIA Extension or implants on the uterus  or fallopian 
tubes, no malignant ascites 
 Stage IIB                                     Extension to other pelvic tissues, no malignant 
ascites 
 Stage IIC Stage IIA or IIB with malignant ascites  
Stage III Tumour involves one or both ovaries with peritoneal implants outside 
the pelvis or retroperitoneal lymph node metastasis 
 Stage IIIA Microscopic peritoneal metastasis beyond the pelvis 
 Stage IIIB Macroscopic peritoneal metastasis beyond the 
pelvis 2 cm or less 
 Stage IIIC Peritoneal metastasis beyond the pelvis more than 2 
cm or regional lymph node metastasis 
Stage IV Distant metastasis including liver parenchyma 
         Source.- Adapted  from reference Spiessl B, 1989 [33] 
 
 
1.1.4 Pathogenesis 
Approximately 90% of all ovarian cancers are epithelial, i.e., derived from relatively 
pluripotent cells of the celomic epithelium or ―modified mesothelium‖ [25].  These 
cells originate from the primitive mesoderm and can undergo metaplasia.  
Neoplastic transformation is the product of an accumulation of genetic events, such 
as a genetic predisposition or exposure to carcinogenic agents, leading to activation 
of oncogenes and loss of tumour suppressor genes.  About 10% to 20% of epithelial 
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ovarian neoplasms are borderline or low malignant potential tumours, which are 
characterized by a high degree of cellular proliferation in the absence of stromal 
invasion [28].  Of the invasive epithelial ovarian cancers, about 75% to 80% are 
serous, ~10% are mucinous, and ~10% are endometrioid. Less common types 
include clear cell, Brenner, small cell, and undifferentiated carcinoma.  Many of 
these histologic subtypes represent the epithelial features of the lower genital tract, 
e.g., papillary serous tumours have an appearance resembling the glandular 
epithelium lining the fallopian tube, mucinous tumours contain cells resembling 
endocervical glands, and endometrioid tumours contain cells resembling the 
endometrium.  Non-epithelial types of ovarian cancer include the sex cord-stromal 
tumours (6% of ovarian cancers), germcell tumours (3%), and indeterminate tumours 
(1%) [34]. 
 
1.1.5 Histotypes of Ovarian Cancer 
Epithelial ovarian cancer (EOC) consists of various histotypes, each of which has 
distinct genetic, biological and histological features that might affect response to 
treatment and clinical outcome.  Therapies that target specific proteins that have 
become deregulated might benefit patients with EOC, as they may provide a tailored 
treatment option for the various EOC histotypes [35]. 
As indicated above epithelial ovarian cancers develop from simple flattened 
epithelial cells into four distinct main histotypes that resemble the well-
differentiated normal cells that line the fallopian tube (serous), endometrium 
(endometrioid) and endocervix (mucinous), or that form nests within the vagina 
(clear cell) (Figure 1) [4].  The distinct ovarian cancer histotypes differ with regard to 
their epidemiology, genetic changes, gene expression, tumour markers and 
responsiveness to therapy.  Although each histotype shows a distinctive pattern of 
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gene expression, similarities have been observed between serous and endometrioid 
subtypes in some studies [36-37] and between endometrioid and clear-cell 
histology in others.  Clear-cell and mucinous cancers generally do not respond as 
well as serous and endometrioid cancers to platinum- and taxane-based 
chemotherapeutic regimens. 
 
                                  
Figure 1.  Histotypes of Epithelial Ovarian Cancer.  Epithelial ovarian cancers 
develop from simple flattened epithelial cells into four distinct main histotypes that 
resemble the well-differentiated normal cells that line the fallopian tube (serous), 
endometrium (endometrioid) and endocervix (mucinous), or that form nests within 
the vagina (clear cell) (Adapted from; Mills, 2009 [28]). 
 
 
1.2 Molecular and cellular pharmacology of Cisplatin  
 
1.2.1 Cisplatin 
The biochemical mechanisms of cisplatin (CIS), cis-diamminedichloroplatinum(II) 
cytotoxicity involve the binding of the drug to DNA and non-DNA targets and the 
subsequent induction of cell death through apoptosis, necrosis, or both [38].  
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The era of platinum-based anticancer drugs was heralded by the clinical 
introduction of cisplatin, a square-planar platinum(II) complex whose antitumour 
properties were first reported by Rosenberg in 1969 [39].  
Cisplatin is highly effective in the treatment of testicular and ovarian cancers and is 
also employed for treating bladder, cervical, head and neck, esophageal, and small 
cell lung cancer[40].  Resistance to cisplatin is generally multifactorial and has been 
shown to be due to reduced drug accumulation, inactivation by thiol containing 
species, increased repair/tolerance of platinum−DNA adducts, and alterations in 
proteins involved in apoptosis. 
Moreover, only four platinum drugs are currently registered for clinical use 
(marketed drugs) [41].  Among the registered platinum drugs, carboplatin, [cis-
diammine-1,1‗-cyclobutane dycarboxilate platinum(II)], is less toxic than cisplatin 
but possesses the same spectrum of antitumour activity.  The only registered 
platinum drug that has consistently demonstrated antitumour activity against 
cisplatin resistant tumours such as colorectal cancers is oxaliplatin, [trans-L-1,2-
diaminocyclohexaneoxalatoplatinum(II)].  
 
1.2.1.1 Intracellular Accumulation of Cisplatin 
Cisplatin is highly polar, and cellular accumulation generally occurs at a slower rate 
than most other small-molecule anticancer drugs [42].  The uptake of cisplatin is 
influenced by factors such as sodium and potassium ion concentrations, pH, and 
the presence of reducing agents; and a role for transporters or gated channels has 
been postulated in addition to passive diffusion [43].  For many years it had been 
taken for granted that cis-[Pt(NH3)2Cl2] enters cells largely by passive diffusion.  In 
aqueous solution, cisplatin undergoes stepwise aquation reactions in which the 
chloride ions are replaced by water ligands with retention of the cis configuration 
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[43].  The final result is the formation of the [Pt(H2O)2(NH3)2]2+ cation.  This diaquo 
species is very reactive toward nucleophile centers of biomolecules because H2O is 
much better leaving group than Cl. [44]. 
 
1.2.1.2 Mechanism of Cisplatin Uptake and Efflux  
The mechanisms of cellular uptake and efflux of cisplatin are still not fully 
understood [45].  Several studies have revealed that both passive and active 
mechanisms are involved (Figure 2).     
1.2.1.3 Molecular Bases of Cisplatin Resistance 
The occurrence of resistance is a common drawback of cancer chemotherapy, and 
cis-DDP is no exception [46].  Moreover, the patterns of cisplatin resistance vary 
considerably between tumour types.  
In most preclinical models of cisplatin resistance (either acquired or intrinsic), 
multiple mechanisms appear to operate.  Thus, cancer cells that are resistant to cis-
DDP often exhibit several resistance mechanisms acting simultaneously.  The 
molecular mechanisms of resistance against CIS can be divided into two main 
groups: mechanisms that prevent CIS reaching DNA as its main therapeutic target; 
i.e. reduced uptake and/or increased efflux; increased cellular thiol levels (Figure 2) 
and mechanisms that block the induction of cell death (apoptosis or necrosis) after 
the formation of the cisplatin−DNA adduct, namely enhanced DNA repair and/or 
increased damage tolerance; and failure of cell-death pathways [46-47]. 
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Figure 2.  Platinum drugs might enter cells using a combination of passive diffusion 
and active and facilitated transport, significant one being the copper transporter 
CTR1.  Once inside cells, cisplatin is activated by the addition of water molecules to 
form a chemically reactive aqua species.  This is facilitated by the relatively low 
chloride concentrations that are found within cells.  The activated species are able 
to react with thiol-containing biomolecules such as glutathione and 
metallothioneins, as well as its pharmacological target—DNA.  Any remaining drug 
that fails to reach the nucleus is believed to be sequestered into the lysosomes.  
Active export of platinum from the cells is mediated by the copper efflux 
transporters ATP7A and ATP7B as well as through the glutathione S-conjugate 
export GS-X pumps, a family of ATP-dependent organic anion transporters, (also 
known as MRP2).  (Adapted from Klein & Kellen, [48-49]). 
 
1.2.2 Biochemical Mechanisms of Action of Cisplatin 
It is generally accepted that binding of cisplatin to genomic DNA (gDNA) in the cell 
nucleus is largely responsible for its antitumour properties [38].  The damage 
induced upon binding of cisplatin to gDNA may interfere with normal transcription 
and/or DNA replication mechanisms.  Eventually, these disruptions in DNA 
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processing would trigger cytotoxic processes that lead to the death of the cancer 
cell [50]. 
1.2.2.1 Binding of Cisplatin to DNA Targets  
Many cellular components that have nucleophilic sites such as DNA, RNA, proteins, 
membrane phospholipids, cytoskeletal microfilaments, and thiol-containing 
molecules react with cisplatin, although only approximately 1% of the intracellular 
cisplatin reacts with nuclear DNA to yield a variety of adducts that include 
interstrand and intrastrand DNA cross-links and DNA-protein cross-links (Figure 
3).  The N7 atoms of the imidazole rings of guanine and adenine located in the 
major groove of the double helix are the most accessible and reactive nucleophilic 
sites for platinum binding to DNA [51].  The most common adducts are the 1,2-or 
1,3- intrastrand cross-links between adjacent guanines and a lower number of 
interstrand crosslinks [46].  These adducts cause distortions in the DNA structure, 
including unwinding and bending, and are recognised by a number of cellular 
proteins that elicit replication arrest, transcription inhibition, cell-cycle arrest, DNA 
repair and ultimately triggering apoptotic cell death [11, 45].  
 
Although genomic DNA is generally accepted as the critical pharmacological target 
of cisplatin-induced cytotoxicity, there is evidence that other cellular targets may 
also be involved in the cytotoxicity of the drug.  Thus, cisplatin binds to 
mitochondrial DNA, interacts with phospholipids and phosphatidylserine in 
membranes, disrupts the cytoskeleton, and affects the polymerisation of actin [52]. 
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Figure 3.  Main adducts formed in the interaction of cisplatin with DNA. (a), 
interstrand cross-link. (b), 1,2-intrastrand cross-link. (c), 1,3-intrastrand cross-
link. (d), protein-DNA cross-link.  (Adapted from Gonsalez, 2001, [38]). 
 
1.2.2.2 Binding of Cisplatin to Non-DNA Targets  
One aspect of the biochemical mechanism of action of cisplatin that has been very 
little studied is the degree of contribution of targets other than DNA to the 
cytotoxic effects of the drug.  In fact, it is known that only 5−10% of covalently 
bound cell-associated cisplatin is found in the DNA fraction, whereas 75−85% of 
the drug binds to proteins. 
Cisplatin binds to mitochondrial DNA, interacts with phospholipids and 
phosphatidylserine in membranes, disrupts the cytoskeleton, and affects the 
polymerization of actin [52].  In the cytoplasm, many cellular constituents that have 
soft nucleophilic sites such as thiocontaining peptides, and proteins react with 
cisplatin [53].  Due to the strong reactivity of platinum compounds against S-donor 
molecules, the most important non-DNA target of CIS is probably the tripeptide 
glutathione (GSH), which is present in cells at high concentrations (0.5−10 mM) 
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[46].  GSH is the most abundant non-protein thiol in eukaryotic cells [54].  Owing to 
its reactivity and high intracellular concentrations, GSH is involved in cell protection 
against free radicals, and in many cellular functions being particularly relevant in 
regulating carcinogenic mechanisms [55]; sensitivity against xenobiotics, ionising 
radiation [56] DNA synthesis; and cell proliferation.  
GSH and other thiol-containing biomolecules such as metalothioneins (MT) bind 
rapidly to platinum and this binding has primarily been associated with 
development of resistance and toxicity.  
 
1.2.2.3 GSH 
Three mechanisms have been proposed for the role of GSH in regulating CIS 
sensitivities that affects its ultimate cell-killing ability [57].  The first mechanism 
involves the effects of GSH on the ATP-binding cassette (ABC) transporter-mediated 
CIS  transport; the second mechanism involves the redox-regulating capacity of 
GSH in detoxifying CIS toxicity; the third mechanism involves regulation of the 
intracellular copper pool that affects CIS uptake [57]. 
The ABC transporters are a family of cytoplasmic membrane-spanned proteins that 
function as efflux pumps for eliminating antitumour agents, xenobiotics, and 
anionic lipophilic endogenous constituents [58-59].  Therefore, many of these 
transporters are also known as multidrug resistance proteins (MRPs) [57].  Some  
MRPs require GSH for substrate transport [58-59] and GSH may serve as substrate 
for conjugation reaction with CDDP prior to MRP-mediated transport . 
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1.2.3 Proteins that recognise cisplatin-induced DNA damage 
 
Following platinum-induced DNA modification, cellular repair systems act to 
recognize the damage and continuously function until the fate of drug-treated cells 
is decided [60].  Several proteins have been described that recognize and bind to 
cisplatin−DNA adducts.  These proteins are called ―damage-recognition proteins‖ 
and include among others[11] :1) nucleotide excision repair (NER) proteins, 2) 
mismatch repair (MMR) proteins, 3) DNA-dependent protein kinase (DNA-PK), and 
4) high-mobility group (HMG) proteins [38].  
1.2.3.1 Nucleotide Excision Repair  
NER removes platinum intrastrand cross-links from DNA [61].  During the early 
stage of NER, platinum lesions are recognized by different mechanisms for two 
sub-pathways of NER, transcription-coupled repair (TCR) and global genomic repair 
(GGR). Stalled RNA polymerase II acts as a damage recognition flag to initiate TCR.  
After initial recognition of DNA damage, TCR and GGR are thought to follow similar 
paths since the NER proteins required for both are the same except for XPC-HR23B.  
In particular, after damage recognition, TFIIH, XPA, and RPA are the next set of 
proteins to assemble on the DNA.  Although the exact binding order of these 
proteins is controversial, they may be cooperatively recruited to the damage site  
[62-63].  In a subsequent step, XPB and XPD helicases, components of TFIIH, 
unwind the DNA in a process that requires ATP. XPC-HR23B is released when 
endonuclease XPG binds to this unfolded DNA.  The structure-specific 
endonuclease XPF-ERCC1 is finally recruited to the NER complex, and dual incision 
occurs to remove platinated oligonucleotides.  Excised oligonucleotides (24−32 
nucleotides in length), containing a platinum lesion, and dual incision factors are 
then released from the DNA.  Small oligonucleotides are degraded in the nucleus 
[63], and the excised platinated oligomer is most likely processed in a similar 
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manner.  The fate of the platinum is unknown and would be very difficult to track in 
cells.  RPA remains associated with the incised DNA and possibly recruits DNA 
resynthesis factors such as PCNA and replication factor C (RFC) to fill in the gap [62] 
(Figure 4). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.  Steps in the mechanism of nucleotide excision repair of platinum 
lesions.  (Adapted from Jung, 2007, [60]). 
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1.2.3.2 Mismatch Repair  
MMR is a post-replication repair system that corrects unpaired or mispaired 
nucleotides.  The relationship between DNA damage recognition by MMR proteins 
and cytotoxicity remains incompletely defined [38]. 
The MMR system eliminates base−base mismatches as well as deletion and 
insertion mutations [64].  In eukaryotic cells, hMutSα (MSH2−MSH6 heterodimer) 
initiates MMR by binding to single mismatches and small insertion/deletion loops 
and hMutSβ (MSH3−MSH6 heterodimer) starts MMR through recognition of 
insertion/deletion loops of different sizes.  Following damage recognition by 
hMutSα, hMutLα (MLH1-PMS2 heterodimer) and PCNA are recruited to the site of 
DNA mismatch to carry on the repair. Several exonucleases and helicases - the 
replication machinery - and DNA ligase I are subsequently recruited to degrade the 
error-containing strand and fill in the gap. 
MMR proteins are probably also engaged in active attempts to repair newly 
synthesized DNA opposite platinum adducts generated by translesion synthesis 
(TLS) past the platinum lesions.  It is proposed that this process can bring about a 
futile cycle of attempted repair of cisplatin damage, which may lead to cell death 
[65].  Upon replication bypass, both cisplatin and DNA methylation damage may 
share a common signalling pathway.  In addition to their ability to repair DNA, MMR 
proteins also mediate DNA damage-induced apoptosis as part of the cellular 
response to endogenous and exogenous stress[66]. 
 
1.2.3.3 DNA-PK 
The ability of cancer cells to repair DNA damage is an important determinant of 
their susceptibility to chemo- or radio-therapy in the treatment of cancer [67].  
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DNA double-strand breaks (DSBs) are one of the most severe types of DNA damage, 
which if left unrepaired are lethal to the cell [68].  Several different DNA repair 
pathways combat DSBs, with nonhomologous end-joining (NHEJ) being one of the 
most important in mammalian cells.  In response to the threat of DSBs, eukaryotic 
cells have evolved several mechanisms to mediate their repair.  In higher 
eukaryotes, the predominant of these mechanisms is DNA nonhomologous end-
joining (NHEJ); DNA-dependent protein kinase (DNA–PK) plays a key role in this 
pathway.  It has been proposed that DNA-PK is a molecular sensor for DNA damage 
that enhances the signal via phosphorylation of many downstream targets. 
DNA–PK is a nuclear serine/threonine protein kinase with a molecular mass of ~470 
kDa, that is activated upon association with DNA.  DNA-PK is a member of the 
phosphatidylinositol-3 kinase (PI3K)–related protein kinase (PIKK) family of 
enzymes, involved in the signalling of cellular stress responses, however, DNA-PKcs 
does not possess lipid kinase activity. 
DNA-PK is a heterotrimeric complex comprising a large catalytic subunit (DNA-
PKcs) and a Ku70/Ku80 regulatory component with DNA binding properties.  DNA-
PK binds to globally cisplatin-modified DNA, with the Ku80 subunit being 
responsible for the interaction [69].  Unlike undamaged DNA, which activates the 
kinase activity of DNA-PK through binding of Ku proteins to DNA ends [70], 
cisplatin-damaged DNA fails to activate DNA-PK.  Ku80 also strongly interacts with 
DNA containing a cisplatin 1,2-d(GpG) adduct, which is only <2-fold weaker 
binding than Ku80 interaction with DNA ends [71].  Cisplatin-DNA adducts appear 
to inhibit translocation of Ku proteins along DNA, resulting in decreased association 
of DNA-PKcs to the Ku−DNA complex and therefore diminished kinase activity [72].   
The core components of mammalian NHEJ are the catalytic subunit of DNA protein 
kinase (DNA-PKcs), Ku subunits Ku70 and Ku80, Artemis, XRCC4 and DNA ligase IV. 
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DNA-PK is a nuclear serine/threonine protein kinase that comprises a catalytic 
subunit (DNA-PKcs), with the Ku subunits acting as the regulatory element.  Ku 
locates at the break first, recruiting DNA-PKCS to bring about synapsis of the ends.  
Artemis, which associates with a complex of three proteins, Mre11, Rad50, and 
Nbs1 (MRN) processes the DNA ends, and the final ligation of the juxtaposed ends 
is accomplished by the XRCC4/ligase IV complex[73].  Cells deficient in components 
of the NHEJ pathway are defective in DSB repair and highly sensitive to ionizing 
radiation and chemosensitisation such as  topoisomerase II poisons [74].  Inhibition 
of NHEJ is therefore an attractive approach to modulating resistance to 
therapeutically induced DNA DSBs. 
Along with DNA-PKcs, other members of this protein family include the ataxia 
telangectasia mutated protein (ATM), ataxia telangectasia-related protein (ATR) and 
mTOR [75].  Inhibitors of PI3K, such as wortmannin and LY294002, also inhibit 
DNA-PK in a noncompetitive and competitive manner, respectively [76].  Both 
wortmannin and LY294002 have been reported to retard DSB repair and enhance 
the cytotoxicity of ionizing radiation and etoposide, which has largely been 
attributed to inhibition of DNA-PKCS [77]. 
 
1.2.3.4 HMGB1 
High-mobility group protein 1 (HMGB1) is one of the early proteins discovered to 
bind cisplatin-modified DNA [78].  HMGB1 is an abundant ( 106 copies per cell) 
and highly conserved non-histone chromosomal protein, involved in gene 
regulation and maintenance of chromatin structure [79].  As a non-sequence-
specific DNA binding protein, it regulates numerous nuclear functions including 
transcription, replication, recombination, and general chromatin remodelling, 
serving as an architectural facilitator by assisting the assembly of nucleoprotein 
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complexes [80].  HMGB1 preferentially binds to DNA with bent or distorted 
structures, and it physically interacts with many cellular proteins such as p53, 
RAG1/2, TBP, MutSα, and steroid hormone receptors.  It has been revealed that 
HMGB1 is an extremely mobile protein in the nucleus with a residence time on DNA 
of less than a second.  Because of the high abundance of HMGB1 and affinity for 
bent DNA, the protein has a high probability of encountering platinum adducts and 
could be involved in drug action [38]. 
 
1.2.3.5 p53 
The tumour suppressor protein p53 is one of the most commonly mutated proteins 
in human cancer.  The p53, considered to be ―guardian of the genome‖, regulates 
DNA repair, cell-cycle arrest, and apoptosis by modification of other genes and 
their products, including those involved in transcription, DNA repair and many 
signalling processes [81].  Expression of p53 is positively correlated to cell 
sensitivity to the four platinum compounds cisplatin, carboplatin, oxaliplatin, and 
tetraplatin [82].  It is known that p53 protein plays a central role in chemotherapy-
induced apoptosis.  In fact, p53 is a strong transcriptional activator of the gene 
encoding p21WAF1/CIP1, a protein that mediates cell cycle arrest and that may also 
protect cells from apoptosis [83]. 
p53 monomer is a polypeptide protein of 393 amino acids containing two DNA-
binding domains.  The first domain, located in the core of the protein, binds to 
sequence-specific DNA elements located close to promoters of the p53 target 
genes, unlike other transcription factors, p53 has a second DNA-binding domain 
that maps onto its C-terminus and provides p53 with the ability to form complexes 
with non-specific DNA targets, including mismatched DNA, double-strand breaks 
(DSBs), single-stranded DNA (ssDNA) [84].  Under normal conditions there is a low 
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level of a latent form of p53, which is induced, activated, and stabilized under 
stress conditions including DNA damage [81].  Activation of p53 occurs through 
post-translational modification, mainly phosphorylation.  Cisplatin induces 
phosphorylation at serine 20 or 15 of the protein.  Both DNA binding sites are 
required for p53 binding to platinated DNA [85], although the C-terminal domain is 
more critical for the preferential p53 binding to cisplatin-modified DNA over 
undamaged DNA [86].  p53 interacts with the cisplatin damage recognition proteins 
XPC, RPA, YB-1, HMGB1, and mtTFA, and it significantly enhances the binding 
affinities of HMGB1 [87] to cisplatin-modified DNA through a direct physical 
interaction. 
1.2.3.6 PARP-1 
As p53 protein, Poly (ADP-ribose) polymerase 1 (PARP-1) has also been described 
as a ―guardian of the genome integrity‖.  PARP-1 is a large (1014 amino acids) 
nuclear enzyme that utilises NAD+ as a substrate for the synthesis and attachment 
of poly(ADP-ribose) polymers to a range of target proteins, as well as to itself in 
response to DNA damage [88].  Severe DNA damage appears to cause overactivation 
of PARP-1, which leads to the depletion of NAD+ and ATP in cells, ultimately leading 
to their death by necrosis.  Therefore, poly(ADP)-ribosylation may be a system of 
cell death which operates when the cell is so badly damaged that ATP levels are 
exhausted and when apoptotic pathways cannot take place [60].  Cisplatin 
treatment increases overall poly(ADP-ribosyl)ation [89], with PARP-1 being a major 
contributor to the modification [88].  Increased PARP activity is one of the 
mechanisms by which tumour cells avoid apoptosis caused by DNA-damaging 
agents[90].  Moreover, PARP-1 inhibitors sensitise various human cancer cell lines 
to cisplatin [91]. 
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1.2.3.7 DNA Recombination  
A role for recombinational repair (RR) in protecting cells from cisplatin treatment 
has been established in experiments using E. coli [92].  Many recombination-
deficient strains show enhanced sensitivity to cisplatin compared to wild-type cells 
[93].  DNA recombination has been more closely associated with the cellular repair 
of DNA interstrand rather than intrastrand cross-links [94].  At present, the manner 
by which RR proteins specifically recognize platinum adducts is unclear.  Moreover, 
the several repair proteins that bind specifically to platinum intrastrand cross-links 
do not interact with interstrand cross-links [95].  It was recently proved that 
replication forks stalled by non-histone-protein/DNA complexes possibly including 
platinum adducts, recruit recombination proteins to the site of fork stalling which 
dramatically induces intrachromosomal recombination that lead directly to gross 
chromosomal rearrangements and restore synthesis. 
 
1.2.4. Biochemistry of Cisplatin-Induced Cell Death Pathways and Molecules of 
apoptosis 
 
It is generally accepted that futile attempts to repair cisplatin-induced DNA damage 
may finally result in the triggering of apoptosis [96].  Apoptosis, also called 
―programmed cell death‖ or ―cell suicide‖, is considered a controlled pathway that 
requires ATP (adenosine triphosphate) and de novo protein synthesis. 
To trigger apoptosis it is believed that cellular damage has to pass a certain 
threshold level [38].  However, damaged genes are common in cancer cells in which 
proteins involved in apoptotic pathways often malfunction and as a result certain 
types of cancer become rather insensitive to CIS damage [97].  Upstream factors 
involved in the cellular response to the damaged DNA mediate the induction of a 
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network that transmits both pro- and antiapoptotic signals.  So, any interference 
that induces antiapoptotic signal transduction or abrogates proapoptotic pathways, 
including transcriptional and translational responses, is a potential mechanism of 
CIS resistance [38].  
The bcl2  family of genes encodes a group of proapoptotic (e.g., Bax, Bak, Bad) and 
antiapoptotic (e.g., Bcl-2, Bcl-XL) proteins, which form homo- and heterodimers 
with one another (Figure 4).  It is currently thought that the relative level of pro- 
and antiapoptotic proteins may function as a cell survival/cell death to influence 
sensitivity and resistance to cisplatin-induced apoptosis [50].  Bcl-2 is an oncogene 
that appears to be at the convergence of many apoptotic pathways and the ratio of 
Bcl-2 to Bax proteins at the effector phase might be the final determinant as to 
whether a cell enters the execution phase.  Bax is a gene which encodes a dominant 
inhibitor of Bcl-2 [98].  High levels of Bcl-2 may induce resistance to CIS through 
inhibition of apoptosis and decrease sensitivity to CIS in human ovarian cancer cells 
[99-100]. 
Another molecule that has been implicated in drug resistance is the caspase 
inhibitor XIAP.  In cells that are sensitive to drug, cisplatin down-regulates XIAP, 
leading to a corresponding activation of caspase 3 [101].  Ectopic expression of 
XIAP can render cells more resistant to cisplatin and this appears to depend on 
activation of the PI 3-kinase/AKT signalling pathway.  Bcl-2 and Bcl-XL inhibit 
apoptosis by regulating the release of cytochrome c from the mitochondrial 
membrane.  Expression of Bcl-XL is associated with a shorter disease-free survival 
period in patients receiving platinum-based therapy for ovarian cancer [102]. 
A general property of the execution phase of apoptosis is the specific degradation 
of a series of proteins by the cysteine aspartate-specific proteinases (caspases).  
Caspases are activated when an apoptotic stimulus induces the release of 
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cytochrome c from mitochondria [103].  It has been recently found that 
mitochondria play a central role in apoptosis.  Mitochondrial rupture releases 
cytochrome c and procaspase-9 that bind to cytosolic Apaf-1 and ATP in an 
apoptosome complex, leading to the activation of caspase-9.  Activated caspase-9 
induces other caspase interactions, resulting in activation of caspase-3, caspase-6, 
and caspase-7 with the subsequent cleavage of key substrates.  The final outcome 
is the dismantling of the cell by formation of apoptotic bodies [104]. 
Another possible apoptotic pathway is the one in which the activation of Fas 
receptor by Fas ligand (FasL) induces the formation of an apoptosome complex 
between Fas-associated death domain (FADD) and procaspase-8 that subsequently 
activates caspase-8.  Then caspase-8 activates the caspase-3−6−7 system that 
finally cleaves key substrates, and the cell is digested through apoptosis.  Caspase-
8 may also activate the proapoptotic protein Bid that triggers apoptotic cell death 
through the mitochondrial pathway [105].  FLice-like inhibitory protein (FLIP) is an 
intracellular anti-apoptotic protein, which modulates the cell surface receptor-
mediated cell death process by inhibiting the activation of caspase-8.  FLIP inhibits 
apoptosis by preventing the assembly of the death-induced signalling complex by 
Fas receptor.  Several cytotoxic agents have been shown to induce FasL, the ligand 
for Fas, and this likely contributes to drug-induced apoptosis [106].  In light of this 
it is understandable that ectopic expression of FLIP inhibits cisplatin-induced 
apoptosis [101]. 
Similarly TRAIL, another ligand that induces apoptosis, is able in some cells to 
potentiate apoptosis induced by cytotoxic agents, including carboplatin and taxol 
[107], Cisplatin [108] and this appears to depend on activation of the PI 3-
kinase/AKT signalling pathway [109].  
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Figure 5.  Apoptosis signalling pathways implicated in drug resistance in 
ovarian cancer.  Chemotherapeutic agents can induce apoptosis.  
Consequently inhibition of pro-apoptotic pathways and activation of anti-
apopotic pathways can lead to drug resistance.  (Adapted from Kaye & 
Richardson, 2005, [101]). 
 
1.3 PI3K Signalling Cascades Regulates Cell growth and Cell Survival  
 
Signal transduction in cancer cells frequently involves the conditional or constitutive 
activation of receptor tyrosine kinases (RTKs) that trigger multiple cytoplasmic 
kinases, which are often serine/threonine kinases.  Three major signalling pathways 
that have been identified as important in cancer include the phosphatidylinositol 3-
kinase (PI3K)/AKT kinase cascade [110-111], the protein kinase C (PKC) family 
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[112], and the mitogen-activated protein kinase (MAPK)/Ras signalling cascades 
[113]. 
Recent human cancer genomic studies have revealed that many components of the 
PI3K pathway are frequently targeted by germline mutations or somatic mutations 
in a broad range of human cancers [114]. 
1.3.1 Activation and Regulation of PI3K 
Constitutive pathway activation can result from the distinct and/or complementary 
biological events including (i) constitutively active mutants or amplification of 
receptor tyrosine kinases (for example, epidermal growth factor receptor or ErbB2) 
leading to constitutive recruitment and activation of PI3K and downstream effectors; 
(ii) amplification of PI3K; (iii) presence of activating mutations in the PIK3CA gene 
encoding the p110α catalytic subunit; (iv) overexpression of the downstream kinase 
AKT; (v) loss or inactivating mutations of the tumour suppressor gene PTEN, an 
endogenous negative regulator of the PI3K pathway or (vi) constitutive recruitment 
and activation by mutant forms of the Ras oncogene [115].  The preceding 
alterations trigger a cascade of biological events, from cell growth and proliferation 
to survival and migration, which drive tumour progression.  
In addition, for these cell autonomous survival and proliferation functions, PI3K is a 
key regulator of angiogenic pathways and upregulated metabolic activity in 
tumours.  Finally, this pathway also plays a major part in the resistance of tumour 
cells to conventional cytotoxic and targeted anticancer therapies.  Blocking the 
PI3K/AKT pathway could therefore simultaneously inhibit the proliferation and 
growth of tumour cells and sensitise them toward programmed cell death [116]. 
The eight members of the PI3K family have been classified into three groups based 
on their primary sequence, in vitro substrate preference, domain structure and 
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mode of regulation.  Class I PI3Ks, is composed of two subgroups, IA and IB [115].  
In regulating proliferation and in tumourigenesis, the most important PI3K proteins 
are those that belong to class IA. 
1.3.1.1 Class 1A PI3K 
The class IA PI3K subgroup consists of three catalytic subunits, p110α, p110β and 
p110δ, that form heterodimers with one of five regulatory domains: p85α, p85β, 
p85γ, p50α and p55α.  These PI3Ks are activated by cell-surface receptor tyrosine 
kinases.  The regulatory subunit, p85, directly binds to phosphotyrosine residues 
on RTKs and/or adaptors.  This binding relieves the intermolecular inhibition of the 
p110 catalytic subunit by p85 and localises PI3K to the plasma membrane where its 
substrate, phosphatidylinositol 4,5-bisphosphate (PI[4,5]P2), resides [117].  The 
primary in vivo substrate is PI[4,5]P2.  In quiescent cells, p85 binds to p110α, 
stabilising p110α and inactivating its kinase activity. 
PI3Ks IA catalyse the phosphorylation of inositol-containing lipids, known as 
phosphatidylinositols (PtdIns), at their 3-position, producing PtdIns(3,4,5)P3 (PIP3).  
It is this process that is reversed by the action PTEN. 
1.3.1.2 PIP3 phosphatases / PTEN 
PIP3 levels are barely detectable in mammalian cells under unstimulated growth 
conditions and are tightly controlled, owing to the combined effects of stringent 
PI3K regulation and the action of several PIP3 phosphatases (PTEN, SHIP1 and 
SHIP2).  The PIP3 phosphatase that is most clearly involved in oncogenesis is PTEN 
(also called MMAC1, an important tumour suppressor), a 3-position lipid 
phosphatase that converts PIP3 back to PIP2.  PIP2 — the product of the PTEN 
reaction — might be a second messenger in its own right, as well as being a 
substrate for several other phosphinositides that have signalling functions.  
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The SHIP phosphatases also act on PIP3, but remove phosphate from the 5-position 
rather than the 3-position, creating PtdIns(3,4)P2.  PtdIns(3,4)P2 can function as a 
second messenger (like PIP3) to recruit pleckstrin-homology (PH)-domain-
containing proteins, such as AKT.  So, although both PTEN and SHIP reduce the level 
of PIP3 in cells, PTEN seems to have primary responsibility for controlling the 
mitogenic effects of phosphoinositides because it reduces the levels of all those 
phosphorylated at the D3 position.  Once it became clear that PTEN functions 
primarily as a PIP3 lipid phosphatise [118-120], the central importance of PIP3 
regulation in cancer became indisputable.  Loss of PTEN results in unrestrained 
signalling by the PI3K pathway, leading to cancer [121]. 
PIP3 propagates intracellular signalling by directly binding pleckstrin homology (PH) 
domains of various signalling proteins [122] (Figure.6).   
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Figure 6.  The phosphatidylinositol 3-kinase (PI3K) signalling cascade.  PI3K 
signalling impacts on cell growth, survival, and metabolism.  Arrows represent 
activation, while bars reflect inhibition.  A negative feedback loop has been 
described from the downstream target S6 kinase (S6K) to the adaptor protein IRS-1.  
RTK, receptor tyrosine kinase; GPCR, G-protein coupled receptor; P, phosphate; G, 
G protein; PTEN, phosphatase and tensin homologue; IRS-1, insulin receptor 
substrate 1; eIF4E, eukaryotic initiation factor 4E; S6, ribosomal S6 protein; PIP2, 
phosphatidylinositol 4,5-bisphosphate; mTORC2, rapamycin (mTOR) –containing 
protein complex 2. (*) p110α, β , or δ (Adapted from Courney, 2010,[123]). 
 
1.3.2 Downstream of PIP3: the AKT pathway 
PIP3 functions as a second messenger to recruit PH-domain-containing proteins to 
the inner surface of the cell membrane.  PH domains — function as lipid-binding 
modules in a range of proteins, including several cytoplasmic kinases (Figure7).  
PIP3 brings two PH domain-containing serine/threonine kinases, phosphoinositide-
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dependent kinase 1 (PDK1) and AKT, into close proximity.  PDK1 activates AKT by 
phosphorylating AKT at threonine 308 [124-125]. 
 
                   
Figure 7.  Activation of AKT is initiated by membrane translocation, which occurs 
after cell stimulation and PtdIns(3,4,5)P3 (PIP3) production.  Localisation of AKT to 
the plasma membrane is accomplished by an interaction between its pleckstrin-
homology (PH) domain and PIP3.  At the membrane, association with carboxy-
terminal modulator protein (CTMP) prevents AKT from becoming phosphorylated 
and fully active.  Phosphorylation of CTMP by an as yet unidentified kinase releases 
CTMP from AKT and allows AKT to be phosphorylated by PDK1 and PDK2 at Thr308 
and Ser473, respectively.  Phosphorylation at these two sites causes full activation 
of AKT.  (Adapted from Vivanco, 2002, [126]). 
 
1.3.2.1 AKT/PKB 
AKT (also known as PKB) is a serine/threonine kinase belonging to the AGC PK 
subfamily.  Three mammalian isoforms—AKT1, AKT2 and AKT3—have been 
identified and are broadly expressed although isoform-specific patterns of 
expression exists in some tissues.  The three enzymes have a similar organisational 
structure: an N-terminal PH domain, a central serine/threonine catalytic domain 
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and a short regulatory region at the C-terminal end containing the so called 
hydrophobic motif [127-128].  AKT catalyses the phosphorylation of 
serine/threonine residues at consensus phosphorylation sites—R-X-R-X-X-S/T—in 
molecular targets, including proteins with key roles in the regulation of cell growth 
and survival.  AKT is a key downstream effector of PI3K.  
The serine/threonine kinase AKT/PKB has emerged as a critical signalling node 
within all cells of higher eukaryotes and as one of the most important and versatile 
protein kinases at the core of human physiology and disease [129]. 
AKT is now known to include a family of three closely related, highly conserved 
cellular homologues, dubbed AKT1, AKT2 and AKT3.  The encoded proteins are 
serine/threonine kinases that belong to the protein kinase B (PKB) family, and the 
AKT1, AKT2 and AKT3 proteins are also referred to as PKBα, PKBβ and PKBγ, 
respectively [130]. 
AKT/protein kinase B (PKB) is a cardinal node in diverse signalling cascades 
important in both normal cellular physiology and various disease states.  AKT 
signalling regulates cell proliferation and survival, cell growth (size), glucose 
metabolism, cell motility and angiogenesis [131].  Aberrant regulation of these 
processes result in cellular perturbations considered hallmarks of cancer [132], and 
numerous studies testify to the frequent hyperactivation of AKT signalling in many 
human cancers.  Various oncoproteins and tumour suppressors intersect the AKT 
signal transduction pathway and are activated or inactivated, respectively, in cancer.  
As perturbations of the AKT pathway appear to occur in so many human cancers, 
and in light of the diverse biologic consequences of AKT activation, this signalling 
cascade is considered an attractive target for therapeutic intervention.  
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AKT activation promotes resistance to standard chemotherapy and radiation 
therapy, and inhibition of AKT signalling induces apoptosis and decreased growth 
of tumour cells dependent on elevated AKT signalling for survival and growth [133]. 
1.3.3 Biological Effects of AKT Activation 
The main biological consequences of AKT activation that are relevant to cancer-cell 
growth can be catalogued loosely into three categories — survival, proliferation 
(increased cell number) and growth (increased cell size).  AKT has additional effects 
on tumour-induced angiogenesis that is mediated, in part, through hypoxia-
inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF). 
1.3.3.1 Cell Survival  
AKT plays a critical role in promoting cell survival downstream of growth factors, 
oncogenes, and cell stress [134].  AKT enhances the survival of cells by blocking the 
function of proapoptotic proteins and processes.  AKT negatively regulates the 
function or expression of several Bcl-2 homology domain 3 (BH3)-only proteins, 
which exert their proapoptotic effects by binding to and inactivating prosurvival 
Bcl-2 family members.  
 
For instance, AKT directly phosphorylates and inhibits the BH3-only protein BAD 
[135-136].  Survival factors stimulate AKT-mediated phosphorylation of BAD on 
S136, and this creates a binding site for 14-3-3 proteins, which triggers release of 
BAD from its target proteins [137].  AKT also inhibits the expression of BH3-only 
proteins through effects on transcription factors, such as FOXO and p53.  AKT 
phosphorylates FOXO1 on T24, S256, and S319, and it phosphorylates FOXO3a and 
FOXO4 on three equivalent sites [138].  AKT's phosphorylation of FOXO proteins 
occurs in the nucleus, and, as with BAD, phosphorylated T24 and S256 are bound 
by 14-3-3 proteins, which displace FOXO transcription factors from target genes 
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and trigger their export from the nucleus.  Through this mechanism, AKT blocks 
FOXO-mediated transcription of target genes that promote apoptosis, cell-cycle 
arrest, and metabolic processes. 
 
A third target of AKT that promotes survival by inhibiting BH3-only proteins is 
MDM2 (or HDM2 in humans), an E3 ubiquitin ligase that triggers p53 degradation. 
AKT phosphorylates MDM2 on S166 and S186, and this promotes translocation of 
MDM2 to the nucleus, where it negatively regulates p53 function [139-140].  
 
AKT also phosphorylates GSK3 isoforms on a highly conserved N-terminal 
regulatory site (GSK3α-S21, GSK3β-S9), and this phosphorylation inactivates the 
kinase [141].  Although GSK3 has many substrates that could explain a 
proapoptotic role for this Ser/Thr kinase [142], the prosurvival Bcl-2 family member 
MCL-1 has recently been found to be a direct target inhibited by GSK3 [143].  
Downstream of the Bcl-2 family members within the mitochondrial pathway of 
apoptosis are a cascade of caspase-family proteases initiated by caspase-9.  
Caspase-9 is proteolytically processed and activated from its procaspase form upon 
cytochrome c release from the mitochondria.  Therefore, AKT activation prevents 
the processing of procaspase-9 through the effects on Bcl-2 family members 
described above.  AKT has also been found to directly phosphorylate S196 on 
human procaspase-9, and this phosphorylation correlates with a decrease in the 
protease activity of caspase-9 in vitro [144]. 
 
It is also possible that AKT exerts some of its cell-survival effects through crosstalk 
with other pathways or through effects on nutrient uptake and metabolism.  An 
important, but more indirect, effect of AKT signalling on cell survival is through its 
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roles in nutrient uptake, metabolism, and the maintenance of mitochondrial 
membrane potential[145-146].  
1.3.3.2 Cell Growth 
One of the best-conserved functions of AKT is its role in promoting cell growth (i.e., 
an increase in cell mass).  The predominant mechanism appears to be through 
activation of mTOR complex 1 (mTORC1 or the mTOR-raptor complex), which is 
regulated by both nutrients and growth factor signalling.  mTORC1 is a critical 
regulator of translation initiation and ribosome biogenesis and plays an 
evolutionarily conserved role in cell growth control [147].  The enhanced sensitivity 
of cancer cells and mouse tumour models exhibiting oncogenic activation of the 
PI3K/AKT pathway to mTORC1 inhibitors, such as rapamycin, illustrates the 
importance of mTORC1 activation downstream of AKT [148].  AKT has been 
suggested to directly phosphorylate mTOR on S2448, which often correlates with 
mTORC1 activation, but mutational analysis has failed to demonstrate any 
functional significance for this phosphorylation [149].  Moreover, S6K1 rather than 
AKT has recently been shown to be responsible for phosphorylation of this site 
[150].  The tuberous sclerosis complex 2 (TSC2; also known as tuberin) tumour 
suppressor is a critical negative regulator of mTORC1 signalling [151-152].  AKT-
mediated phosphorylation inhibits TSC2 function [153-154] and TSC2, in a complex 
with its binding partner TSC1 (also known as hamartin), acts as a GTPase-activating 
protein (GAP) for the Ras-related small G protein Rheb, which strongly activates 
mTORC1 when in its GTP-bound active form [155].  Therefore, AKT activates 
mTORC1 indirectly by inhibiting TSC2, thereby allowing Rheb-GTP to activate 
mTORC1 signalling. 
 
More recently, a second AKT substrate has been found to be involved in mTORC1 
regulation.  Like TSC2 [154], the proline-rich AKT substrate of 40 kDa (PRAS40) was 
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identified using the AKT phospho-substrate antibody and was found to be a major 
protein bound to 14-3-3 in response to insulin [156].  PRAS40 was independently 
identified for its ability to bind to 14-3-3 proteins in a growth-factor- and 
nutrient-regulated manner [157].  Although the function of the protein was 
unknown, AKT was shown to directly phosphorylate PRAS40 on T246 [156], and this 
phosphorylation was later shown to be important for 14-3-3 binding [158].  
PRAS40 has been found to associate with mTORC1 and appears to negatively 
regulate mTORC1 signalling [159] and therefore, there appears to be two parallel 
and, perhaps, functionally redundant mechanisms by which AKT activates mTORC1.  
It will be interesting to determine the relative importance of TSC2 and PRAS40 for 
AKT-mediated mTORC1 activation under different physiological conditions. 
Aside from the ability of mTORC1 to enhance protein synthesis through its 
downstream targets, both mTORC1-dependent and -independent functions of AKT 
in nutrient uptake and metabolism are likely to contribute to increases in cell 
growth [160].  mTOR also presents a potential second target — namely, its mTORC2 
complex that functions as a PDPK2 and phosphorylates the C-terminus of AKT at 
ser473, an obligatory event for full activation of AKT [161].  Although the clinical 
importance of PDPK2 function in cancer is unknown, a recent study showed that 
mTORC2 is required for the development of prostate tumours that are induced by 
PTEN loss [162]. 
 
1.3.3.3 Cell Proliferation 
AKT activation can also stimulate proliferation through multiple downstream targets 
impinging on cell-cycle regulation.  Several groups have independently found that 
AKT phosphorylates the p27Kip1 cyclin-dependent kinase inhibitor on T157 [163-
165] and this leads to cytosolic sequestration via 14-3-3 binding [166].  Preventing 
p27 localisation to the nucleus attenuates its cell-cycle inhibitory effects.  
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AKT also inhibits p27 expression through phosphorylation and inhibition of the 
FOXO transcription factors [167].  AKT has also been found to phosphorylate the 
cyclin-dependent kinase inhibitor p21Cip1/WAF1 on T145, and, like p27, this 
phosphorylation leads to p21 cytosolic localisation [168].  Interestingly, it has been 
suggested that AKT1, but not AKT2, phosphorylates and inhibits p21, whereas 
AKT2 appears to bind and stabilize p21, thereby blocking cell-cycle progression 
[169].  AKT might also inhibit p21 expression through its phosphorylation and 
activation of MDM2 and subsequent downregulation of p53-mediated transcription 
of p21[139-140]. 
 
AKT-dependent phosphorylation of targets, such as GSK3, TSC2, and PRAS40, is 
also likely to drive cell proliferation through regulation of the stability and synthesis 
of proteins involved in cell-cycle entry.  GSK3-mediated phosphorylation of the G1 
cyclins, cyclin D and cyclin E and the transcripton factors c-jun and c-myc, all of 
which play a central role in the G1-to-S-phase cell-cycle transition, targets them 
for proteasomal degradation [170-172].  Therefore, phosphorylation and inhibition 
of GSK3 by AKT should enhance the stability of these proteins.  AKT signalling also 
controls the translation of proteins important for cell-cycle progression, 
predominantly through phosphorylation of TSC2 and PRAS40 and subsequent 
activation of mTORC1.  
Although best known for its role in promoting cell growth, mTORC1 is a critical 
regulator of cell proliferation.  The predominant cellular effect of mTORC1 
inhibitors, such as rapamycin, is to cause a G1 cell-cycle arrest, and AKT-mediated 
cell proliferation and oncogenic transformation has recently been shown to be 
dependent on mTORC1 activation [173].  AKT signalling leads to activation of eIF4E 
through mTORC1's inhibition of 4E-BP1, and eIF4E promotes the cap-dependent 
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translation of many target mRNAs, including those encoding cyclin D1 and c-Myc 
[174].  Therefore, as with cell survival and growth, AKT controls cell proliferation 
through multiple complementary downstream pathways. 
 
1.3.3.4 Cellular Metabolism 
In response to growth factors, AKT signalling regulates nutrient uptake and 
metabolism in a cell-intrinsic and cell-type-specific manner through a variety of 
downstream targets.  One of the most important physiological functions of AKT is 
to acutely stimulate glucose uptake in response to insulin.  AKT2, the primary 
isoform in insulin-responsive tissues, has been found to associate with glucose 
transporter 4 (Glut4)-containing vesicles upon insulin stimulation of adipocytes 
[175], and AKT activation leads to Glut4 translocation to the plasma membrane.  
 
Glut1 is the main glucose transporter in most cell types, and unlike Glut4, it 
appears to be regulated primarily through alterations in expression levels. 
Activation of mTORC1, through AKT-mediated phosphorylation of TSC2 and 
PRAS40, can contribute to both HIFα-dependent transcription of the Glut1 gene and 
cap-dependent translation of Glut1 mRNA [176-177].  The frequent occurrence of 
PI3K-AKT pathway activation and HIFα accumulation in human cancers is likely to 
explain the high levels of Glut1 and enhanced glucose uptake observed in tumours 
[124, 178]. 
 
AKT activation can also alter glucose and lipid metabolism within cells.  AKT 
activation also increases the rate of glycolysis [179], and this is probably a major 
factor contributing to the highly glycolytic nature of tumour cells.  AKT‘s ability to 
enhance the rate of glycolysis is due, at least in part, to its ability to promote the 
expression of glycolytic enzymes through HIFα [180]. 
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Upon entry into the cell, glucose is converted to its active form glucose 6-
phosphate through the action of hexokinases.  AKT has been demonstrated to 
stimulate the association of hexokinase isoforms with the mitochondria, where they 
more readily phosphorylate glucose, but the direct target of AKT responsible for 
this is currently unknown [146].  Glucose 6-phosphate can be stored by conversion 
to glycogen or catabolised to produce cellular energy through glycolysis, and AKT 
signalling can regulate both of these processes.  Particularly important in muscle 
and liver, AKT-mediated phosphorylation and inhibition of GSK3 prevents GSK3 
from phosphorylating and inhibiting its namesake substrate glycogen synthase, 
thereby stimulating glycogen synthesis. 
 
1.3.3.5 Angiogenesis 
Tumour angiogenesis is essential for the growth and metastatic spread of several 
solid tumours.  Angiogenesis represents the sprouting of new capillaries from 
existing microvasculature.  Angiogenesis is a multistep process orchestrated by a 
host of angiogenic factors and inhibitors, which offer a wide range of targets for 
therapeutic interventions and imaging [181].  
Without angiogenesis tumour expansion cannot proceed beyond 1–2 mm or 
metastasize to another organ, because tumour proliferation is severely limited by 
nutrient supply [182].  Therefore, angiogenesis is a crucial factor in the progression 
of solid tumours [183], including ovarian cancer [184]. 
The initiation of blood vessel formation is the result of a complex series of 
molecular events.  One of the central factors is VEGF, which acts as a potent 
endothelial mitogen and stimulates endothelial cell survival, migration, 
differentiation, and self-assembly [185].  On binding to its receptor, VEGF initiates a 
signal transduction cascade, which involves activation of multiple downstream 
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protein kinase pathways.  VEGF mRNA expression is regulated by several 
transcription factors, including HIF-1α.  HIF-1α is an oxygen-dependent 
transcriptional activator, which plays an important role in gene expression required 
for angiogenesis, metabolic adaptation to low oxygen, and survival [186].  
Endothelial cells play a crucial role in angiogenesis, bridging the gap between a 
microtumour and the essential factors for tumour expansion.  After mitogenic 
stimulation by a proangiogenic signal, endothelial cells proliferate and migrate into 
the perivascular stroma, initiate capillary sprouting by forming capillary-like tubes, 
and thus supply a microtumour with essential nutrients and oxygen [187]. 
 
AKT plays important roles in both physiological and pathological angiogenesis 
through effects on both endothelial cells and cells producing angiogenic signals, 
such as tumour cells.  In endothelial cells, the PI3K/AKT pathway is robustly 
activated by vascular endothelial growth factor (VEGF), and phosphorylation of the 
AKT targets is likely to contribute to endothelial cell survival, growth, and 
proliferation [17].  
VEGF is a crucial growth and permeability factor for tumour angiogenesis and is 
frequently up-regulated in human solid tumours [188].    
 
1.3.3.6 PI3K/AKT deregulation in Cancer 
The gene that encodes the p110 catalytic subunit of PI3K is amplified in some cases 
of ovarian cancer, and amplification of AKT2 can occur in ovarian cancer [17, 189-
191].  In both cases, the overexpression of a structurally normal protein is 
presumed to contribute to transformation.  The regulatory p85 subunit of PI3K is 
also targeted for mutation in human cancer [192].  Some primary ovarian cancers 
have mutations in p85α, which produce deletions in the inter-SH2 region and lead 
to PI3K activation [192].  These structural alterations presumably release the p85–
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p110 complex from negative regulation, bypassing the normal role of RTK 
signalling in PI3K activation. 
AKT isoforms are overexpressed in a variety of human tumours, and, at the 
genomic level, are amplified in ovarian cancer (AKT2).  The biological consequences 
of uncontrolled AKT activation in tumour cells are critical for inducing, among other 
effects, a survival signal that allows them to withstand apoptotic stimuli.  Thus, AKT 
protects tumour cells from death by phosphorylating and inactivating components 
of the intrinsic apoptosis pathway [193]. 
As alluded to earlier, the most compelling evidence for the PI3K/AKT pathway being 
involved in human cancer comes from studies of the PTEN tumour-suppressor 
gene.  Comprehensive surveys of several human cancers for PTEN gene deletion or 
mutations indicate that PTEN loss occurs in a wide spectrum of human cancers 
[194].  As loss of PTEN function can also occur through transcriptional silencing or 
protein instability [195-196], it is likely that the frequency of PTEN abnormalities in 
human cancer will rise as additional surveys are conducted using 
immunohistochemical analysis. 
1.3.3.7 Inhibitor of AKT; API-2 
Following the identification of a small molecule inhibitor of AKT pathway, 
AKT/protein kinase B signalling inhibitor-2 (API-2), also known as triciribine(TCN), 
by the Yang group [197],  API-2 was found to potently inhibits AKT signalling in 
human tumour cells with aberrant AKT, leading to inhibition of cell growth and 
induction of apoptosis, by suppressing both kinase activity and phosphorylation 
level of AKT [197]. 
API-2 is a tricyclic nucleoside, which, once inside cells, is phosphorylated to its 
monophosphate derivative, TCN-P, by adenosine kinase.  TCN-P is the active 
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metabolite of TCN, as in cells lacking adenosine kinase, it is 5000-fold less active 
[198].  However the precise mechanism of action of API-2 in inhibiting AKT remains 
to be determined [199].  As AKT regulation is complex, in theory, several strategies 
exist to inhibit AKT, such as (1) direct inhibition of AKT enzyme activity, (2) 
inhibition of AKT phosphorylation, (3) activation of AKT dephosphorylation or (4) 
prevention of AKT translocation to the plasma membrane, which is a prerequisite 
for the critical phosphorylations at T308 and S473 [199]. 
This compound does not inhibit AKT kinase activity per se, but in whole cells 
prevents phosphorylation of AKT1, AKT2 or AKT [197].  Furthermore, API-2 does 
not inhibit PI3-K, PDK1 and other protein kinases, but inhibits proliferation, induces 
apoptosis and inhibits tumour growth in animals much more potently in tumours 
that contain persistently hyperphosphorylated AKT, suggesting that API-2 is a 
selective AKT activation inhibitor. 
Berndt et al.[199], have recently demonstrated that TCN-P, but not TCN, binds to 
the PH domain of AKT and prevents its recruitment to the plasma membrane and 
subsequent phosphorylation at T308 and S473.  It has been proposed that TCN-P 
competes with PIP3, preventing PIP3 from recruiting AKT to the plasma membrane, 
possibly by competing with PIP3 for binding to the AKT PH domain or binding to an 
adjacent pocket that induces conformational changes preventing PIP3 binding 
[199]. 
 
1.4 PET tracers as Imaging Probes 
 
The term ―molecular imaging,‖ currently defined as ―in vivo imaging of biological or 
biochemical processes,‖ originally describes the visualisation of a target molecule in 
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vivo by virtue of its interaction with a probe at the molecular level.  The field of 
molecular imaging includes several different modalities [e.g., nuclear imaging, 
magnetic resonance imaging, magnetic resonance spectroscopy, computed 
tomography (CT), ultrasound, bioluminescence, and fluorescence imaging [200]. 
Molecular imaging techniques may also allow us to tailor therapy to individual   
patients.  Visualisation of specific molecular targets prior to therapy may identify 
patients most likely to benefit from a particular molecular therapy.  Many emerging 
anticancer therapies are cytostatic rather than cytotoxic and conventional methods 
of measuring treatment response may be particularly insensitive when significant 
tumour shrinkage is not anticipated early following therapy initiation but where 
functional changes may be marked [201]. 
Among the modalities for molecular imaging, nuclear molecular imaging with 
positron emission tomography (PET) represent the prototype for noninvasive 
quantitative tracing of biochemical processes in vivo [202]. 
The major advantage of nuclear medicine methods is that only picomolar 
concentrations of radiotracers are required to provide a measurable signal without 
interfering with the process under investigation [201].  In oncology, this has the   
potential advantage of not only being able to detect abnormal function related to 
malignant tissue at diagnosis but also to identify changes as a result of therapy 
earlier than is possible with anatomical techniques alone. 
Functional imaging with PET is playing an increasingly important role in the 
diagnosis and staging of malignant disease, image-guided therapy planning, and 
treatment monitoring [203].  For staging, response evaluation and restaging the 
extent of the disease, the tracer uptake has to correlate with the therapeutic effect 
(biomarker) at all imaging time points (before and after therapy).  Here, tracers 
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with high sensitivity are required, allowing for the early assessment of therapeutic 
effects and response evaluation [202]. 
 
The nuclear tracer technique in combination with PET imaging has advanced the 
functional evaluation of cancer in vivo.  2-[18F]fluoro-2-deoxy-D-glucose 
([18F]FDG); constitutes a large part of the success story of PET and is extensively 
used for diagnosis, staging, and therapy control of cancer.  But other 
radiopharmaceuticals, addressing proliferation, hypoxia, angiogenesis, apoptosis, 
receptor expression, metastasis, or gene expression, have also been established in 
part in the clinic [202] and continue to be developed in preclinical and clinical 
studies[204-205]. 
 
PET imaging of small animals enables researchers to bridge the gap between in 
vitro science and in vivo human studies.  Small animal PET (saPET) imaging enables 
assessment of baseline focal pathophysiology, pharmacokinetics, biological target 
modulation and the efficacy of novel drugs [204].   
Current PET technology for mice is of moderate spatial resolution (~1 mm), but this 
is compensated by its unparalleled sensitivity in detecting tumours [206].  Standard 
PET technology currently exploits the high glucose avidity of cancer lesions by the 
use of labelled analogues of glucose.  The capacities of PET are rapidly expanding 
to measure other functional properties of tumours, such as cellular proliferation, 
hypoxia, or apoptosis [207].  
1.4.1 Principle of PET  
The basis of PET imaging is the labelling of small, biologically important molecules, 
such as sugars, amino acids, nucleic acids, receptor-binding ligands, or even water 
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and molecular oxygen, with positron-emitting radionuclides.  When these positron-
emitting tracers undergo radioactive decay, positrons are emitted and collide with 
electrons in the tissue to form positroniums.  The positronium then annilates in the 
form of two 5110 keV gamma rays 1800 apart, which are then detected by rings of 
detectors that make up the PET scanner and their gamma rays can be detected by 
the PET scanner [208-209].  By imaging the temporal distribution of these labelled 
compounds, we can create ―physiologic maps‖ of the functions or processes 
relevant to the labelled molecules [210]. 
 
Most positron emitting isotopes are produced by a cyclotron (Figure 8).  The 
radiotracer or radioligand is produced by replacing a molecule of interest with the 
radiolabelled molecule e.g. carbon-11 for carbon-12, or fluorine-18 for hydrogen 
or fluorine-19 [211].  The half-life of the commonly used isotopes ranges from 
minutes to several days.  Frequently used radionuclides include oxygen-15 
(physical half-life, t½ =2.03min), nitrogen-13 (t½ =10min), carbon-11 (t½ 
=20.4min), fluorine-18 (t½ =109.8min) and iodine-124 (t½ =4.2 days).  Studies 
using a radionuclide with a short half-life (e.g. carbon-11) usually require a 
cyclotron on site, and have limited time available for radiochemical synthesis. 
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Figure 8.  Principles of PET.  A, A cyclotron is used to accelerate charged particles to 
create relatively short-lived positron-emitting isotopes (for example, 18F, the half-
life of which is 110 min).  B, Automated synthesisers can then couple the isotope to 
a molecule of interest to produce the molecular probe (tracer).  C, The molecule 
[18F]FDG can be synthesised and intravenously injected in non-pharmacological 
doses into a subject of interest.  The positron emitter decays by emitting a positron 
from its nucleus.  The positron loses energy and eventually annihilates with a 
nearby electron to produce two gamma-rays that are almost 1800 apart.  D, The PET 
scanner can detect the coincident gamma-rays, and images can be reconstructed 
showing the location(s) and concentration of the tracer of interest.  E, Cross-
sectional [18F]FDG PET images are shown after injection with [18F]FDG.  Normal 
uptake in brain (Br) and myocardium (C), and renal excretion into the urinary 
bladder (B) are visible.  (Adapted from Massood and Gambir, 2002, [207]). 
 
Malignant cells are known to have accelerated metabolism, high glucose 
requirements, and increased glucose uptake.  Conversion of glucose to lactic acid in 
the presence of oxygen is known as aerobic glycolysis and was reported by Otto 
Warburg at the beginning of the 20th century as a specific metabolic abnormality of 
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cancer cells [212].  As pointed out recently by Gatenby and Gillies [213], enhanced 
glycolysis seems at odds with an evolutionary model of carcinogenesis, because 
energy production by glycolysis is relatively inefficient.  In order to explain this 
apparent paradox, it has been proposed that the increase in glycolytic flux is a 
metabolic strategy of tumour cells to ensure survival and growth in environments 
with low oxygen concentrations [212]. 
Transmembrane transport mediated by specific transporters is considered to be one 
of the most important mechanisms for enhancing glucose influx into cells [214]. 
Furthermore, increased concentrations of hexokinase [215] with decreased rates of 
glucose-6-phosphatase have been reported to accelerate glucose phosphorylation, 
which results in increased glucose consumption.  Among several subtypes, glucose 
transporter protein, type 1 (Glut-1) and glucose phosphorylation enzyme type II 
(Hexokinase II, or HK-II) are known to be the most important subtypes for glucose 
metabolism in cancer cells [216-217]. 
 
Transport of glucose across the plasma membrane of mammalian cells is the first 
rate-limiting step for glucose metabolism and is mediated by facilitative glucose 
transporter (GLUT) proteins.  Increased glucose transport in malignant cells has 
been associated with increased and deregulated expression of glucose transporter 
proteins, with overexpression of GLUT1 and/or GLUT3 a characteristic feature 
[214]. 
 
1.4.2 Radiotracers and Imaging Probes 
1.4.2.1 [18F]FDG- Glucose utilisation  
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2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG) was synthesised [218] to image living 
subjects specifically and non-invasively with PET.  [18F]FDG was first used to study 
tumours in the 1980s by Di Chiro and others, who showed that the degree of 
malignancy of cerebral tumours was correlated with their [18F]FDG uptake [219].  
Tumours have a higher rate of glucose use leading to increased accumulation 
[18F]FDG.  
After FDG has been injected into the bloodstream, it is transported from the 
vascular space into the interstitial space.  From here, specific glucose transporters 
recognize and transport it into cells.  [18F]FDG is phosphorylated by hexokinase to 
form [18F]FDG-6-phosphate [220].  Unlike glucose,[18F] FDG lacks a hydroxyl group 
in the 2-position and its metabolite, [18F]FDG-6-phosphate, cannot act as a 
substrate for further glycolysis.  The molecular targets of [18F]FDG are therefore 
glucose transporters and hexokinase [220-221]. 
 
1.4.2.2 [18F]FLT-Cell proliferation 
Tumour cell proliferation is a hallmark of the malignant phenotype [208].  Cell 
proliferation increases with malignant transformation, which consequently increases 
the number of cells undergoing DNA replication. 
Loss of regulation of the cell cycle is fundamental to cancer progression.  All 
eukaryotic cells have a cell cycle divided into four phases through which they 
progress in order to divide: G1, S, G2 and M (Figure 9).  Normally, the cell cycle is 
tightly regulated so that there is a balance between proliferating and non-
proliferating cells appropriate for the tissue concerned.  Loss of regulation at the 
restriction point towards the end of G1 is thought to be critical in the development 
of cancer and may occur as a result of altered signal transduction pathways [222] 
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(Figure 9).  Once past this crucial phase, cells become independent of mitogenic 
signals and growth factors [208]. 
 
 
 
                     
             Figure 9.  The cell cycle, (Adapted from Kenny, 2004, [208]). 
 
Cells in the resting phase of the cycle can re-enter the cycle after mitogenic 
induction.  Phosphorylation of the retinoblastoma (Rb) tumour suppressor protein is 
one of the key mechanisms that controls progression through the G1/S phase of the 
cell cycle [223].  Hypophosphorylated Rb is bound to and inhibits E2F [224].  Upon 
phosphorylation, E2F is released and activates transcription factors such as 
dihydrofolate reductase, thymidine kinase, thymidylate synthetase, DNA polymerase 
δ, E2F itself and cyclin E [225].  Repression of E2F is mediated by histone 
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deacetylase recruitment to Rb and by direct inhibition of transcription factors at the 
E2F promoter [226]. 
 
Most oncogenic processes exert their greatest effect by targeting the regulation of 
the G1phase [227].  Cyclins complexed with cyclin-dependent kinases (cdks) drive 
cells in G1to initiate S phase and in G2 to initiate mitosis [228].  Cdks are expressed 
at a constant level during the cell cycle.  The level of cyclin expression, however, 
varies with cell-cycle stage, as they are subject to ubiquitin-proteosome 
degradation [229].  
Exploitation of thymidine analogues permits targeting of DNA replication machinery 
for imaging [230].  Several agents, including [11C]thymidine, have been studied, but 
the most promising agent so far is 3'-deoxy-3'-[18F]fluorothymidine ([18F]FLT) 
[231].  Our research group has contributed significantly to the 
validation/qualification of [18F]FLT -PET [205]. 
[18F]FLT is phosphorylated by thymidine kinase 1 (TK1) at the 5'-OH position to give 
[18F]FLT-phosphate, which is charged and therefore retained within cells to give the 
specific PET signal.  Cellular uptake of [18F]FLT depends on TK1 and ENT1 
transporter activity [232-233]  Unlike thymidine, the relationship between FLT and 
cell proliferation is not by virtue of its incorporation into DNA (there is very little 
incorporation of [18F]FLT into DNA) but rather the regulation of TK1 within the cell 
cycle [205].  The retention of [18F] FLT within the cell, therefore, provides a measure 
of cellular TK1 activity, an enzyme which is closely tied to cellular proliferation.  
Studies have demonstrated that TK activity increases about 10~fold as cells enter 
the DNA synthetic phase [231]. 
Kenny et al. [234], further demonstrated that the [18F]FLT flux constant, i.e., the net 
irreversible trapping of [18F]FLT at steady state, was more strongly associated with 
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cell proliferation as assessed by histology.  This decrease in[18F]FLT-PET signal is 
associated with reduced expression of Ki67, and TK1 [205]. 
[18F]FLT exhibits high in vivo stability, which facilitates tracer kinetic modelling, and 
is becoming accepted for the imaging and quantification of proliferative activity in 
both animals and patient [208, 235].  
 
1.4.2.3 [18F]ICMT11-Apoptosis  
Cell death is an essential strategy for the control of the dynamic balance in living 
systems, and two fundamentally different forms of cell death, apoptosis and 
necrosis, have been defined [236]. 
Apoptosis or programmed cell death involves the activation of an energy-requiring 
intracellular machinery, which is tightly regulated and conserved throughout 
evolution [237].  This extremely well organised process includes cellular shrinkage, 
membrane blebbing, nuclear chromatin condensation and fragmentation.  
Eventually, the cell breaks into membrane-surrounded fragments (apoptotic bodies) 
which are engulfed in vivo by professional phagocytes [238].  In contrast, necrosis 
is an accidental passive process resulting in an early disruption of the cell 
membrane and in the progressive breakdown of ordered cell structures in response 
to violent environmental perturbations such as severe hypoxia/ischaemia, extremes 
of temperature and mechanical trauma.  This type of cell death is associated with 
organelle swelling [239].  
 
Deregulation of apoptosis (i.e., deregulation of programmed cell death) is a 
hallmark of cancer, and most anti-cancer agents kill tumour cells by inducing 
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apoptosis [132, 240-241].  Excessive apoptosis can lead to ischemic damage and 
neurodegenerative diseases, whereas conditions such as cancer can result from 
excessive cell proliferation or  insufficient apoptosis [242]. 
 
Apoptosis is a natural form of cell death.  It is an energy dependent and genetically 
controlled process without inflammatory response that maintains homeostasis in 
proliferating tissues in adults [12, 243].  Dysregulation of apoptosis is linked to 
increased cell proliferation or enhanced cell death, resulting in a variety of diseases.  
While an increased apoptosis rate occurs in acute myocardial infarction [244],  
atherosclerosis [245], allograft rejection [246], decreased apoptosis rate can be 
observed during tumourigenesis [247-248], and autoimmune diseases [249].  Both 
the diagnosis and therapy of such diseases demand noninvasive and serial imaging 
of apoptosis in vivo, e.g., as a surrogate marker of successful chemotherapy of 
tumours.  Therefore, apoptosis imaging with PET would be a clinically important 
tool for disease management.  For this, a biological target for specific apoptosis 
imaging is crucial [250]. 
 
1.4.2.3.1 Caspases 
Caspases, a family of cysteine-dependent aspartate-directed proteases, are 
proposed to play a critical role in the majority of cell death pathways characterised 
thus far.  Caspase 3,  a member of the class of effector caspases  has been found to 
be activated in nearly every model of apoptosis encompassing several different 
signalling pathways [251]. 
The caspase family of cysteine proteases has two different classes of caspases 
involved in apoptosis, the initiator caspases and the executioner caspases [252].  
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The initiator caspases, which include caspase-2, -8, -9, and -10, are located at the 
top of the signalling cascade; their primary function is to activate the executioner 
caspases, caspase-3, -6, and -7.  The executioner caspases are responsible for the 
physiological (e.g., cleavage of the DNA repair enzyme poly(ADP-ribose) 
polymerase-1, nuclear laminins, and cytoskeleton proteins) and morphological 
changes (DNA strand breaks, nuclear membrane damage, and membrane blebbing) 
that occur in apoptosis [104].  A third class of caspases, caspases-1, -4, -5, and -
13, are involved in cytokine maturation and are not believed to play an active role in 
apoptosis [104]. 
Among them, caspase 3 is a frequently activated death protease, and has been 
found to be activated in nearly every model of apoptosis encompassing several 
different signalling pathways [251].  As such, caspase 3 is a potential therapeutic 
target for the treatment of diseases involving dysregulated apoptosis [253] .  
 
On the basis of the decisive role of caspases in apoptosis, caspase inhibitors have 
been designed to therapeutically prevent apoptosis and rescue tissues – obviously 
for non-cancer applications [254].  The isatin sulfonamides were the first reported 
examples of potent and selective inhibitors of caspases 3 and 7 and represent a 
novel strategy for the development of active agents which block apoptosis by Lee et 
al. [255] (Figure 9A).  The compounds are potent and selective non-peptide 
inhibitors of the effector caspases 3 and 7 [253].  Apart from therapeutic 
applications, these inhibitors could also be used for molecular imaging of caspase 
activity because they typically bind to activated caspases [253].  
In the past few years, several groups have made attempts to develop isatin-based 
inhibitors of caspase 3 and caspase 7, as specific radiotracers for imaging apoptosis 
using PET [250, 256-257]. 
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These nonpeptidic 5-pyrrolidinylsulfonyl isatins do covalently and reversibly bind to 
the active site of the activated caspase enzymes.  The mechanism of action of 
isatins involves formation of an intracellular enzyme−inhibitor complex with 
caspase 3 (and 7) through covalent binding to the enzyme active site of the 
activated caspase [255, 258].  The C-3 carbonyl carbon of the isatin skeleton acting 
as an electrophile forms a thiohemiketal with the nucleophilic Cysteine thiolate 
function, and this in turn happens when the dicarbonyl functionality of the isatin 
binds to the Cysteine residue of the active site [255, 258].  It is for these reasons 
that radiolabelled 5-pyrrolidinylsulfonyl isatins were suggested as 
radiopharmaceuticals for clinical imaging of apoptosis by  PET by our group [259] . 
Our group has reported the development and characterisation of a novel 
[18F]labelled isatin with improved metabolic profile, reduced lipophilicity, and 
subnanomolar affinity for caspase 3 (Figure 10B; bottom panel).  However, direct in 
vivo application of labelled peptide-based caspase inhibitors as caspase imaging 
agents failed due to poor cell permeability [260].  
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Figure 10.  Structure of isatin sulphonamide scaffold (A; 5-
Dialkylaminosulfonylisatins); [R group-phenoxymethyl, R' group –benzyl] and the 
novel [18F] isatin ICMT11 tracer developed by our group (B).  Adapted from Smith G, 
et al. 2008 [259]. 
 
An aspect of this thesis, initially, was to characterise a small library of isatins 
compounds as potential lead apoptotis compound imaging agent. 
 
1.4.2.4 [18F]fluciclatide -angiogenic probe 
The PET tracer [18F]fluciclatide (formerly known as [18F]AH111585), which is 
selective for αvβ3-integrin and αvβ5-integrin, has been used previously to monitor 
tumour response in xenograft tumour model in mice [261] and in patients studies 
[262].   
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Cell matrix interactions are fundamental to tumour invasion and formation of 
metastases [263], as well as to tumour-induced angiogenesis [264].  The integrins, 
are heterodimeric transmembrane glycoproteins that compose a diverse family of 
19 α and eight β subunits, play a key role in these interactions [265]. 
αvβ3 integrin is the most abundant integrin expressed on the surface of proliferating 
endothelial cells and has been implicated in cell migration and cell survival 
signalling.  These properties have made αvβ3 integrin a target of choice for the 
imaging of angiogenesis;αvβ3 expression in quiescent endothelial cells is very low 
[266-267].  The discovery of the cyclic RGD [arginine(Arg)-glycine(Gly)-
aspartate(Asp)] sequence as the main binding motif for integrins was the starting 
point for the rapid development of probes targeted at αvβ3 integrin and having 
suitable in vivo characteristics for the molecular imaging of angiogenesis [181]. 
Haubner et al. reported the synthesis and characterisation of a series of 
radiolabelled αvβ3 antagonists, the cyclic RGD peptides, known to bind to the αvβ3 
integrin [268-269].  These radiolabelled RGD peptides exhibited high affinity for 
the αvβ3 integrin and specific binding in several tumour cell lines expressing αvβ3.  
This preliminary work supported the potential for radiolabelled targeting of αvβ3 for 
imaging of angiogenesis.   
During the past decade, a variety of αvβ3 integrin–targeted lead constructs, such as 
the cyclic RGD core, evolved, allowing for the optimisation of pharmacokinetics (via 
the attachment of carbohydrates, charged amino acids, and polyethylene glycol 
analogues) and binding characteristics (via multimerisation) [270].  Based on theses 
promising reports, a new RGD peptide, [18F]fluciclatide, was design to detect 
tumours in metastatic breast cancer patients using PET [262].  [18F]fluciclatide is a 
cyclic peptide containing an RGD motif that binds to integrin receptors such as αvβ3 
and αvβ5 [271] with high affinity [272].  Despite similarities in the RGD motif, the 
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design strategy for [18F]fluciclatide [271] is distinct from [18F]galacto-RGD, which 
was modified with a sugar amino acid to enhance systemic elimination [268]. 
 
1.4.2.5 Preliminary Study of [18F]Inositol analogues as Imaging Probes  
Inositols play an important role in membrane lipid metabolism and mitogenic 
signalling of most cancer cells.  A limited number of deoxyfluoro cyclitols have 
been synthesised and evaluated as probes of the phosphatidylinositol pathway.  The 
first reported deoxyfluoro cyclitol, 1-deoxy-1-fluoro-scyllo-inositol, was 
synthesised by Yang et al. [273].  Cyclitol is a generic term that is used to describe 
compounds that are cyclohexanehexitols, the most important of which is myo-
inositol [274-275].  There are several hypotheses that might explain inositol uptake 
and trapping into cells, including; i) inositols are phosphorylated and trapped and 
that the phosphorylation is dominated by PI3K in cancer cells.  If the activity of the 
pathway goes down then bulk inositol trapping will go down by inference; ii) 
Inositol transporter is regulated by PI3K; iii) binding of inositol phosphates to PH 
domains [276]. 
 Key to the success of any cyclitol being useful as an imaging probe in intact cellular 
systems is that it must: (1) be lipophilic enough to cross cellular membranes and; 
(2) be a reasonably good substrate for the first enzyme, thus facilitating its 
incorporation into the PtdIns cycle [277]. 
Inositol is a simple polyol with eight naturally occurring stereoisomers, the most 
commonly found in nature are myo–, chiro–, epi–, and scyllo–inositol [278].  myo–
inositol is the most abundant isomer and is a ubiquitous component of all 
eukaryotic cells.  It is a constituent of phosphatidylinositol, which is an important 
phospholipid in membranes and second messenger systems. 
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PtdIns, the basic building block for the intracellular inositol lipids in eukaryotic 
cells, consists of D-myo-inositol-1-phosphate (Ins1P) linked via its phosphate 
group to diacylglycerol (Figure 11) [279].  The inositol head group of PtdIns has five 
free hydroxyl groups, as many as three of which have been found to be 
phosphorylated in cells, in different combinations.  The 2 and 6 positions in these 
lipids have not been documented to be susceptible to esterification with phosphate.  
PtdIns and its phosphorylated derivatives are collectively referred to as 
phosphoinositides [280].  Please refer to Section 1.3.1 and 1.3.1.1 for the role of 
PtdIns in PI3K signalling. 
 
                                         
 Figure11.  Chemical structure of PtdIns (Adapted from Vanheasebroek, 2001 [280]). 
 
In contrast, with the notable exception of inositol 1,4,5-trisphosphate and its 
pivotal role in the mobilisation of intracellular calcium, less emphasis has been 
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placed on the functional significance of the water-soluble components of the 
phosphoinositide pathway, i.e. myo-inositol and its phosphorylated derivatives.  To 
date, seven of the 63 possible inositol phosphate esters have been assigned 
putative physiological roles [281] and many others have been detected in a variety 
of organisms.  In addition, at least four pyrophosphorylated inositol phosphates 
and enzymes that synthesise [282] and degrade them [283], in brain have been 
identified.  Given their structural diversity, it appears likely that cellular functions of 
other inositol phosphates remain to be discovered. 
Myo-Inositol and its derivatives (PtdIns, PtdIns(4)P and PtdIns(4,5)P2) have been 
recognised for many years as important intermediates in the biosynthesis of the 
‗second messenger' compounds, inositol 1,4,5-trisphosphate [Ins(1,4,5)PIP3] and 
diacylglycerol (1,2-DAG) that are associated with cell proliferation, cell growth, 
smooth muscle contraction, inflammatory cellular events, secretion, and other 
processes [284-285].  Certain malfunctions of these processes are implicated with a 
number of disease states (Figure 12).  Myo-Inositol serves not only as a precursor 
molecule for inositol lipid synthesis, but also as a physiologically important 
osmolyte.  Myo-inositol also acts as a "compatible osmolyte" in specific tissues, 
such as brain and kidney medulla, where variations in milieu osmolarity may 
threaten normal cell function [286]. 
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Figure 12.  Intracellular signalling by phosphoinositides.  The biological versatility 
of PtdIns derives from its unique ability to be reversibly phosphorylated at three 
distinct positions of the inositol headgroup.  Single or combinatorial 
phosphorylation of the 3, 4 and 5 positions on the inositol ring of PtdIns can 
generate at least seven unique phosphoinositides, which have diverse roles in 
receptor-mediated signal transduction, cytoskeletal remodelling, nuclear events 
and membrane trafficking.  Imbalances of these major lipid signalling pathways 
contribute to disease progression in chronic inflammation, cancer, atherosclerosis, 
metabolic and degenerative diseases among others.  (Adapted from Wymann, 2008 
[287]). 
 
Active transport of inositol stereoisomers across cellular membranes occurs via 
inositol transporters.  Three such myo-inositol cotransport systems have been 
identified, two of which are sodium dependent (SMIT1 and SMIT2) whereas the third 
is proton dependent (HMIT) [288].  Both SMIT1and SMIT2 co-transport two sodium 
ions along the concentration gradient, to generate enough energy to actively 
transport myo-inositol. 
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Transport inhibitors, 2-aminoethoxydiphenyl borate (2-APB) have been previously 
used to study inositol flux into cells in vitro.   We have also included 2-APB  in our 
in vitro assay to see whether there is an effect on inositol flux across cell 
membranes with inhibitors. 
 
1.4.2.5.1 2-aminoethoxydiphenyl borate (2-APB) 
2-APB  was introduced as a novel modulator of intracellular calcium release which 
appeared to inhibit opening of the channel domain of the IP3 receptor without 
affecting the binding of IP3 to the receptor[289].  D-myo-inositol 1,4,5-
trisphosphate (IP3) acts as a second messenger to induce the release of Ca2+ from 
Ca2+ stores upon binding to IP3 receptors (IP3R) and regulates the dynamics of 
intracellular Ca2+concentration in many types of cells [290]. 
 
 
Neil Vasdev et al. [291] demonstrated uptake of [18F]fluoro-scyllo-inositol in MDA-
MB-231 human breast cancer xenografts and suggested that scyllo-inositol 
derivatives would represent a new class of PET radiopharmaceuticals for illnesses 
such as breast cancer.  Here in our group, myo-inositol was radiolabelled in an 
analogous method, to yield [18F]fluoro-myo-inositol and compared to scyllo-
inositol in different tumour cell lines, MDA-MB-231, IGROV-1, PEO1and PEO4 cells.   
These tumour cells lines were chosen because they have a constitutive PI3K pathway 
and overexpress EGFR [292-294].  The family of growth factor receptors has been 
shown to activate phosphoinositide hydrolysis.  The binding of polypeptide 
mitogens like epidermal growth factor (EGF) to their specific cell surface receptors, 
stimulate phosphoinoside turnover, increase cytosolic Ca2+, DNA and protein 
synthesis, and enhanced cell proliferation in several cell types [295].   
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1.5 Aims of Project 
 
Advanced ovarian cancer initially responds to platinum-based chemotherapy, 
however, the natural history of the disease is often characterised by subsequent 
resistance to these agents. 
As the a better understanding of the molecular basis for platinum resistance via 
altered signalling pathways evolves, the identification of signalling transduction 
inhibitors will hopefully lead to new strategies to treat platinum-refractory tumours 
or prevent resistance from emerging.  We wish to provide an understanding of 
platinum drug resistance in mouse models of ovarian cancer by studying molecular 
characteristics using PET imaging. 
 
Relevance to Cancer: 
This is a translational research project that has direct relevance to cancer.  It aims 
to provide a comprehensive understanding of how clinically-derived (expression-
altered) platinum resistance genes work in vivo.  The methodologies aim to give an 
insight of potential biomarkers that might be of both predictive and prognostic 
utility, as well as provide the platform for developing new modulators of platinum 
resistance. 
Molecular and functional imaging tools are increasingly being used in the clinic to 
assess early response to treatment before tumour size reductions are observed by 
cross sectional imaging methods such as Computed Tomography or Magnetic 
Resonance Imaging. 
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Hypothesis and specific aims:  
This thesis was to attempt to provide an understanding of platinum drug resistance 
in xenograft model by studying molecular interaction using PET imaging.  The 
overall aim of this project was to establish phenotypic characteristics of this tumour 
with imaging and non-imaging methods, and assess whether imaging can be used 
to evaluate modulation of resistance with pharmacological antagonists.  The 
specific aims were: 
 
 To validate selected imaging methods in subcutaneous tumour models of 
sensitive and platinum resistant ovarian cancer 
 To evaluate the in vivo  phenotypic characteristics of tumours derived from 
these models by imaging and molecular biochemical methods 
 To assess whether imaging methods developed above can provide a 
measure of the efficacy of such pharmacological modulators 
 
Our collaborator‘s laboratory has established clinically-derived isogenic cell lines 
that are either sensitive or resistant to platinum.  These cell lines, PEO1 (sensitive) 
and PEO4 (resistant) cells were derived from an individual ovarian cancer patient 
both before and after the transition from platinum sensitivity to platinum 
resistance.  Furthermore, using cDNA microarrays to profile cell lines derived from 
platinum sensitive and platinum resistant tumours, they have identified a number of 
genes that are upregulated or downregulated in platinum resistance [296-298].  
One of these targets (PI3K/AKT pathway) was probed to assess its relevance in vivo 
using pharmacological inhibitors.  We used triciribine (API-2), a pan-AKT inhibitor, 
as the pharmacological modulator in these in vivo studies.  Two other targets, that 
were also found to be upregulated, VEGF and CpG methylation, did not form part of 
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this project, but initially these targets were used to characterise the isogenic paired 
cells. 
 
Methods to be used in this project 
Imaging was used to assess the phenotype of platinum-resistant ovarian cancer.  
This was followed by molecular biochemical analysis of phenotype in excised 
tissues. 
Imaging Methods.  The imaging methods included: 
 [18 F]FDG-PET to detect glucose metabolism 
 [18 F]FLT-PET to detect TK1 activity and cell proliferation 
 [18 F]ICMT11-PET to detect caspase 3/7-dependent apoptosis 
 [18F]fluciclatide to detect angiogenesis (specifically αvβ3integrin receptor 
expression) 
 [18F]fluoro-scyllo -inositol and [18F]fluoro-myo-inositol to detect inositol flux 
in tumour xenografts IGROV-1, MDA-MB-231, PEO1 and PEO4 at baseline 
 
Immunohistochemistry and western blot studies.  For further characterisation of the 
subcutaneous model, immunohistochemistry and western blot studies will be 
performed on a selection of frozen (and formalin fixed) post-mortem tumour 
tissues, using methodologies for the analysis of proliferation (Ki67), apoptosis 
(TUNEL) and angiogenesis (CD31/H&E) in tumour samples. 
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2.0 METHODS AND MATERIALS 
 
2.1 Cell Culture 
The cell lines PEO1 and PEO4 were obtained from Dr Simon Langdon (Cancer 
Research UK, Medical Oncology Unit, Edinburgh, UK) and have been described 
previously [299-301].  Briefly, both cell lines were derived from a single patient with 
stage III, grade 3 serous adenocarcinoma of the ovary.  The patient was a BRCA2 
mutation [5193C>G (Y1655X)] carrier with a secondary mutation 
[5193C>T(Y1655Y)] detected in relapsed resistant cells that restored wild type 
BRCA2 sequence at the site of the inherited mutation [301].  The PEO1 line was 
derived from cells in the platinum sensitive phase of the disease and possess 
platinum and poly(ADP-ribose) polymerase inhibitor sensitivity in culture; the 
stocks of cell lines were recently sequenced, and showed reversion mutation 
[5192A>T;5193C>G (Y1655L)] restoring full length BRCA2 sequence [302], whereas 
PEO4 was derived following acquired clinical platinum resistance (the stocks carry 
the same secondary mutation as described in [302], i.e., 5193C>T(Y1655Y )).  
Transcriptional analysis of the paired cell lines identified 91 up- and 126 
downregulated genes common to acquired resistance [297].  
Non-isogenically paired ovarian adenocarcinoma cell lines: SKOV3 and IGROV-1 
were kindly provided by Dr Euan Stronach, Imperial College, London, UK.  MDA-MB-
231 breast cancer cell line was purchased from LGC Standards, Middlesex, UK. 
Cells were grown as monolayer cultures in RPMI 1640 (GIBCO, Paisley, UK) 
supplemented with 10% foetal bovine serum (FBS; Lonza, Wokingham, UK), 2mM L-
glutamine (GIBCO) and antibiotics (100units/mL;streptomycin/penicillin, GIBCO) in a 
humidified atmosphere of 5% CO2 at 370C.  Cell viability was routinely greater than 
90%, as judged by trypan blue exclusion.  
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2.2 In vitro drug exposure 
To establish a schedule for API-2-cisplatin combination treatment, growth 
inhibition (sulforhodamine B (SRB) assay) and apoptosis (Caspase-Glo assay) were 
assessed in PEO1 and PEO4 cells.  The cells were trypsinised and plated in 96 well 
plates at a density of 2x104 cells/ml for PEO1 and 4x104 cells/ml for PEO4 cells.  
Growth inhibition studies were performed using log-phase cells seeded in 96-well 
flat bottomed tissue culture plates and incubated to reach 40% to 60% confluence 
before treatment.  Cells were treated with cisplatin (25 µM, Sigma-Aldrich Ltd, 
Dorset, UK) alone, API-2 alone (20 µM; Merck-Chemicals Ltd, Beeston, UK) or the 
combination for 48h; the drug concentration was selected based on previous 
studies that demonstrated effect of drug on AKT phosphorylation [197].  The PI3 
kinase inhibitor, LY294002 (20 µM), and the DNA methyltransferase inhibitor 5-
aza-2'-deoxycytidine (decitabine; 1µM) (Merck-Chemicals Ltd) were used as 
positive controls for pathway activity and non-pathway dependent cytotoxicity.  
Cells were pre-treated with modulators for 1, 6, 12 and 24h following which 
medium containing drug was removed and fresh medium containing both cisplatin 
and modulator was added (continuous exposure).  In one case cells were 
simultaneously exposed to modulator and cisplatin.  The cytotoxic effects were 
evaluated at the end of drug exposure (48h).  In drug washout experiments, cells 
were pre-treated as described above; the modulator drug was washed out 
immediately prior to cisplatin treatment.  SRB (SRB kit; Sigma-Aldrich) and Caspase-
Glo (Caspase-Glo kit, Promega, Southampton, UK) assays were performed following 
48h exposure to cisplatin.  Control cells were treated with equivalent concentrations 
of DMSO (<1% v/v final concentration). 
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2.3 Sulforhodamine B (SRB) growth assay 
To assess cell proliferation, SRB (Sigma-Aldrich), an aminoxanthene dye, is allowed 
to bind to cellular protein following experimental procedures.  The amount of dye 
extracted from stained cells is proportional to cellular content.  At the end of drug 
exposure, cells cultured in 96-well plates, were fixed with 50% trichloroacetic acid 
(Sigma-Aldrich) at 4°C (50µl/well, final concentration, 10%) for 1h.  After five 
washes with tap water, cells were stained with 0.4% SRB dissolved in 1% acetic acid 
(100µl/well) for 30 min incubation at RT on a shaking platform and subsequently 
washed four times with 1% acetic acid to remove unbound stain.  Plates were air 
dried, and protein-bound stain was solubilised with 100µl of 10mM unbuffered Tris 
base, pH10.5 and allowed to homogenise for 1h on a shaking platform.  The 
absorbance of treated cells was determined in a 96-well microtiter plate reader 
(Thermo Electron Corporation, Basingstoke, UK) at a wavelength of 540 nm and 
reading substrated from background absorbance detected at 620 nm.  Six replicate 
wells were used for each drug combination and experiments were repeated three 
times.  Vehicle (DMSO) treated cells were used as control.  Measurements were 
calculated and normalised to control. 
2.4 Determination of apoptosis by Caspase-Glo 3/7 assay 
The Caspase-Glo 3/7 Assay (Promega, Southampton, UK) is a luminescent assay 
that measures caspase-3 and -7 activities, which are members of the cysteine 
aspartic acid-specific protease (caspase) family, and play key effector roles in 
apoptosis[303].  The assay provides a proluminescent caspase-3/7 substrate, which 
contains the tetrapeptide sequence DEVD.  This substrate is cleaved to release 
aminoluciferin, a substrate of luciferase used in the production of light. 
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Cells were plated into white-walled 96-well plates and grown until 50-60 % 
confluent.  Following drug exposure, caspase activities in cell-based models of 
apoptosis were evaluated using the Caspase-Glo reagent.  The assay provides a 
proluminescent caspase-3/7 substrate, which contains the tetrapeptide sequence 
DEVD.  Caspase cleavage of the substrate produced a luminescent signal which is 
proportional to the amount of caspase activity present.  The reagent was added to 
cells in culture media in a 1:1 (v/v) ratio and incubated at RT on a shaking platform 
for 1 h.  A blank reaction was also included to the 96-well plate, i.e. cell culture 
medium without cells.  The blank reaction was used to measure background 
luminescence associated with the culture system.  The value for the blank reaction 
was subtracted from experimental values.  Treatments were performed in triplicate 
and performed three times and normalised to cell numbers.  Enzymatic activity of 
caspase-3/7 was measured using a Luminometer (TopCount NXT, Packard 
Instruments, Meriden, CT).  
2.5 Measurement of total GSH by the DTNB-GSSG reductase recycling assay 
The total glutathione content of biological samples is conveniently determined with 
an enzymatic recycling assay based on glutathione reductase as described by the 
method of Griffith [304].  The recycling for total GSH is a sensitive and specific 
enzymatic procedure.  The GSH content was expressed as nmol per mg protein.  
PEO1 and PEO4 cells were seeded in 12 well plates at 1 x 106 cells /well for 48h and 
treated with cisplatin (25µM) and or vehicle (DMSO) for 24h.  On the day of the 
experiment, cells were treated with 0.5mM Diethyl maleate in 1ml of culture 
medium, by adding the drug directly to each well for 4h.  Treatment groups 
included cisplatin with or without DEM and nontreated cells with or without DEM.  
Cells were trypsinised, rinsed in cold PBS and centrifuged at 40C.  Cells were then 
resuspended in cold 5% sulfosalicylic acid, vortexed and centrifuged at 1300 rpm 
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for 5 min at 40C.  GSH depletion was determined at 4h by the GSH assay.  GSH is 
oxidized by 5, 5‘-dithiobis (2-nitrobenzoic acid)( DTNB) to give GSSG with 
stoichiometric formation of 5-thio-2-nitrobenzoic acid (TNB).  GSSG is reduced to 
GSH by the action of highly specific gluthatione reductase (GSSG reductase) and 
NADPH.  The rate of TNB formation was followed at 412nm and was proportional to 
the sum of GSH and GSSG present. 
2 GSH +DTNB                    GSSG +TNB                         (1)     
GSSG + NADPH + H +                       2 GSH + NADP+      (2) 
 
Reagents (from Sigma-Aldrich) were used as follows; the stock buffer consisted of 
sodium phosphate (143 mM) and Na-EDTA (6.3mM), final pH 7.5.  The daily buffer 
consisted of NADPH (0.248 mg/ml) prepared in stock buffer, stored at 40C and 
prepared daily.  DTNB (6mM) was prepared in stock buffer (stored frozen).  GSSG 
reductase (the yeast enzyme was diluted to final concentration 266 U/ml in stock 
buffer and stored at 4 0C.  GSH standards were diluted daily in 5-sulfosalicylic acid 
from frozen stock solution (100 mM GSH).  The reaction buffer consisted of 700 µl 
NADPH, 100 µl DTNB, 25 µl samples, 10 µl enzymes, 165 µl water.  965 µl of the 
reaction buffer (i.e., NADPH, DTNB, water) was warmed in a glass vial for 12 to 15 
min at 30 0C in a water bath.  25 µl of the sample was added and mixed.  This was 
followed by adding 10µl of the enzyme to initiate the reaction.  All reaction buffers 
were pipetted into a cuvette immediately before measurement.  The cuvette was 
covered with a clingfilm and mixed without any bubble.  The absorbance was read 
at 412nm in a UV spectrophotometer (Thermo Electron Corporation). 
 
 
Reductase 
GSSG 
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2.6 Radiopharmaceuticals  
[18F]FDG was purchased from Siemens Medical Solutions, UK and [18F]FLT were 
produced on-site by Imaging Research Solutions Ltd. (MRC Cyclotron Building, 
Hammersmith Hospital, London, UK).  [18F]FDG was produced by a stereospecific 
nucleophilic fluorination reaction followed by deprotection to obtain a no-carrier-
added product as reported previously [305].  [18F]FLT was prepared by 
radiofluoridation of the 2,3′-anhydro-5′-O-(4,4′-dimethoxytrityl)-thymidine 
precursor and has been described previously (GE Healthcare UK Limited) [306-307].  
The radiosynthesis of the caspase-3/7 high affinity inhibitor [18F]ICMT11 has been 
described previously [259].  [125I]ICMT1 was radiolabelled with iodine-125 (t1/2 = 
59.9 days) by iodo-destannylation using the method of Kopka [257].  The chemical 
synthesis of the precursor for [18F]fluciclatide has previously been described [271].  
Radiosynthesis was performed at Hammersmith Imanet on an automated module 
(TRACERlab FX F-N; GE Healthcare) by coupling an aminooxy-functionalised 
precursor of [18F]AH111585 with 4-[18F]fluorobenzaldehyde at pH 3.5 to form the 
oxime [18F]AH111585.  A full description of the synthesis has been published 
elsewhere [308].  All samples had >98% radiochemical purity as determined by 
high-performance liquid chromatography with radiochemical detection, and the 
specific radioactivity ranged from 76 to 170 GBq/μmol at the end of the synthesis 
for the tracers.  The synthesis of [18F]-1-deoxy-1-fluoro-scyllo-inositol has been 
previously described by the method of Vasdev [291].  The radiosynthesis of the 
stereoisomer [18F]-1-deoxy-1-fluoro-myo-inositol was carried out in an analogous 
fashion in our Lab by Laurence and co-workers [309].   
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2.7 Tumour induction and in vivo drug treatment 
Six to eight-week old female athymic BALB/c mice were obtained from Harlan, UK 
Ltd. (Bicester).  The in vivo experimental model (bilateral tumours) was established 
by s.c. injection of 100 µl of phosphate-buffered saline (PBS) containing 1x 107 of 
PEO1 or PEO4 ovarian cancer cells in 50% matrigel (BD Biosciences, UK) on the right 
and left shoulder region of the same mouse, respectively.  For IGROV1 and MDA-
MB-231 xenografts model, tumours were established by s.c injection of 100µl of 
phosphate-buffered saline (PBS) containing 5 X 106 cells and 1x107 cells in 50% 
matrigel respectively.  All procedures involving matrigel were carried out on ice to 
prevent polymerisation.  All animal work was performed by licensed investigators in 
accordance with the United Kingdom's ―Guidance on the Operation of Animals 
(Scientific Procedures) Act 1986‖ (HMSO, London, United Kingdom, 1998) [310]), 
and animal welfare guidance [311].  Tumour dimensions were measured 
continuously using a digital calliper and tumour volumes were calculated using the 
equation: volume = ( /6) x a x b x c, where a, b, and c represent three orthogonal 
axes of the tumour.   
When xenografts reached ~100-200 mm3, mice were randomised into 4 treatments 
groups.  1) In the first treatment scheduling (Figure 13A), mice were injected i.p., 
with API-2 and/or cisplatin, given once daily; the treatment groups were: vehicle 
(DMSO in PBS) [197], cisplatin dissolved in vehicle (5mg/kg, n=7-8), API-2 
dissolved in vehicle (1 mg/kg, n=7-8), or combination treatment (pre-treatment 
with 1 mg/kg API-2 for 1h followed by 5 mg/kg cisplatin) given once daily.  Also 
one pre-treatment group was included.  2) In the second treatment scheduling 
(Figure 13B), mice were injected i.p., with API-2 and/or cisplatin, given once daily 
over 3 consecutive days.  The treatment groups were: vehicle (DMSO in PBS) [197], 
cisplatin dissolved in vehicle (3 mg/kg, n=6), API-2 dissolved in vehicle (1 mg/kg, 
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n=6), or combination treatment (pre-treatment with 1 mg/kg API-2 for 1h followed 
by 3 mg/kg cisplatin).  All drugs were injected at a volume of 0.005 ml/g body 
weight.  Body weight was measured daily and doses given according to the weight 
of the mice.  PET imaging was performed 48h after the single dose, first treatment 
scheduling or 24h after the last dose of drug second treatment scheduling (Figure 
13).  3) For the antitumour study with NU7441, BALB/c mice-bearing bilateral PEO1 
and PEO4 tumour implants (n= 5 /group) were treated with single agent NU7441 (a 
gift from DR Euan Stronach; NU7441 were dissolved in DMSO as 10 mmol/L stocks 
and stored at −20°C.  NU7441 was formulated in 40% PEG 400 in saline and was 
given 10 mg/kg; i.p., daily over 3 days.  For combination treatment, NU7441 was 
given 1h before cisplatin (3 mg/kg in saline).  4) For the [18F]ICMT11 PET study, 
PEO4 tumour-bearing mice were randomised into 4 treatment groups, and mice 
were treated as described in the second treatment scheduling (Figure 13B).  5) For 
[18F]fluciclatide, [18F]fluoro-scyllo-inositol and [18F]fluoro-myo-inositol PET studies, 
PET dynamic scans were only performed at baseline in tumours-bearing mice with 
no treatment.  6) For the dose-dependent modulation study with API-2, mice 
bearing bilateral tumours were injected with 0 (vehicle; DMSO in PBS), 1, 10, 20, 30 
and 40 mg/kg API-2 (DMSO in PBS), i.p..  Tumours were excised after 1h treatment, 
snap-frozen in liquid nitrogen and stored at −80°C until analysis.  Blood glucose 
was measured from tail vein nicks.   
Mice were sacrificed by exsanguination after PET imaging and blood glucose was 
measured.  Parts of tumours were snap-frozen and formalin-fixed for Western blot 
analysis and immunohistochemistry (IHC) studies, respectively or other part of the 
tumours were kept for biodistribution study. 
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1st Treatment Regimen 
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4 treatment groups:
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Figure 13.  Summary of drug scheduling treatments used to assess imaging 
changes that occurred following combinations of cisplatin (CIS) and API-2. (A) 
Briefly for the 1st treatment regimen, mice were given single bolus injection of the 
drug, randomised into four treatment groups as shown.  An [18F]FDG scan was done 
48h later.  Tumours were excised for ex vivo validation by Western blot or 
immunohistochemistry (IHC).  (B) In the 2nd treatment regimen, mice were 
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randomised into four treatment groups, treated over 3 days, and [18F]FDG, [18F]FLT 
or [18F]ICMT11 scan were done on day 4.  Tumours were excised soon after the scan 
for further validation of imaging biomarkers. 
 
2.8 PET imaging 
Animals were scanned on a dedicated small animal PET scanner (Siemens Inveon 
PET module, Siemens Molecular Imaging Inc.) following a bolus i.v. injection of ~3.7 
MBq of either [18F]FDG, [18F]FLT, [18F]ICMT11, [18F]fluciclatide, [18F]-fluoro-scyllo-
inositol or [18F]-fluoro-myo-inositol.  Dynamic emission scans were acquired in 
list-mode format over 60 min.  The acquired data were then sorted into 0.5-mm 
sinogram bins and 19 time frames (4 x 15 s, 4 x 60 s, and 11 x 300 s) for image 
reconstruction, which was done by filtered back-projection using a two-
dimensional Hamming filter (cut off 0.6).  Cumulative images of the dynamic data 
(30 to 60 min) were iteratively reconstructed (OSEM 3D) and used for visualisation 
of radiotracer uptake and to define the regions of interest (ROIs) with the Siemens 
Inveon Research Workplace Software.   
2.9 Image Analysis and Quantification 
Cumulative images comprising of 30 to 60 min of the dynamic data were used for 
visualisation of radiotracer uptake and to draw regions of interest.  Regions of 
interest were defined on tumour and heart, liver or muscle-slices (each 0.5 mm in 
thickness).  Dynamic data from these slices were averaged for each tissue and at 
each of the 19 time points to obtain time versus radioactivity curves for these 
tissues (TAC).  Tumour radioactivity was corrected for physical decay and 
normalised to that of a reference tissue to obtain a standardised uptake value 
(NUV).  Tumour TACs were normalised to that of 1) liver ([18F]FLT, [18F]FDG [312]), 2)  
heart ([18F]-1-deoxy-1-fluoro-scyllo-inositol or [18F]-1-deoxy-1-fluoro-myo-
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inositol), 3) muscle ([18F]fluciclatide )or 4) whole body ([18F]ICMT11[313]), at each of 
the time points to obtain the normalised uptake value (NUV).  The NUV at 60 min 
post injection (NUV60) was used for comparisons.  The area under the NUV curve 
(AUC) was calculated as the integral of NUV from 0 to 60 min.  The fractional 
retention of tracer (FRT) at 60 min relative to that at 1.5 min was also calculated 
[314]. 
2.10 Direct counting of tissue radioactivity 
Tumour-bearing mice were administered a bolus injection of the tracer 
intravenously, via the lateral tail vein at a dose of 60–100 µCi (2.22–3.7 MBq).  The 
mice were sacrificed 60 min after radiotracer injection by exsanguination via cardiac 
puncture (under general anaesthesia with isofluorane inhalation).  Blood, normal 
tissues, as well as tumour samples were rapidly excised.  In addition plasma was 
obtained from heparinised blood following centrifugation.  All samples were 
weighed, and the radioactivity was measured using a Cobra II Auto-Gamma counter 
(formerly Packard Instruments Meriden CT USA Packard Instrument), applying a 
decay correction.  The results were expressed as %ID/g and tissue to blood ratio.   
2.11 Western blotting –In vitro lysates 
Pathway inhibition was examined by Western blotting analysis.  PEO1 and PEO4 cells 
were serum starved overnight, pre-treated with modulators API-2 (20 μM), 
LY294002(20μM) for 1h prior to adding cisplatin (25μM) or washing x2 with PBS 
then adding cisplatin (25µM).  Cells were lysed after 1h or 24h following exposure 
with modulators and/or cisplatin as indicated.  PEO1 and PEO4 cells were cultured 
in 6 cm dish (Falcon Labware, UK), and treated with control or drugs overnight in 
serum-free medium for various time periods.  The cells were rinsed in ice-cold PBS 
(x 2) and then extracted with lysis buffer (Radioimmunoprecipitation assay (RIPA) 
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containing 2 mM PMSF, 2mM NA3VO4, 2 mM NaF, aprotinin, leupeptin and pepstatin 
of 2 μg/ml each) supplemented with protease inhibitor tablets (Roche, UK) for 30 
min at 4°C, and centrifuged for 10 min, 2500 rpm at 4°C.  Protein concentrations of 
the samples were performed using the commercial bicinchoninic acid (BCA) protein 
assay kit (Perbio Science, UK).  For detection of proteins, 30 μg of protein was 
subjected to western blot analysis.  Samples were resuspended in Laemmli SDS 
(GIBCO) sample buffer, and analysed by immunoblotting.  Proteins were 
electrophoresed by SDS-PAGE (12 % acrylamide, GIBCO) and gels were blotted onto 
nitrocellulose filters using a Bio-Rad Mini Transblot apparatus (GIBCO) and blocking 
of non-specific binding was done with incubation for 1h with 5% fat free dry milk in 
TBS at RT and then overnight in primary antibody mixed with 5% BSA in TBS.  
Membranes were stained with the following primary antibodies at 1:1,000 dilution: 
phospho-PRAS40 (Thr246), PRAS40, phospho-AKT (Ser473), AKT (Cell Signalling 
Technology; Hichin, Herts, UK), for 16h at 40C.  Anti-rabbit or anti-mouse 
immunoglobulin secondary antibodies conjugated with horseradish peroxidase 
(1:1000, Cell Signalling Technology) were used.  
Blots were washed 15 min each (x 3) at RT with 0.025% Tween 20 in TBS.  The 
secondary antibody was diluted in 5% fat-free dry milk in TBS and added to blots for 
1 h at RT.  Blots were washed again at RT for 15 min each (x 3) in 0.025% Tween 20 
in TBS.  Specific signals were detected using an enhanced chemiluminescence (ECL) 
detection system (Amersham Pharmacia Biotech UK Limited, Buckinghamshire, UK) 
according to the manufacturer‘s protocol.  The extent of specific staining was 
quantified by chemiluminescence using the ECL kit.  Quantification of band 
intensities was performed on a GS-710 Calibrated Imaging Densitometer (Bio-Rad 
Laboratories, UK).   
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2.12 Immunohistochemistry (IHC) for GLUT-1 and Ki67 
GLUT-1 transporter expression and proliferative activity using the monoclonal Ki-
67 specific antibody MIB-1 (DAKO, Cambridgeshire, UK) were detected by IHC using 
the labelled streptavidin biotin (LSAB) procedure.  Tumours were fixed in 10% 
neutral buffered formalin and embedded in paraffin.  Slides containing formalin-
fixed, paraffin-embedded samples were deparaffinised in histoclear and rehydrated 
ethanol solutions of decreasing concentrations (100-70%).  The sections were 
subjected to heat-induced antigen retrieval by pre-treatment with sodium citrate 
buffer (DAKO), pH 6.0, in a microwave oven for 40 min at 10min interval.  The 
sections were left to cool for approximately 30 min.  Endogenous peroxidase was 
neutralised with 3% hydrogen peroxidase for 15 min.  The sections were rinsed in 
PBS (X 2), pH 7.4 for 5 min each.  Non-specific binding was blocked by incubating 
with 3 % bovine serum albumin (BSA, Sigma-Aldrich) for 1h.  For assessment of 
glucose transporter (Glut-1) expression, sections were incubated with rabbit 
polyclonal anti-human Glut-1 antibody raised against a 12-amino acid synthetic 
peptide corresponding to the carboxyl terminus of human Glut-1 (1:100, Millipore, 
Watford, Herts, UK) overnight at 40C.  The sections were then rinsed and detected 
with a streptavidin-biotin peroxidase kit (DAKO) according to the manufacturer‘s 
instructions.  Briefly, mouse anti-rabbit secondary antibody was applied to the 
slides for 25 min in a humidified chamber.  The slides were again washed and 
incubated with streptavidin peroxidase for an additional 25 min.  The peroxidase 
activity was developed with the substrate, 3, 3‘-diaminobenzidine 
tetrahydrochloride (DAB, DAKO) for 5 min.  Tissues were counterstained with 
haematoxylin (DAKO) and examined by light microscopy.  Areas of 
immunoreactivity for GLUT-1 were brown cytoplasmic membrane staining and Ki67 
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were brown nuclear staining.  Nuclei were blue (haematoxylin).  Negative control 
experiments were carried out by replacing the primary antibody with serum only 
which showed no nonspecific staining.  Images were captured on imaging camera 
using an Olympus BX51 microscope (Olympus, UK Ltd) at magnification x 400.  The 
degree of tumour proliferation was assessed in tumour sections as previously 
described [312, 314].  For each tumour section, the total number of Ki67-positive 
brown-stained cells and haematoxylin-stained cells were counted in 5 or more 
randomly selected fields of view using an Olympus BX51 microscope at × 400 
magnifications (two tumour sections/treatment groups).  The Ki67 labelling index 
(LIKi67) was calculated using the equation, LIKi67 = [Ki67-positive cells / (total cells)] 
× 100%.  
2.13 Double –labelled immunofluoresence for ki67 and CD31 in paraffin sections 
Paraffin sections (5μm) were used for histochemical analysis.  Sections were 
deparaffinised in histoclear for 20min (x 2).  Sections were rehydrated through 
graded alcohol (absolute alcohol) 100%, 95%, 90%, 70% for 5 min each (x 2) and 
distilled water for 5 min each.  Sections were not allowed to dry.  Pap pen was used 
to draw a hydrophobic circle around slide mounted-tissues.  Epitopes were 
unmasked with 20µg/ml proteinase K (Sigma-Aldrich) in PBS at RT for 30 min.  
Samples were incubated for 10 min with PBS containing 0.3% Triton X-100 (Sigma-
Aldrich).  Sections were washed in PBS for 5min (x 3).  Sections were blocked in 
blocking buffer (CAS BLOCK; GIBCO) for 30 min at RT.  Sections were incubated 
overnight at 40C, in the mixture of 2 primary antibodies in 1:50 dilution in blocking 
buffer [rat monoclonal anti CD31, clone MEC 13.3; (BD Pharmingen), and mouse 
monoclonal anti Ki67 (DAKO)].  CD31 was used as an endothelial cell-specific 
membrane protein.  The mixture solution was decanted, sections washed in PBS (X 
3), 5 min each.  Sections were incubated with the mixture of two secondary 
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antibodies (AlexaFluor 594 goat anti-rat 1in 400 dilutions in blocking buffer and 
AlexaFluor 488 goat anti-mouse 1in 400 dilutions in blocking buffer (GIBCO) for 1h 
at RT in the dark.  The mixture of secondary antibodies solution was decanted 
washed with PBS (x 3), 5 min each in the dark.  One drop of Antifade reagent with 
DAPI (GIBCO) was added and mounted with coverslip and viewed under the Olympus 
BX51 microscope.  
2.14 Detection of apoptosis on tumour sections by immunohistochemistry 
Tumour tissues were excised, fixed in formalin, embedded in paraffin, sectioned (5 
μm slices) and processed for active caspase-3 and DNA degradation terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) fluorescent detection 
assays using the Cleaved Caspase-3 (Asp 175) monoclonal antibody (Cell Signalling 
Technology) coupled with the Alexa Fluor 594 goat anti-rabbit (GIBCO) and the In 
Situ Cell Death Detection Kit (Roche), respectively.  The ProLong Gold Antifade 
mounting solution (GIBCO) containing 4′,6-diamidino-2-phenylindole (DAPI) was 
added to tissue sections prior to coverslip mounting.  All assays were performed 
according to the manufacturer instructions.  Images from two histological sections 
separated by 1 mm, 10 random fields per section (at 400× magnification), were 
captured using an Olympus BX51 fluorescent microscope. 
2.15 Western blot Analysis of tumour lysates 
Western blot analysis was done on excised frozen tumour material.  After the 
imaging studies, tumours were snap-frozen in liquid nitrogen and stored at −80°C 
until analysis.  Tumour xenografts were ground briefly in liquid nitrogen and 
homogenised with the PreCellys 24 (Bertin Technologies) in ice-cold lysis buffer 
[10mmol/L Tris (pH 7.5), 1mmol/L EDTA, 130 mmol/L NaCL, 1% Triton X-100, 10 
mmol/L NaPi, 10 mmol/L NaF, 1ug/ml microcyctin LR plus the protease inhibitors 
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aproptinin (10µg/ml), leupeptin (10µg/ml) and 2mmol/L phenylmethyl-sulfonyl 
fluoride, (Sigma-Aldrich)].  Homogenates were centrifuged at 12000 rpm at 40 C for 
15 min and the supernatants were recovered and aliquoted.  Protein concentrations 
of the lysates were determined using a BCA protein assay kit (Perbio Science).  For 
Western blot analysis, 50 µg of protein from the total cell lysate were 
electrophoresed by SDS-PAGE, 12 % acrylamide (GIBCO).  The proteins were then 
electrotransfered onto nitrocellulose membranes (Millipore), using transfer buffer 
(25 mmol/L Tris, 190 mmol/L glycine, and 10% methanol).  Membranes were 
treated with blocking buffer (50 mMol/L Tris, 200 mMol/L NaCl, 0.2% Tween 20, 5% 
nonfat dry milk) for 1h RT and incubated with 1:1,000 dilution of antibodies 
(phospho-p70S6K (Thr 389), p70S6K, phospho-Fox01, phospho-ribosomal protein 
S6 (Ser240/244), ribosomal protein S6 (rpS6), AKT, phospho-AKT ( Ser473) all from 
(Cell Signalling Technology) and GLUT-1, GLUT-3 and anti-TK1 (Abcam, 
Cambridge, UK) for 16 h at 4°C, after washing with washing buffer for 30 min, these 
primary antibodies were incubated with an anti-rabbit immunoglobulin secondary 
antibody conjugated with horseradish peroxidase 1:1000 (Cell Signalling 
Technology) for 1h.  Membranes were then washed with washing buffer and 
immune detection was done using the enhanced chemiluminescence (Amersham).  
For quantification of band intensities, the films were scanned using a GS-710 
Calibrated Imaging Densitometer (Bio-Rad Laboratories) and analysed with the 
Quantity One software (version 4.0.3; Bio-Rad Laboratories).  The molecular weight 
of the detected bands was estimated from molecular weight marker bands, which 
were blotted in parallel with the original samples.  
2.16 Hexokinase enzyme activity 
Hexokinase enzyme activity was determined by a modification of the method 
described by Shimke and Grossbard [315].  Briefly, tumours were ground in liquid 
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nitrogen, homogenised in 50 mmol/L Tris-HCl buffer (pH 7.6) at 40C, and 
centrifuged for 1 h (40C at 9,000 × g).  The supernatant was retained and assayed 
for total hexokinase activity in a reaction mixture comprising 1 mmol/L NADP, 5 
mmol/L glucose, 2 mmol/L MgATP, and 50 mmol/L Tris-HCl buffer (pH 7.6, all 
chemicals were from Sigma-Aldrich), at 220C, in the presence of 1 unit/mL of 
glucose-6-phosphate dehydrogenase (Sigma-Aldrich).  This reaction measures the 
release of NADPH by glucose-6-phosphate dehydrogenase after glucose activation 
by hexokinase; the rate of change in absorbance at 340 nm was determined over 20 
min in a UV spectrophotometer (Biomate, Thermo Electron Corporation).  Results 
were expressed as nanomoles of NADPH released (by hexokinase-induced glucose-
6-phosphate dehydrogenase activity) per min per milligram of cellular protein.  
2.17 Caspase enzyme inhibition assays  
Recombinant human caspases-1, -3, -6,-7, and -8 and their peptide-specific 
substrates [257] were purchased from Biomol International, UK.  Inhibition of the 
recombinant caspases by non-radioactive isatins was assessed using a fluorometric 
assay that measures the accumulation of a fluorogenic product, 7-amino-4-
methylcoumarin (7-AMC).  All assays were performed in 96-well plates at a volume 
of 200 µl per well.  The assays were performed at 370C in an appropriate reaction 
buffer as described below for each caspase.  For caspase 1, the buffer comprised of 
0.1% CHAPS, 100mM NaCl, 5mM 2-mercaptoethanol, 100 mM HEPES (pH 7.4), 2mM 
EDTA, 10% sucrose, and 10µM of the peptide substrate Ac-YVAD-AMC.  For caspase 
3: 20mM HEPES (pH 7.4), 10% sucrose, 100mM NaCl, 0.1% CHAPS, 2mM EDTA, and 
10 µM Ac-DEVD-AMC.  For caspase 6: 20mM HEPES (pH 7.4), 10 % sucrose, 100mM 
NaCl, 0.1% CHAPS, 2mM EDTA, and 10µM Ac-VEID-AMC.  For caspase 7: 20mM 
HEPES (pH 7.4), 10 % sucrose, 5mM 2- mercaptoethanol, 100mM NaCl, 0.1% CHAPS, 
2mM EDTA, 10µM Ac-DEVD-AMC.  For caspase 8: 20mM HEPES (pH 7.4), 10 % 
sucrose, 100mM NaCl, 0.1% CHAPS, 2mM EDTA, and 10µM Ac-IETD-AMC.  The 
108 
 
buffers contained non-radioactive isatins in DMSO at a final concentration of 500, 
50, 5 µM; 500, 50, 5nM; 500, 50, 5pM; the final concentration of DMSO in all wells 
was 5% of the total volume.  Recombinant caspases were used at 0.5 units per assay 
(~500 pmol substrate converted per h).  All reagents except the peptide substrate 
were pre-incubated for 10 min.  The peptide substrate (final concentration 10µM) 
was then added and the plate was incubated for a further 30min; the 30 min time 
point was selected after initial linearity study.  Reaction was also performed at 10, 
30, 60 or 90 min.  Respective control wells contained all reaction components 
without enzyme.  The amount of 7-AMC produced was measured on a fluorescence 
microplate reader (Victor3; Perkin-Elmer Life sciences) at excitation and emission 
wavelengths of 355 nm and 460 nm, respectively.  The concentration of isatin that 
inhibits the caspase activity by 50% (EC50) was estimated by non-linear regression 
analysis using GraphPad Prism (Version 3.0 for Windows, GraphPad Software, San 
Diego California USA).  All the isatins were analysed in duplicate. 
 
2.18 Binding studies of radiolabelled [125I]ICMT1 or [18F]ICMT11 to apoptotic cells in 
vitro 
The biological activities of radiolabelled [125I]ICMT1 and [18F]ICMT11 were evaluated 
in exponentially growing PEO1 and PEO4 cells.  For binding assay 2x 105 cells were 
used per well.  Cells treated with cisplatin (25 µM) for 24h (5% CO2 incubator at 
37°C) ± 20µM API-2 which was added 30 min prior to cisplatin treatment.  Control 
cells were treated with DMSO.  After incubation with 5µCi of radiolabelled tracer per 
sample for 1h, reaction was stopped with 1 ml ice-cold PBS.  Cells were lysed and 
centrifuged (5000 rpm. for 5 min at 4°C) to obtain the pellet.  The pellet together 
with the decanted supernatant was washed with ice-cold PBS (5ml) and centrifuged.  
Pellets were transferred to gamma tubes and radioactivity counted on a Packard 
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Cobra II gamma counter (Perkin–Elmer) to determine the percentage of radioactivity 
in labelled cells, i.e; % bound radioactivity =[100 x(bound radioactivity in treated 
cells –control)]/ (bound radioactivity in control cells) x protein content)].  After 
radioactive decay, pellets were lysed and aliquots were used for assessment of 
protein content using the BCA kit (Pierce).  All experiments were performed in 
quadruplate and repeated 3-4 times. 
 
2.19 Determining specificity of binding of [18F]ICMT11 determined with z-VAD-FMK 
in PEO4 cells 
 
PEO4 cells were plated in triplicate in 12-well plates at 4X 105 cells.  On the day of 
the experiment, PEO4 cells were treated with cisplatin (25 µM) for 24h with ± 20µM 
API-2 which was added 1h prior to cisplatin treatment.  Also included were vehicle-
treated cells (DMSO) and a treatment group whereby 30µM of z-VAD-FMK was 
added for 15 min to the combination-treated PEO4 cells prior to adding the 
radioactivity.  The experiment was carried out exactly as in section 2.17.  Data was 
expressed as counts per mg protein.  For the Caspase-Glo assay, PEO4 cells were 
treated using the same conditions as described above to induce apoptosis and 
Luminescent caspase-3/7 activation assay was performed on each sample 
according to the manufacturer's instructions (Caspase-Glo 3/7 assay, Promega, 
section 2.4).  Briefly, cells were transferred in a white opaque 96-well plate, 
incubated for 1h with Caspase-Glo reagent and the enzymatic activity of caspase-
3/7 was measured using a Luminometer (Topcount).  Experiments were repeated 3 
times.  
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2.20 Binding of [125I]ICMT1 to cellular model of necrosis as determine by binding 
activity and Caspase-Glo assay 
PEO1 and PEO4 cells were plated in triplicate in identical seedings in 12-well plates 
in conditions described above.  On the day of the experiment, cells were submitted 
to a 56 °C heat shock for 30 min or cold shock by immersing in liquid nitrogen for 
15 min to induce necrosis.  For the binding assay, 5µCi/well of [125I]ICMT1 was 
added to the cells and allowed to accumulate for 1h at 37 °C.  Reaction was stopped 
by adding ice-cold PBS, and washed in PBS (x 3).  Cells were trypsinised and 
collected.  Samples were transferred into gamma counting tubes and radioactivity 
was determined using a Packard Cobra II gamma counter (Perkin–Elmer).  Data was 
expressed as counts per dose solution.  For the Caspase-Glo assay, the cells were 
treated using the same conditions as described above to induce necrosis. 
Luminescent caspase-3/7 activation assay was performed on each sample 
according to the manufacturer's instructions (Caspase-Glo 3/7 assay, Promega, 
section 2.4).  Briefly, cells were transferred in a white opaque 96-well plate, 
incubated for 1 h with Caspase-Glo reagent and the enzymatic activity of caspase-
3/7 was measured using a Luminometer (Topcount).  Experiments were repeated 4 
times.  
2.21 In vitro-tritiated [3H]-myo-inositol uptake assay studies in IGROV-1 and 
SKOV3 cells 
IGROV-1 and SKOV3 cells were grown at seeding of 5 x104/well in 24-well opaque 
plate (Perkin-Elmer) in full growth medium as above until 50% confluent.  Cells were 
fed with fresh media for 24h prior to do the experiment.  All the chemicals were 
purchased from Sigma-Aldrich (UK), unless otherwise stated.  There were 4 
treatment groups at 2 different doses; 1: LY294002 (2, 20 µM), 2: Wortmannin (10, 
100 nM), 3: 2-APB (5, 50 µM), 4: control DMSO-treated cells (n=4 wells for each 
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treatment group).  Cells were treated with the above drugs at 1, 6 or 24h.  The cells 
were incubated with tritiated myo-inositol (Specific activity: 10-25Ci (370-925GBq 
)mmol; 1mCi (37MBq); Perkin- Elmer) at 2µCi/well in full medium for 1h, 370C.  
After the 1h incubation time point, the medium was removed by washing with ice-
cold PBS (x 3), the radioactivity in the wells was counted by counting the activity of 
the pellet.  200 µl of ice-cold Rippa buffer was added to each well on ice until cells 
were completely lysed.  30 µl of the cells lysates were taken and frozen for protein 
analysis (BCA protein assay kit), the remaining 170 µl of cell lysates was left to dry.  
Aliquots of 200 µl of scintillant (Microscint- 40; Perkin-Elmer) were added to each 
well and the radioactivity in each well was counted on a β-counter (TopCount).  
Data were expressed as % of control (counts per minute (cpm)/mg protein). 
2.22 Statistical Analysis 
 
Data were expressed as mean ± standard error of the mean (SEM) and the 
significance of comparison between two data sets was determined using Student's t 
test (Prism 3.03 software, GraphPad).  Group comparisons were assessed using the 
nonparametric Mann-Whitney test.  Correlations between tumour radiotracer levels 
and LIKi67 were determined (Pearson correlation).  Analysis of correlation was 
performed by linear regression.  Two-tailed P ≤ 0.05 were considered significant.   
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3.0 RESULT SECTION 
 
As part of the characterisation of the paired PEO1 and PEO4 phenotype, in vitro and 
subsequent in vivo evaluations were carried out. 
 
3.1 Cell lines Characterisation  
 
The optimal schedule of platinum modulation using API-2 was unknown at the start 
of the thesis.  Hence optimisation of the best treatment schedule was undertaken. 
This involved use of growth inhibition (SRB) and apoptosis (Caspase-Glo) assays. 
LY294002, which inhibits PI3K upstream of AKT, was used as a positive comparator 
in the in vitro system.  
 
3.1.1 Effect of API-2 on platinum sensitisation with continuous time -course 
exposure as assessed by SRB and Caspase-Glo in vitro   
In the sensitive cells (PEO1), treatment with cisplatin alone resulted in 50% cell 
growth inhibition compared to vehicle control (Figure14 A).  API-2 pre-treatment 
followed by cisplatin resulted in a 50% decrease in cell growth and modest increase 
in caspase 3/7 activation relative to cisplatin alone (Figure14 A, C).  In the resistant 
cells (PEO4) treatment with cisplatin alone resulted in only ~10% decrease in growth 
inhibition relative to vehicle control and the degree of caspase 3/7 activation was 
greater than vehicle treated cells but less than that seen with PEO1 cells.  In 
contrast, there was a 50% decrease in cell growth and increased caspase 3/7 
activation in the combination (Figure14 B, D) relative to cisplatin only, indicating 
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that API-2 resensitises platinum resistant cells.  Notably, pre-treatment time 
(schedule used: 1-24h) did not impact significantly on cell growth or caspase 3/7 
activity. The PI3 kinase inhibitor, LY294002, showed similar levels of 
growth/apoptosis modulation as API-2 indicating that the observed modulation 
may be a pathway effect.  In keeping with these findings, Altomare et al. [316] 
showed that LY294002 augments cisplatin-induced apoptosis in SKOV-3 cells, 
which exhibit constitutive AKT activity under low serum conditions.  By contrast, 
this effect was not observed in cell lines that had a low basal AKT activity.  API-2 
treatment alone had no effect (Figure15). 
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Figure 14.  Resensitisation of PEO1 and PEO4 ovarian cancer cells to platinum in 
vitro.  (A-D)  Cells were pre-treated with modulators API-2 (20μM), LY294002 
(20μM) at indicated time points prior to adding cisplatin (CIS; 25μM); control, 
equivalent amount of DMSO in media.  Cells were then exposed continuously to the 
modulators and cisplatin for 48h and then evaluated for growth inhibition (SRB 
assay) or apoptosis (Caspase-Glo assay).  Data are mean ± SEM of 4 independent 
experiments. 
 
The effect of API-2 alone on growth inhibition and apoptosis were assessed on 
PEO1 and PEO4 cells after 48h following a continuous time-course exposure to the 
drug (Figure 15).  A less than 50% cell growth inhibition was seen with treatment 
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compared to vehicle in the sensitive cell line (Figure 15A).  This effect was lesser in 
the resistant cell line (Figure 15B).  There was a modest increase in caspase 3/7 
activation relative to vehicle-treated PEO1 cells (Figure 15C) but less than was seen 
with the PEO4 cells (Figure 15D).  The schedules treatment (1-24h) used did not 
significantly have an impact on cell growth or caspase 3/7 activity. 
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Figure 15.  Effect of modulators, API-2and LY294002, on growth and apoptosis 
the absence of cisplatin of PEO1 and PEO4 ovarian cancer cells in vitro.  (E-G)  
Cells were pre-treated with modulators API-2 (20μM), LY294002 (20μM) at 
indicated time points; control were treated with equivalent amount of DMSO in 
media.  Cells were then exposed continuously to modulators for 48h and then 
evaluated for growth inhibition (SRB assay) or apoptosis (Caspase-Glo assay).  
Data are mean ± SEM of 3 independent experiments. 
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3.1.2 Effect of API-2 on platinum sensitisation with acute  time -course exposure as 
assessed by SRB and Caspase-Glo in vitro   
Given the effects of drug modulation demonstrated above, it was important to 
investigate if washout of modulator (simulating the in vivo situation) might abolish 
growth inhibition/apoptosis induction.  Growth inhibition and caspase 3/7 activity 
were unchanged with washing in the PEO1 cells (Figure 16E, G).  PEO4 cells were 
less sensitive in the growth inhibition assay following washing of cells but caspase 
3/7 activity remained high in these cells with washing (Figure 16F, H).  Again API-2 
treatment alone had no effect (Figure 17). 
 
 
          
          
 
 
 
 
 
 
 
 
118 
 
                    
A
PI
-2
LY
2
9
4
0
0
2
0
50
100
Control
CIS alone
1h
6h
12h
24h
C
e
ll
 v
ia
b
il
it
y
(%
 o
f 
c
o
n
t
r
o
l)
A
PI
-2
LY
2
9
4
0
02
0
1000000
2.010 0 6
3.010 0 6
C
a
s
p
a
s
e
 a
c
ti
v
it
y
 (
R
L
U
)
A
PI
-2
LY
29
40
02
0
50
100
C
e
ll
 v
ia
b
il
it
y
(%
 o
f 
c
o
n
tr
o
l)
A
PI
-2
LY
29
4
00
2
0
1000000
2.010 0 6
3.010 0 6
C
a
s
p
a
s
e
 a
c
ti
v
it
y
 (
R
L
U
)
A B
C D
PEO1 PEO4
 
Figure 16.  (A-D) Acute effects of modulators, API-2and LY294002, on growth and 
apoptosis in the presence of cisplatin.  To assess the acute effects (dosing and 
washout) of the modulators, cells were pretreated with the modulators API-2, 
LY294002 as above for indicated time points, after which modulators were removed 
by washing x2 with PBS.  The cells were then incubated with cisplatin (CIS) alone for 
48h and assessed for growth inhibition and apoptosis.  Data are mean ± SEM of 4 
independent experiments. 
 
We have also looked at whether treatment alone with modulator has an impact on 
cell growth inhibition or apoptosis induction (Figure 17).  Cell growth inhibition was 
unchanged following washing of modulator in the paired cells (Figure 17E, F) but 
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caspase 3/7 activity was even lesser in these cells following washing (Figure 17G, 
H).  LY294002 showed similar effects on both cell growth inhibition and apoptosis 
induction. 
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Figure 17. (E-H)  Acute effect of modulators, API-2 and LY294002, on growth and 
apoptosis in the absence of cisplatin.  To assess the acute effects of the 
modulators, cells were pretreated with modulators API-2, LY294002 as above for 
indicated timepoints, after which modulators were removed by washing x2 with PBS.  
The cells were then incubated with medium alone for 48h and assessed for growth 
inhibition and apoptosis.  Data are mean ± SEM of 3 independent experiments. 
 
The in vitro characterisation of the isogenic pair demonstrating constitutive 
activation of the PI3K/AKT pathway, is in keeping with published work from the 
Gabra Laboratory[296]. 
 
3.1.3 Effect of decitabine on resensitisation in vitro as assessed by SRB and 
Caspase-Glo 
To provide further clarity on mechanism of action, an alternate, pathway 
independent, mechanism of resensitisation was assessed involving the DNA 
methyltransferase (DNMT) inhibitor 5-aza-2_deoxycytidine (decitabine) [317]. 
Decitabine was combined with cisplatin using schedule treatment as described in 
Materials and Methods (2.2).  Growth inhibition and caspase 3/7 activity in the 
isogenic pair was evaluated (Please see Appendix A1).  Decitabine induces DNA 
demethylation and re-expression of epigenetically silenced genes, and is known to 
increase carboplatin sensitivity of tumour xenograft models [318].   Pretreating with 
decitabine for 1h followed by cisplatin reduces cell growth to less than 50 % in the 
paired cells, similarly a lesser caspase 3/7 activity was seen with combination 
treatment in PEO4 cells compare to combination treatment with API-2 and cisplatin 
in PEO1 cells. 
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3.1.4 Assessing the basis of the in vitro  sensitivity, by measuring level of p-AKT 
and its downstream target following pretreatment with API-2, by Western Blotting 
In all cases, comparison to biochemical changes occurring with drug treatment p-
AKT (S473) was established.  Furthermore, p-AKT expression was assessed at 
baseline. 
The growth-factor-stimulated phosphorylation of an AKT site, should be sensitive 
to pretreatment with PI3K inhibitors, such as LY294002 as class I PI3Ks are 
upstream activators of AKT and API-2, as an AKT inhibitor. 
PEO1 and PEO4 cells were serum starved overnight, pre-treated with modulators 
API-2 (20 μM), LY294002 (20μM) for 1h prior to adding cisplatin (25μM) or washing 
x2 with PBS then adding cisplatin (25µM) (Figure 18-19).  Cells were lysed after 1h 
(Figure 18) or 24h (Figure 19) following exposure with modulators and/or cisplatin 
as indicated. 
Western blot analysis of cell lysates following treatment with AKT pathway inhibitors 
and cisplatin showed reduction in p-AKT (S473) with corresponding loss in 
downstream p-PRAS40 (Thr246) following API-2 treatment in PEO4 cell lysates.  
This effect was seen at both 1- 24h with continuous treatment [Figures: 18 (B); 
19(F)] and were significant.  A reduction of p-AKT and p-PRAS40 were also seen in 
the PEO4 cell lysates after removing the modulator API-2 by washing (acute 
treatment).  This effect was reversed with acute treatment with LY294002 at both 
treatment time points [Figures: 18 (D); 19 (H)].  This reduction in p-AKT and p-
PRAS4O was also seen with the sensitive cell line at both time points [Figures: 18 
(A); 19(E)].   
LY294002, which inhibits PI3K upstream of AKT, was used as a positive comparator 
in the in-vitro system.  LY294002 appeared less effective in platinum sensitive 
PEO1 cells however reduced p-AKT and p-PRAS40 effectively in platinum resistant 
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PEO4 cells.  It has been shown that LY294002 greatly enhanced chemotherapy- or 
radiation-induced apoptosis and potentiated radiation-induced decreases in 
clonogenic cell growth in cells with high AKT levels.  LY294002 was ineffective in 
cells with low levels of AKT activity [319].   
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Figure 18.  Western blot analysis of AKT activation and its downstream target 
PRAS40 in the isogenic pair of PEO1 and PEO4 cells following treatment.  PEO1 and 
PEO4 cells were pre-treated with modulators API-2 (20μM), LY294002 (LY; 20μM) 
for 1h prior to adding cisplatin (CIS; 25μM).  Cells were lysed after 1h following 
continuous [(PEO1; A), (PEO4; B)] or acute [(PEO1; C), (PEO4; D)] exposure with both 
modulators and cisplatin.  Cells were probed for both p-AKT (S473) and p-PRAS40 
(Thr246) as readout of p-AKT expression.  Bar charts showed the densitometry 
analysis of phosphorylated protein normalised to their corresponding total protein 
content following the treatments indicated above..  β-actin was used as a loading 
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control.  Significant differences are indicated by asterisks.  A p value ≤ 0.05 is 
considered significant.  Data are mean ± SE of 3 independent experiments. 
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Figure 19.  Western blot analysis of AKT activation and its downstream target 
PRAS40 in the isogenic pair of PEO1 and PEO4 cells following treatment.  PEO1 and 
PEO4 cells were pre-treated with modulators API-2 (20μM), LY294002 (LY; 20μM) 
for 1h prior to adding cisplatin (CIS; 25μM).  Cells were lysed after 24h following 
continuous [(PEO1; E), (PEO4; F)] or acute [(PEO1; G), (PEO4; H)] exposure with both 
modulators and cisplatin.  Cells were probed for both p-AKT (S473) and p-PRAS40 
(Thr246) as readout of p-AKT expression.  Bar charts showed the densitometry 
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analysis of phosphorylated protein normalised to their corresponding total protein 
content following the treatments indicated above.  β-actin was used as a loading 
control.  Significant differences are indicated by asterisks.  A p value ≤ 0.05 is 
considered significant.  Data are mean ± SE of 3 independent experiments. 
 
3.1.5 Baseline level of p-AKT in the paired cell lines compare to other ovarian 
cancer cells 
As part of the characterisation of the isogenic pair use in these studies, p-AKT 
levels were determined by Western blotting in PEO1 and PEO4 tumour cells and 
compared with other ovarian cancer cells, including OVCAR-3 which is known to 
have an aberrant AKT activity (Figure 20).  Baseline expression of p-AKT activity was 
detected in the paired cells which further them to be a good model to use with API-
2.  OVCAR-3 was used here as a positive control.  The p-AKT levels varied in other 
ovarian cancer cell lines examined (Figure 20), AKT activated under normal cell 
conditions varied between cell types, and this might have implication when using an 
AKT inhibitor which only inhibit ovarian cancer cells overexpressing AKT[197].  
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Figure 20.  Baseline expression of p-AKT (S473) in the isogenic pair PEO1 and PEO4 
compared with other ovarian carcinoma cell lines.  OVCAR-3 that constitutively 
express active AKT was first used by Yang group [99] in a xenograft tumour model 
to show tumour growth inhibition by API-2 and was used here as a positive control.  
β-actin was used for equal loading of protein. 
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3.2 Initial investigation of the biological action of platinum and AKT 
modulation in vivo as evaluated by [18F]FDG PET  
 
To investigate if imaging approaches could be used to evaluate the efficacy of 
modulating platinum resistance, a bilateral xenograft model comprising of PEO1 
and PEO4 tumours was established.  This model was then used together with 
[18F]FDG-PET to assess platinum resensitisation, initially after a single dose.  Our 
group has demonstrated in a mouse tumour model that sensitivity to cisplatin is 
also detectable by [18F]FDG-PET [320].  This could be due in part to regulation of 
glucose transporters and hexokinase activity by hypoxia inducible factor-1 or 
oncogenes [321].  We investigated whether platinum resistance has a direct effect 
on glucose metabolism in the isogenic tumour pairs by [18F]FDG-PET. 
 
3.2.1 [18F]FDG-PET study in PEO1 and PEO4 tumour-bearing mice following the first 
schedule treatment                                                                   
Based on previous work [322], the effects of cisplatin, API-2 alone and in 
combination, were examined to assess the effects of treatment on tracer uptake.  
To optimise the response to API-2, based on the work of Yang [197]  and on our in 
vitro model, BALB/c mice were inoculated s.c. with PEO1 and PEO4 (bilateral 
implants).  Once tumour reached 100-200mm3, mice were randomly placed into 
four groups and were given a single i.p., dose, of the following treatment with 
vehicle control (DMSO); 2) cisplatin (5mg/kg); API-2 (1mg/kg); API-2 and cisplatin 
where API-2 was given 1h followed by cisplatin (Figure 13A, Materials and 
Methods).  
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[18F]FDG scans were performed 48h later, as illustrated in Figure 21B.  A small 
decrease in tracer uptake was seen with combination treatment in both PEO1 and 
PEO4 tumours (Figure 21C).  A small significant difference was seen in the PET 
parameters, AUC and NUV60 with combination treatment compared to single 
treatment in both tumour types (Table 2), however FRT remained unchanged in all 
treatment groups.  There were no significant changes in tumour sizes in the 
treatment groups (Figure 21 A). 
The 5mg/kg single dose of platinum was selected based on work by Leyton and co-
workers within our group[312]; and the 1mg/kg API-2 dose was selected based on 
the work of Yang [197] in tumour overexpressing AKT.  Because a small change was 
seen with this schedule, treatment was changed to 3 single doses given i.p., over 3 
days, followed by an [18F]FDG or [18F]FLT scan 24h after the last dose was given 
(Figure 21B).  To ensure that the dosing schedule will be non-toxic, we assessed in 
a separate cohort of mice, prior to the imaging study, the effect of cisplatin 
(3mg/kg, i.p.,) over 5 days by monitoring the weight of the mice were over that 
period.  There was no significant loss in weight compared with the weight of the 
mice prior to start of the experiment, except for 1 mouse that lost ~ 20% body 
weight and was as such immediately sacrificed; this mouse was 16g prior to start of 
treatment (this data set was left out and not included here).  Overall the mice 
tolerated the dosing regimen well.  As part of the initial optimisation of treatment, a 
baseline group (as opposed to vehicle treated) was also included, where mice-
bearing bilateral tumour implants, were subjected to an [18F]FDG scan prior to any 
treatment.  PET parameters did not change significantly between the baseline group 
and vehicle-treated group, in both tumour types indicating that vehicle treatment 
with DMSO alone did not have an effect on tracer uptake.  
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Figure 21.  Effect of first schedule treatment on glucose metabolism as assessed by 
[18F]FDG PET.  (A) Effect of drugs on tumour size of PEO1 and PEO4 xenografts in 
mice.  Mice were randomised into 4 treatment groups; vehicle as a single dose; API-
2 as a single dose (1mg/kg/day); cisplatin (CIS) as a single dose (5mg/kg/day; i.p.,) 
or combination treatment involving 1h pretreatment with API-2 followed by 
cisplatin treatment.  Day 0 was start of treatment and Day 2 was 48h after 
treatment.  The graph represents the mean tumour volume as a % of control (n=6-8 
for each group).  (B) [18F]FDG-PET images of PEO1and PEO4 tumour-bearing mice 
acquired on a Siemens Inveon PET(/SPECT/CT) animal scanner.  (C) Tumour TACs, 
normalised to the liver radioactivity, obtained from untreated and treated mice 
[PEO1 and PEO4)]; 48h after treatment).  TACs were derived from 60 min [18F]FDG-
PET scanning of tumour-bearing mice after i.p., injections of vehicle or combination 
treatment (cisplatin 5mg/kg/day and 1mg/kg/day API-2).  Points, mean 
radioactivity per unit volume (comprising of several slices) at each of 19 midframe 
times in tumour normalised to that of liver (n=7-8 tumour per group); bars, SEM. 
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PEO1 
 
Tumour (n=7-9) Baseline Vehicle      API-2 Cisplatin CIS +API-2 
      AUC    68.3±2.9     
   
 63.3±3.8               57.5±3.7        58.8±3.7       50.9±2.3* 
      
     NUV 60 1.44±0.08 
 
1.42±0.09 1.25±0.08    1.25±0.09     1.1±0.05† 
      
      FRT    3.96±0.77 
 
5.76±0.49 4.3±0.37‡       4.86±0.77  4.95±0.54 
                                         *p ≤ 0.0283        † p≤0.0096       ‡ p≤ 0.0312 
 
PEO4 
 
Tumour (n=7-
9) 
Baseline Vehicle API-2 Cisplatin CIS+ API-
2 
     AUC 60.8±2.5 64.8±2.5 59.5±5.2 59.4±3.2 51.2±3.5
** 
      
    NUV 60 1.44±0.15 1.39±0.08 1.41±0.08 1.33±0.12 1.12±0.1
8† 
      
     FRT 5.38±0.93 4.81±0.77 5.06±0.43 4.25±0.52 4.87±0.4
5 
           ** P≤ 0.0083      † P ≤ 0.034 
 
Table 2.  Uptake of [18F]FDG into PEO1 and PEO4 tumours, as determined in vivo by 
means of dynamic PET imaging. 
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3.2.2 Ex vivo gamma (γ)-Counting of tissue distribution of [18F]FDG after single 
dosing regimen  
To obtain more detailed evaluation of tissue distribution, a biodistribution study 
was performed immediately after PET imaging (60 min).  Uptake of tracer in tumour 
and other tissues, were measured ex vivo soon after the scan and expressed as 
tumour to blood ratio (Table 3).  There was no significant difference in [18F]FDG 
uptake between PEO1 and PEO4 tumours in all treatment groups.  This could be 
partly explained by the fact only a fraction of the tumour was taken for counting 
and also tumours are highly heterogeneous in nature. 
Uptake in heart was high compared to other tissues.  Since uptake in liver was low, 
liver was used as reference tissue in deriving TACs; this was also based on the 
method of Leyton et al. [312].  
Liver was chosen as the reference region because the localisation of [18F]FDG within 
mouse liver is low due to high glucose-6-phosphatase levels [323]; and the 
variability in determining the radiotracer kinetics in liver tissue is low due to its 
size.  Liver TAC profiles were examined with all treatment groups; there were no 
statistically differences between treatment groups (Please see, Appendix A2).  
γ-counting of radioactivity levels in liver tissue excised immediately after PET 
imaging, showed no statistically significant differences in liver percent injected 
activity per gram of tissue for vehicle- and drug-treated mice (Table 3).  Similarly, 
liver was chosen as the reference tissue for the [18F] FLT studies, because [18F] FLT 
uptake in mouse liver is low due to a lack of glucuronidation in the mouse, 
compared with humans [324]. 
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 Baseline  Vehicle API-2 Cisplatin CIS + API-2 
PEO1 4.05±0.72 4.03±0.42 3.32±0.51 4.33±0.78 3.00±0.18 
PEO4 4.11±0.92 4.58±0.46 3.96±0.46 3.98±0.59 3.33±0.15 
Plasma 1.47±0.12 1.13±0.29 1.38±0.29 0.86±0.15 1.06±0.08 
Liver 2.30±0.48 1.87±0.23 2.05±0.25 2.28±0.31 1.65±0.14 
S.intestine 2.90±0.54 3.05±0.39 3.66±0.55 4.2±0.55 3.36±0.36 
Muscle 1.47±0.36 1.21±0.25 1.68±0.54 1.61±0.27 1.07±0.19 
Heart 58.±13.5 32.6±3.82 56.5±9.8 57.7±6.12 41.1±6.12 
 
 
 
3.2.3 Determining tolerability effect of treatments by monitoring weight of mice 
and blood glucose level 
To check whether cisplatin was toxic to the mice, body weight was measured prior 
to treatment and during the treatment, and also given that API-2 inhibits AKT, 
which signals through the insulin pathway, blood glucose was measured soon after 
the scan (Table 4).  There were no detectable differences in body weight and 
glucose levels between the vehicle control group and drug-treated groups 
indicating that the treatment schedule did not cause obvious toxicity. 
 
 
Table 3.  Biodistribution of [18F]FDG in BALB/c bearing PEO1 and PEO4 tumours, 
as determined by ex vivo gamma counting.  Tissues were excised 60 min after 
radiotracer administration.  [18F]FDG uptake is expressed as tumour to blood 
ratio; data are mean ±SEM (n=6-8).  
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                        PEO1                          PEO4 
 Weight (g) Blood glucose 
(mmol/L) 
Weight (g) Blood glucose 
(mmol/L) 
  Baseline 19.6±0.37 6.2±1.22 19.6±0.37 6.18±1.22 
  Vehicle 19.2±0.25 8.9±0.12 18.9±0.7 7.15±0.79 
   API-2 19.0±0.24 8.3±0.64 19.3±0.2 7.59±0.96 
  Cisplatin 19.4±0.37 6.5±0.17 19.9±0.2 7.21±0.39 
 CIS + API-2 20.0±0.34 8.17±1.16 19.9±0.4 8.17±1.16 
 
 
3.2.4 In search of a biomarker of AKT as the drug target in vivo, following 
treatment with API-2 
As part of the initial in vivo characterisation of the treatment response, tumour 
lysates were analysed by western blotting to see whether API-2 +/-cisplatin 
blocked the PI3K/AKT pathway in vivo.  Tumours were harvested from the mice 
treated with vehicle (control), cisplatin alone, API-2 alone, or cisplatin + API-2 
combination and were assessed for AKT phosphorylation status and other 
downstream targets of AKT: p-Fox01, p-P70S6K, p-S6, in both PEO1 and PEO4 
tumours.  AKT and other PI3 kinase/Akt biochemical pathway markers such as 
phospho-p70S6K (Thr389), and phospho-S6 ribosomal protein (Ser240/244) did 
Table 4.  Effect of drug treatment on body weight and blood glucose.  Because 
AKT is a critical regulator of insulin signalling, blood glucose was measured in 
all treatment groups.  Blood glucose level measured immediately after the 
imaging session (Glucose monitoring system, Ref:70917-01, Abbott Diabetes 
Care Ltd, Oxon) did not vary between all treatment groups, indicating that the 
compound was well tolerated in vivo following i.p., treatment for 1 day.  No 
weight loss was seen in treated animals (n=6-8 mice per treatment group). 
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not change consistently with cisplatin, API-2 or combination treatment, suggesting 
that, at the drug concentration and first schedule treatment used, Akt activity did 
not necessarily translate to activity on all downstream targets (data not shown). 
 
3.2.5 Level of hexokinase kinase activity at baseline in PEO1 and PEO4 tumours 
 
Tumour cells are known to be highly glycolytic and high activity of hexokinase, a 
key enzyme in glucose metabolism, has been documented in various cancers 
including the ovarian cancer.  Given that the activity of hexokinase exerts a 
profound effect on the overall rate of glucose uptake, and activated forms of AKT 
have been shown to stimulate hexokinase activity [325], levels of hexokinase 
activity were measured at baseline in the isogenic pair.  The hexokinase activity was 
assayed in a system coupled with glucose-6-phosphate dehydrogenase [315] as 
described in Materials and Methods (2.16). 
Baseline hexokinase activity was significantly higher in PEO4 tumours compared to 
PEO1 tumours (Figure 22). 
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Figure 22.  Baseline hexokinase activity was determined in PEO1 and PEO4 tumours 
spectrophotometrically as described in Materials and Methods and expressed in 
units of activity per milligram of cellular protein.  Significant difference is indicated 
by asterisk, p=0.0207. 
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3.3 Investigation of the biological action of continuous administration of 
platinum and API-2 in modulating AKT activity as evaluated by both 
[18F]FDG-, [18F]FLT- and [18F]ICMT11-PET in vivo 
 
As the single dose of drug was ineffective, a continuous dosing scheme was 
established.  In this case both [18F]FDG- and [18F]FLT-PET were used as measures of 
early tumour response.  As seen with [18F]FDG-PET, most of the platinum resistance 
factors described to date control cellular proliferation and DNA replication.  Our lab 
has demonstrated in a mouse tumour model that sensitivity to cisplatin is 
detectable by [18F]FLT-PET [320].  This technique was also used to assess drug 
resistance. 
 
3.3.1 API-2 resensitises PEO4 tumour xenografts to platinum in vivo 
The efficacy of API-2 and cisplatin on PEO1 and PEO4 tumour–bearing mice was 
determined by measuring changes in tumour volume.  The effects of daily API-2 
and cisplatin treatment (5 days treatment) on growth of established bilateral PEO1 
and PEO4 xenografts were compared (Figure 23).  Tumour growth profiles were 
similar between the two tumour types (vehicle treated).  Cisplatin alone and the 
combination of API-2 and cisplatin decreased PEO1 tumour volumes by day 14 
compared to vehicle control and API-2 alone groups.  In contrast, only the 
combination treatment caused significant tumour shrinkage in PEO4 tumours 
(Figure. 23B).  
 
 
 
 
139 
 
                               
               
0 5 10 15
50
100
150
Cisplatin
API-2
CIS + API-2
PEO1
A
Days after treatment
T
u
m
o
u
r
 V
o
lu
m
e
(%
 o
f
 C
o
n
t
r
o
l)
0 5 10 15
50
100
150
Cisplatin
API-2
CIS + API-2
B
PEO4
Days after treatment
T
u
m
o
u
r
 V
o
lu
m
e
(%
 o
f
 C
o
n
t
r
o
l)
* p=0.0139
** p=0.0089
* p=0.0174
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23.  Effect of drug treatment on tumour sizes following a longitudinal study.  
Mice were randomised into 4 treatment groups, Vehicle (DMSO), 1mg/kg/day API-2, 
3mg/kg i.p cisplatin (CIS), or API-2 and cisplatin combination treatment given as 
API-2 followed 1h later by cisplatin.  Treatment was given daily over 5 days.  Tumour 
growth was monitored by callipers for 14 days after completion of treatment.  Graph 
represents the mean tumour volume (n=5-6 for each group) expressed as a 
percentage of mean size at the start of treatment.  bars SEM  
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3.3.2 Measuring early responses to treatment using [18F]FDG -and [18F]FLT-PET 
imaging biomarkers 
For the PET imaging studies, tumours were randomised into 4 treatment groups 
when they reached a size of ~150-200 mm3, as described in Materials and Methods. 
Daily i.p., treatment was over 3 days and PET imaging was done on day 4.  
In this group of animals tumour sizes were measured and compared to the imaging 
data.  There was a small reduction in PEO1 tumour sizes after cisplatin and 
combination treatments compared to vehicle treatment (Figure 24A).  However only 
a small decreased in PEO4 tumour sizes were observed with combination treatment 
(Figure 24B) over the day 4 periods. 
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Figure 24.  In vivo resensitisation of PEO1 (A) and PEO4 (B) tumour to cisplatin 
assessed by callipers.  Effect of drug treatment on tumour size.  Mice were 
randomised into 4 treatment groups, Vehicle (DMSO), 1mg/kg/day API-2, 3mg/kg 
i.p cisplatin (CIS), or API-2 and cisplatin combination treatment given as API-2 
followed 1h later by cisplatin.  Treatment was given daily over 3 days.  Day 0 was 
start of treatment and Day 4 was 24h after the last dose.  Significant differences 
are indicated by asterisks.  Graph represents the mean tumour volume (n=6 for 
each group); bars SEM. 
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3.3.3 [18F]FDG- and [18F]FLT-PET are sensitive imaging biomarkers of platinum 
resensitisation 
The biological effects of AKT activation results in increase cell proliferation and 
glucose metabolism, thus the potential of [18F]FDG-and [18F]FLT-PET as imaging 
biomarkers were assessed here, to measure early cytostasis induced by drug 
treatment of PEO1 and PEO4 tumour–bearing mice. 
[18F]FDG is widely available in the clinic and is routinely used as a noninvasive 
marker for diagnosis and staging of cancer.  The potential utility of [18F]FLT for the 
noninvasive detection of cell proliferation by PET was first reported by Shields et al 
[231].  [18F]FLT undergoes monophosphorylation to [18F]FLT-phosphate catalysed by 
the cytosolic enzyme thymidine kinase 1 (TK1), which being cell cycle regulated, 
provides a surrogate measure of cells in S phase of the cell cycle [326].  
[18F]FDG-PET (Figure 25) and [18F]FLT-PET (Figure 27) images from representative 
control and treated mice are shown.  [18F]FDG uptake in PEO1 and PEO4 tumours 
were clearly visible in vehicle-treated mice (Figure 25A, C), with diminution of 
signal following combination treatment in the paired tumours (Figure 25B, D).  
Similarly, a decreased in [18F]FLT uptake was seen following combination treatment 
in the paired tumours (Figure 27F, H) compared to vehicle-treated tumours (Figure 
27E, G). 
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[18F]FDG- and [18F]FLT-PET TACs in PEO1 and PEO4 bearing animals treated with 
vehicle, cisplatin or API-2/cisplatin combination for 3 days are shown (Figure 26 
and 28).  The lack of a change in both [18F]FDG and [18F]FLT TACs of PEO4 mice 
treated with cisplatin compared to similarly treated PEO1 mice characterised the 
differences in responsiveness or resistance of the two xenograft models.  The 
Figure 25.  In vivo resensitisation of PEO1 and PEO4 tumour to cisplatin (CIS) 
assessed by imaging.  Typical (0.5mm) transverse [18F]FDG-PET images, taken 
from the late (30-60 minutes summed) time frame after i.v injection of the 
radiotracer in vehicle- and drug-treated PEO1 (A, B) and PEO4 (C, D) BALB/c 
tumour-bearing mice respectively.  Data were acquired on a Siemens Inveon 
PET/SPECT/CT animal scanner.  Qualitative image intensity bar is provided.  Note: 
Bilateral tumours on the back of the mice were imperfectly aligned in the same 
plane; hence, maximum tumour plane for either tumour is shown (white arrow). 
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reduction in [18F]FLT and [18F]FDG time versus radioactivity curves after combination 
treatment compared with vehicle in the PEO4 xenograft model suggested 
resensitisation to platinum.  
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 Figure 26.  [
18F]FDG TACS.  A summary of the TACs expressed as tumour  
radioactivity normalised to liver radioactivity at each of 19 timepoints in vehicle-
and drug treated animals; PEO1-(top panel) and PEO4-(bottom panel) BALB/c 
tumour bearing mice for all treatment groups (3 mg/kg cisplatin; (CIS) and 
1mg/kg/day API-2 combination).  Data are mean ± SEM (n=6 group). 
144 
 
                                       
E- Vehicle
F- CIS + API-2
G-Vehicle
H- CIS + API-2
100%
0%
PEO1 PEO4
[18F] FLT SCAN
 
 
 
 
 
 
 
 
 
 
Figure 27.  In vivo resensitisation of PEO1 and PEO4 tumour to cisplatin (CIS) 
assessed by imaging.  Typical (0.5mm) transverse [18F]FLT-PET images, taken 
from the late (30-60 minutes summed) time frame after i.v injection of the 
radiotracer in vehicle- and drug-treated PEO1 (E, F) and PEO4 (G, H) BALB/c 
tumour-bearing mice.  Data were acquired on a Siemens Inveon PET/SPECT/CT 
animal scanner.  Qualitative image intensity bar is provided.  Note: Bilateral 
tumours on the back of the mice were imperfectly aligned in the same plane; 
hence, maximum tumour plane for either tumour is shown (white arrow). 
 
 
 
145 
 
                               
0 10 20 30 40 50 60
0.0
0.5
1.0
1.5
2.0
Vehicle
CIS
Time (min)[
1
8
F
]F
L
T
 N
U
V
 (
P
E
O
1
)
0 10 20 30 40 50 60
0.0
0.5
1.0
1.5
2.0
Vehicle
API-2
Time (min)[
1
8
F
]F
L
T
 N
U
V
 (
P
E
O
1
)
0 10 20 30 40 50 60
0.0
0.5
1.0
1.5
2.0
Vehicle
CIS+API-2
Time (min)[
1
8
F
]F
L
T
 N
U
V
 (
P
E
O
1
)
0 10 20 30 40 50 60
0.0
0.5
1.0
1.5
2.0
Vehicle
CIS
Time (min)[
1
8
F
]F
L
T
 N
U
V
 (
P
E
O
4
)
0 10 20 30 40 50 60
0.0
0.5
1.0
1.5
2.0
Vehicle
API-2
Time (min)
[1
8
]F
L
T
 N
U
V
 (
P
E
O
4
)
0 10 20 30 40 50 60
0.0
0.5
1.0
1.5
2.0
Vehicle
CIS+API-2
Time (min)[
1
8
F
]F
L
T
 N
U
V
 (
P
E
O
4
)
P
E
O
1
P
E
O
4
       
      
Figure 28.  [18F]FLT TACS.  A summary of the TACs expressed as tumour 
radioactivity normalised to liver radioactivity at each of 19 timepoints in vehicle-and 
drug treated animals; PEO1-(top panel) and PEO4-(bottom panel) BALB/c tumour-
bearing mice for all treatment groups (3 mg/kg cisplatin (CIS) and 1mg/kg/day API-
2 combination).  Data are mean ± SEM (n=6 group). 
 
A summary of all kinetic radioactivity uptake variables for all four treatment groups 
are presented in Table 5.  In the [18F]FDG study (Table 5A), the NUV60 values 
decreased significantly with combination treatment compared with vehicle 
treatment in PEO1 tumour (1.4 ± 0.0 versus 0.8 ± 0.0; p= 0.0022); significant 
changes were also seen in this sensitive model with cisplatin only (1.4 ± 0.0 versus 
1.0 ± 0.0; p=0.021) and API-2 only treatment (1.4 ± 0.0 versus 1.0 ± 0.0; 
p=0.0086).  A decreased in [18F]FDG uptake was, however, only observed in PEO4 
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tumour with combination treatment (1.4 ± 0.1 versus 0.8 ± 0.1; p=0.006), of a 
similar magnitude to the decrease observed with cisplatin alone in the cisplatin 
sensitive xenograft PEO1 suggesting that API-2 induced near complete reversal of 
platinum resistance.  There was also a small decrease in tracer uptake with API-2 
treatment alone that was not significant, but no decrease associated with platinum 
alone in the platinum resistant tumour xenograft PEO4.   
The effects of treatment were similar for [18F]FLT-PET (Table 5B), although with this 
tracer, no change was seen in PEO4 xenografts with either platinum or API-2, and 
only significant decreased was seen with the combination, of a magnitude similar to 
PEO1 with cisplatin alone, suggesting near complete reversal of platinum resistance. 
The variable AUC and NUV60 were found to be sensitive for discriminating between 
vehicle and drug-treated tumour in the paired tumours with both [18F]FDG- and 
[18F]FLT-PET.  FRT was unchanged with both tracers between all treatment groups 
(data not shown). 
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Table 5.  Summary pharmacokinetic PET variables for (A) [18F] FDG and (B) [18F]FLT 
obtained from the time versus radioactivity curve in vehicle-, cisplatin (CIS), API-2, 
cisplatin and API-2 combination-treated PEO1 and PEO4 BALB/c tumour-bearing  
mice.  Significant differences are indicated by asterisks. 
 
 
          Vehicle       API-2                     
(1mg/kg) 
Cisplatin 
    (3mg/kg) 
   CIS +API-2 
          
A    NUV60      AUC   NUV60  AUC NUV60 AUC NUV60 AUC 
[18F] 
FDG 
PEO1   1.4± 
  0.0 
   59.3± 
   1.4 
  1.0± 
  0.1† 
 42.9± 
 2.5† 
 1.0± 
 0.5† 
 47.6± 
 1.8* 
 0.8± 
 0.0‡ 
28.± 
 2.6‡ 
 PEO4   1.4± 
  0.1 
   62.2± 
    3.2 
  1.2± 
  0.8 
 52.6± 
 2.4 
 1.3± 
  0.9 
 64.4± 
 5.0 
 0.8± 
 0.1‡ 
32.± 
 4.6‡ 
B          
[18F] 
FLT 
PEO1   1.2± 
  0.1 
   60.6± 
   1.3 
  1.0± 
  0.1* 
 51.1± 
 2.2* 
 1.0± 
  0.1* 
 44.5± 
 3.5† 
 1.0± 
 0.1* 
49.± 
 4.9† 
 PEO4   1.3± 
  0.0 
   67.5± 
   2.4 
  1.2± 
  0.0 
 62.7± 
 2.4 
 1.2± 
  0.1 
 66.1± 
 2.9 
1.0± 
0.1‡ 
46.± 
2.9‡ 
          
 
Note : Data are mean ± SE (n=6).  Abbreviations: NUV60, normalised uptake value at 
60 min.  AUC, area under the curve. 
[18F]FDG PEO1:  †; 0.02<P≤0.005, *; P> 0.02; ‡; 0.0004≤P<0.0001 
[18F]FDG PEO4: ‡; 0.0004≤P<0.0001 
[18F]FLT PEO1: †; P<0.005, *; 0.005<P>0.02 
[18F] FLT PEO4: ‡; 0.0001<P< 0.0005 
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3.3.4 Biodistribution studies following the [18F]FDG- and [18F]FLT-PET imaging in 
the second treatment scheduling   
Table 6 and 7 summarise the results of the [18F]FDG and [18F]FLT biodistribution 
studies in both treated and untreated mice.  For [18F]FDG, there was a significant 
lower tracer uptake in the combination treatment group compared to vehicle-
treated group in PEO4 tumours.  Although a slightly lower uptake of tracer was seen 
in cisplatin- and combination-treated in PEO1 tumours, this difference was not 
statistically significance (Table 6).  For [18F]FLT, there was a significantly lower tracer 
uptake with combination treatment compared to vehicle-treated mice in the PEO4 
tumours.  Significant differences were seen between vehicle-treated and drug-
treated PEO1 tumours (Table 7).  Radiotracer uptake was higher in untreated PEO1 
and PEO4 tumours with [18F]FDG compared to untreated PEO1 and PEO4 tumours 
with [18F]FLT.  This difference was not statistically significant.  Uptake of either 
[18F]FDG or [18F]FLT was generally low in tissues such as liver, muscle and small 
intestine. 
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Table 6.  [18F]FDG biodistribution study following 3 days treatment in BALB/c PEO1 
and PEO4 tumour-bearing mice as determined by ex vivo gamma counting.  Tissues 
were excised 60 min after radiotracer administration.  [18F]FDG uptake is expressed 
as tumour to blood ratio; data are mean ± SEM (n=6). 
 
    Vehicle          API-2     Cisplatin CIS + API-2 
      Blood    1.00±0.00     1.00±0.00     1.00±0.00   1.00±0.00 
      Plasma   1.09±0.05     1.15±0.06     1.05±0.06   1.05±0.09 
      PEO1   1.58±0.08     1.58±0.16     1.23±0.08†   1.34±0.04 
      PEO4   1.72±0.06     1.70±0.13     1.76±0.13  1.42±0.06* 
      Liver   1.31±0.03     1.30±0.05     1.28±0.02   1.35±0.03 
   S.intestine   1.28±0.14     1.21±0.08     1.56±0.21   1.65±0.16 
      Muscle   0.37±0.04     0.45±0.06     0.45±0.05   0.57±0.10 
      Heart   14.18±3.66   25.80±4.42     30.45±4.53 23.37±4.01 
          
         [18F]FDG: PEO4; *P < 0.0114 
         [18F]FDG: PEO1; †p=0.0091 
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Table 7.  [18F]FLT biodistribution study following 3 days treatment in BALB/c bearing 
PEO1 and PEO4 tumours as determined by ex vivo gamma counting.  Tissues were 
excised 60 min after radiotracer administration.  [18F]FLT uptake is expressed as 
tumour to blood ratio; data are mean ± SEM (n=6). 
        
      Vehicle     API-2     Cisplatin   CIS + API-2 
     Blood   1.00±0.00   1.00±0.00    1.00±0.00    1.00±0.00 
     Plasma   1.05±0.02   1.00±0.02    0.90±0.03    0.91±0.04 
     PEO1   1.28±0.03   1.23±0.08    1.03±0.05†    1.11±0.07‡ 
      PEO4   1.41±0.06   1.22±0.05    1.31±0.03    1.20±0.07* 
     Liver   1.27±0.06   1.22±0.03    1.05±0.02    1.18±0.03 
S.intestine   1.41±0.06   1.23±0.05    1.04±0.03    1.26±0.11 
    Muscle   0.94±0.04   0.87±0.04    0.86±0.02    0.92±0.08 
    Heart   1.16±0.05   1.05±0.04    0.98±0.03    0.99±0.04 
    
 [18F]FLT: PEO4; *P <0.0192 
 [18F]FLT: PEO1; † p=0.0106 
 [18F]FLT: PEO1; ‡ p=0.0421 
 
3.3.5 Effect of drug treatments on the level of proliferation marker, Ki67  
Consistent with upregulation of glycolytic enzymes in proliferative cells, some 
studies have reported correlation between [18F]FDG and [18F]FLT and proliferation 
marker Ki67. 
The ability of API-2 to selectively inhibit the AKT pathway suggests that it should 
inhibit proliferation and/or induces apoptosis preferentially in those tumour cells 
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with aberrant expression/activation of AKT.  Activation of AKT in human 
malignancies commonly results from overexpression of AKT or PTEN mutations 
[197].   
 
Given the modulation of tumour volumes reported above and the imaging changes 
detected, we investigated if treatment leads to changes in the expression of 
proliferation and apoptotic markers in vivo.  Ki67 expression was assessed in the 
treatment groups at day 2 and day 4 of treatment (Figure 30 and 29; respectively).  
Although tumour volume reduction was not seen on day 2 of combination 
treatment, a significant reduction in Ki67 labelling index (LIki67; p=0.0016) was 
present in the sensitive PEO1tumours consistent with the time taken for changes in 
proliferation to manifest as changes in tumour size (Figure 30A).  Cisplatin-only 
and the combination treatment both caused reductions in LIki67 after 3 days of 
treatment (day 4) in PEO1tumours (p=0.001; Figure 29 (A, B)). 
In contrast, reduction of LIki67 was only observed in the combination treatment arm 
in PEO4 tumours (day 2; p<0.001 (Figure 30B), day4; p=0.0018; Figure 29 (A, C)). 
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Figure 29.  In vivo effect of API-2 and cisplatin treatment on tumour proliferation 
(Day 4).  Cisplatin (CIS; 3mg/kg; i.p.,) and API-2 (1mg/kg/day) were given singly or 
as combination treatment over 3 days.  (A) Proliferative activity in tumour cells was 
assessed with anti-Ki67 antibody (brown staining); counterstain, haematoxylin. 
Summary of the Ki67 labelling index (LIki67) for all treatment groups in PEO1 (B) and 
PEO4 (C) BALB/c tumour-bearing mice.  Significant differences are indicated by 
asterisks. 
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3.3.6 Correlation between tumour [18F]FLT and [18F]FDG activity and LIki67 
Biochemical changes in the AKT pathway inhibition underpinning the changes seen 
by imaging were correlated.   
Given the differences in mechanism of tumour accumulation of the two radiotracers, 
TK1 activity for [18F]FLT and glucose metabolism for [18F]FDG, the degree of 
association of tumour radiotracer uptake with cell proliferation was examined. This 
was done by comparing individual NUV60 values with corresponding LIKi67.  
A linear correlation between tumour [18F]FDG NUV60 and LIKI67 was observed (r = 
0.77, P = 0.0012; day 2; Figure 30D) in PEO4 tumours.  A modest but statistically 
non-significant correlation was seen between tumour [18F]FDG NUV60 and LIKI67 in 
PEO1 tumour (r = 0.4509, P = 0.122;day 2; Figure 30 B). 
For day 4, there was a linear correlation between [18F]FDG NUV60 and LIKI67 in both 
tumours (Figure 31A, C); however the correlation was significantly better for PEO4 
tumour (r = 0.8266, P = 0.0017; Figure 31C).  
In addition, there was a modest but significant correlation between LIki67 and 
tumour [18F]FLT area under the NUV curve in both PEO1 (r = 0.3309, P = 0.0303; 
Figure 31B) and PEO4 (r = 0.4437, P = 0.0108; Figure 31D) tumours for day 4, 
although the results in this case were skewed by a few outliers. 
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Figure 30.  Summary of the Ki67 labelling index (LIki67) for all treatment groups 
in PEO1(A) and PEO4 (C) tumours and correlation of [18F]FDG NUV60 with LIki67 in 
PEO1(B) and PEO4 (D) tumours (Day 2).  Significant differences are indicated by 
asterisks.  Solid line, linear regression line. 
Day 2 
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In addition the basis of the imaging changes was also assessed with respect to 
Glut-1, hexokinase and TK1. 
GLUT-1 is the main glucose transporter in most cell types; it appears to be 
regulated primarily through alterations in expression levels, as well as translocation 
Figure 31.  Correlation  of [18F]FDG NUV60 (A-C) and [18F]FLT NUV60 (B-D)  with 
Ki67 labelling index (LIki67) in PEO1 and PEO4 BALB/c tumour–bearing mice 
(Day 4).  Significant differences are indicated by asterisks.  Solid line, linear 
regression line. 
Day 4 
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to the membrane.  Activation of mTORC1, through AKT-mediated phosphorylation 
of PRAS40, can contribute to both HIFα- dependent transcription of the GLUT-1 
gene and cap dependent translation of GLUT-1 mRNA [176].  The frequent 
occurrence of PI3K/AKT pathway activation and HIFα accumulation in human 
cancers is likely to explain the high levels of GLUT-1 and enhanced glucose uptake 
observed in tumours. 
 
In addition to these proliferation markers, we also investigated determinants of 
[18F]FDG uptake.  AKT signals through the insulin pathway and directly affects 
glucose metabolism [327].  Figure 32A shows changes in GLUT-1 membrane 
expression after treatment of both sensitive and platinum resistant tumour.  In 
PEO1 tumour, a decrease of GLUT-1 expression occurred with cisplatin, API-2 and 
combination treatment; in PEO4 tumour, a significant decrease was only observed in 
the combination treatment arm. 
Hexokinase activity decreased after cisplatin treatment in PEO1 tumours (Figure 
32B) but only after combination treatment in PEO4 tumour (Figure 32C).  Hence, 
individually, changes in GLUT-1 and hexokinase did not exactly mirror changes in 
[18F]FDG uptake, but taken together they predicted [18F]FDG uptake.   
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Figure 32.  In vivo effect of API-2 and cisplatin treatment on GLUT-1 expression.  
Cisplatin (CIS; 3mg/kg; i.p.) and API-2 (1mg/kg/day; i.p.) were given singly or as 
combination treatment for 3 days.  (A) GLUT-1 was detected with anti-GLUT-1 
antibody (brown staining). Hexokinase activity was determined 
spectrophotometrically as described in Materials and Methods and expressed in 
units of cellular activity per milligram of cellular protein in (B) PEO1 and (C) PEO4 
tumours.  Significant differences are indicated by asterisks. 
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3.3.7 Evaluating changes in AKT and other downstream biochemical markers in this 
tumour model by Western blot analysis 
It was important to ascertain whether the changes in imaging endpoints mirrored 
changes in AKT downstream biochemical markers in these tumour models.  We 
examined whether the changes in imaging parameters mirrored changes in AKT and 
other downstream biochemical markers in this tumour model.  Increases and 
decreases in p-AKT expression have been reported after treatment with pathway 
inhibitors which has been attributed to direct drug action and feedback activity.  
Analysis of the ovarian tumour lysates showed no consistent changes in p-AKT, p-
P70S6K and p-S6 expression (Figure 33 A-F). 
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Expression of the immediate AKT downstream target p-PRAS40 decreased after 
treatment with the low dose of API-2 (Figure 34 A, B).  There was no change in 
total protein expression indicating that the effect was primarily on protein activity.  
In both sensitive and resistant tumours, pPRAS4/PRAS40 ratio decreased when 
API-2 was administered alone or in combination with cisplatin indicating that it 
was a useful pathway biomarker.   
 
TK1 activity has been proposed as the most important determinant of [18F]FLT 
uptake.  Thus, the effect of drug treatment on tumour protein levels was 
examined.  Notably, TK1 protein expression decreased significantly with cisplatin 
and combination treatment in PEO1 xenografts (Figure 34C); a significant decrease 
in TK1 expression was only seen with combination treatment in PEO4 xenografts 
(Figure 34D) in keeping with the [18F]FLT data. 
 
 
       
Figure 33.  Western blot analysis of p-AKT levels in (A) in PEO1 tumour and (B) in 
PEO4 tumour and its downstream targets: p-S6 ribosomal protein; (C) in PEO1,(D) 
in PEO4 tumours; p-P70S6K protein; (E) in PEO1, (F) in PEO4 tumours;.  The 
proteins were measured as an indication of AKT activity within tumour lysates.  For 
detection of protein expression, 50μg of protein was subjected to western blot 
analysis.  Primary antibodies included p-AKT, p-P70S6K, p-S6 ribosomal protein 
(Cell Signalling Technology).  Western blots were done as described in Materials 
and Methods.  Bar charts are densitometry analysis where the levels of 
phosphorylated protein were normalised to their corresponding total protein 
content.  Cisplatin (CIS).  Summary data are shown for n=3 per treatment group; 
bars, SEM. 
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Figure 34.  Western blot analysis of p-PRAS40 and TK1 levels.  (A) p-PRAS40 in 
PEO1 tumour, (B) p-PRAS40 in PEO4 tumour, (C) TK1 in PEO1 tumour, (D) TK1 in 
PEO4 tumour.  For detection of protein expression, 50μg of protein was subjected 
to western blot analysis.  Total PRAS40 and β-actin were used as loading controls 
for p-PRAS40 and TK1 respectively.  Significant differences are indicated by 
asterisks.  Summary data are shown (densitometry; bars, SEM; n=3 per treatment 
group).   
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3.3.8 Cellular activity of dose-dependent increase of API-2 
Direct measurement of AKT phosphorylation at S473 indicated an increase in p-AKT 
(S473) in vivo following API2 treatment.  Although seemingly counter-intuitive this 
effect has been documented and is associated with on-target alleviation of a 
negative feedback loop via IRS-1[1, 328].  
Expression of the immediate AKT downstream target p-PRAS40, an established 
pharmacodynamic marker of AKT inhibition [1], showed clear dose dependent 
decrease after treatment with increasing doses of API-2 (Figure 35 A, B) reflecting 
inhibition of AKT kinase activity at Thr246 of PRAS40.  The phosphorylation of 
p70S6K and pS6 in tumour cells lysates were not inhibited in a dose-dependent 
manner by API-2.  These targets have several phosphorylation sites which can be 
phosphorylated by other kinases, and both p70S6K and pS6 are regulated by 
MTORC1 independent of AKT.  Furthermore, Berndt et al., have demonstrated that 
TCN-P does not directly interfere with the phosphorylation of AKT by either PDK-1 
or mTOR, in their ability to phosphorylate AKT at T308 and S473, respectively 
[199]. 
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3.3.9 Effect of API-2 on total GLUT-1 and GLUT-3 expression  
In ovarian carcinomas, high levels of GLUT-1 or GLUT-3 in the tumours were 
significant indicators of decreased survival [329].  GLUT-3 protein is also  
expressed in lung, ovarian, and gastric cancers, but not in the corresponding 
normal tissues [330]. 
Other than membrane localisation, changes in total protein expression, assessed by 
western blots, were demonstrated for GLUT-1; API-2 alone decreased GLUT-1 
expression in both tumour models (Figure 36A, B).  GLUT-3 expression was 
unchanged except in the API-2 treatment group of the PEO1 model (Figure 36C) 
and a slight reduction with combination treatment in PEO4 tumours which do not 
seem to be significant (Figure 36D).  
 
 
Figure 35.  Dose-dependent modulation of AKT pathway by API-2 in PEO1 (A) and 
PEO4 (B) xenogratfs.  Western blot analysis shows modest increased p-AKT (S473) 
upon API-2 treatment, an effect that has been reported elsewhere [1].  Dose-
dependent decrease in p-PRAS40 (Thr246), a direct downstream phospho-target 
of AKT, is clearly demonstrable in both PEO1 and PEO4 xenografts indicating 
pathway inhibition.    
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Figure 36.  Western blot analysis of total GLUT-1 and GLUT-3 levels.  (A; C) 
GLUT-1 and GLUT-3 in PEO1 tumour.  (B; D) GLUT-1 and GLUT-3 in PEO4 
tumour.  For detection of protein expression, 50 µg of protein was subjected 
to western blot analysis.  β-actin was used as loading control.  Significant 
differences are indicated by asterisks.  Summary data are also shown for n=3 
per treatment group; bars, SEM. 
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Because AKT is a critical regulator of insulin signalling, blood glucose levels and 
animal body weight were measured in mice after administration of API-2.  The 
drugs, singly or in combination therapy, did not affect blood sugar or body weight 
(Table 8). 
 
 
 
 
 
 
 
 
      Blood sugar (mmol/L)          Weight (g) 
       Vehicle         17.0 ± 2.4          19.0 ± 0.3 
      Cisplatin         13.3 ± 1.8          18.2 ± 0.4 
       API-2         13.6 ± 1.1          17.8 ± 0.3 
    CIS + API-2         14.4 ± 1.0          17.7 ± 0.4 
                
  
 
 
 
 
 
 
Table 8.  Effect of drug treatment on animal body weight and blood glucose.  
Because AKT is a critical regulator of insulin signalling, blood glucose was 
measured in all treatment groups.  Blood glucose level measured immediately 
after the imaging session (Glucose monitoring system, Ref:70917-01, Abbott 
Diabetes Care Ltd, Oxon) did not vary between all treatment groups, indicating 
that the compound was well tolerated in vivo following i.p., treatment for 3 
days.  No weight loss was seen in treated animals (n=6 mice per treatment 
group). 
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3.4.0 Effect of inhibiting DNA-PK by NU7441on [18F]FDG uptake 
As the mechanism of AKT modulation is thought to involve DNA-PKcs, a study was 
done to establish whether similar modulation of target activity could be achieved by 
inhibiting DNA-PK. 
Given the effect on glucose metabolism, the effect of NU7441, alone or in 
combination with cisplatin, was examined by [18F]FDG-PET in BALB/c mice bearing 
bilateral tumour implants, PEO1 and PEO4.  The aim of this study was to provide 
further mechanistic proof for the role of the AKT pathway in modulating glucose 
metabolism and consequently the ability of PET to monitor pharmacodynamic 
response to therapy. 
Zhao et al [331], has demonstrated greater antitumour activity in their xenograft 
model, when NU7441(10mg/kg;i.p.,) was given over 5 days in combination with the  
topoisomerase II inhibitor etoposide, than when given either as a single agent 
alone. In keeping with the dosage of 10mg/kg; i.p.,; NU7441, PEO1 and PEO4 
tumour-bearing mice were treated singly with NU7441(10mg/kg; i.p.,) over 3 days 
or in combination, whereby mice were pretreated with NU7441 followed by cisplatin 
(3mg/kg; i.p.,) 1h later.  An [18F]FDG scan was done 24h later after the last dose of 
the drugs were given. 
There was no significant difference in tumour growth delay between the two 
treatment groups in both PEO1 and PEO4 tumour (Figure 37A).  The TAC shows a 
slight decrease in [18F]FDG uptake with combination treatment compare to single 
treatment following the 60 min dynamic scan (Figure 37B); this was also reflected in 
the PET variables (Figure 37C), NUV60 which was not significant.  There was also a 
slight decrease in FRT values which was only significant in PEO1 tumour.  There 
were no changes in AUC values between the two treatment groups. 
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It would have been useful to explore different doses and schedules with this 
drug/combination but time did not permit this.  Hence further studies are 
warranted. 
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Figure 37.  (A) Effect of drug treatment on tumour size ; Tumour were grown as 
bilateral implants  Mice were randomised into 2 treatment groups ; NU7741 
(10mg/kg i.p.) or NU7741+ cisplatin (CIS; 3mg/kg i.p.,) combination treatment 
given as NU7741 followed by 1h later by cisplatin.  Treatment was given daily over 3 
days.  Day 0 was start of treatment and day 4 was 24h after last dose.  Graph 
represents the mean tumour volume; PEO1 and PEO4-tumour bearing mice.  Control 
represents tumour size at day 0.  (B) [18F]FDG time versus radioactivity curves 
(TACs).  A summary of the TACs expressed as tumour radioactivity normalised to 
liver radioactivity at each of the 19 timepoints in NU7441 given as a single agent 
(10mg/kg; i.p.,) or given as a combination treatment (NU7441 followed 1h later  by 
cisplatin (3mg/kg; i.p.,).  (C) Semiquantitative imaging variables (AUC, NUV60, FRT)  
extracted from the TACs.  Data are mean ± SEM (n= 5 mice/group, bars, SEM.   
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3.5 [18F]ICMT11 as an imaging apoptosis tracer  
 
The inability to undergo apoptosis is a unique characteristic of platinum resistance.  
A number of apoptosis-related genes such as HSXIAPAF1 and DNA-damage 
checkpoint genes are deregulated in the isogenic pairs of cell lines.  Caspase-
dependent apoptosis was assessed with the radiolabelled isatin, [18F]ICMT11-PET, 
developed within our group. 
Following a high throughput screen, Lee and co-workers, identified the isatin 
sulphonamide as an inhibitor of caspase-3.  Structural optimisation led to the 
discovery of the highly potent sulphonamide [253] (Figure 10A; Introduction  
Section).  Validation of the tracer [18F]ICMT11, both in vitro and in vivo formed a 
small part of this thesis. 
The first set of experiments aimed to evaluate the caspase inhibition potencies of 
all 14 synthesised analogues of 5-pyrrolidinylsulfonyl isatins [259] (comprising of 
the nonfluorinated derivatives; ICMT1-ICMT4, and the fluorinated analogues; 
ICMT5-ICMT14, which are potential radiolabelling precursors) and tested their 
inhibition potencies against caspases-1, -3, -6, -7 and 8 by a fluorogenic in vitro 
caspase inhibition assay (Table 9). 
 
3.5.1 Caspase enzyme inhibition assays 
The affinities of the isatins compounds (ICMT1-ICMT14) for different activated 
caspases 1, 3, 6, 7, and 8 were measured by a fluorimetric in vitro caspase 
inhibition assay similar to that described by Kopka et al. [257].  Inhibition of 
recombinant human caspases was assessed by measuring the accumulation of a 
fluorogenic product, 7-amino-4-methylcoumarin (7-AMC) [259].  The results are 
170 
 
summarised in Table 9.  The data are the average for two runs, each done in 
duplicate, at 9 concentrations ranging from 5 pM to 500 μM; the drug concentration 
required to inhibit each enzyme by 50% (EC50) was obtained from nonlinear 
regression analysis of the inhibition profiles.  In this assay, the affinities of ICMT1 
for caspase 3 and 7 (Figure 10B; Top panel) were 59.9 and 25.3 nM, respectively.  
ICMT1 was initially radiolabelled with iodine-125 (125I; t1/2 = 59.9 days) to 
characterise the suitability of the isatin sulphonamides as an apoptosis imaging 
agent [257].  
From the library of the isatin compounds (Table 9), it was found that substituting 
the iodine for fluorine led to a slight increase in affinity for both caspase-3/7.  The 
importance of the phenoxymethyl group (R group; Figure 10) when substituting for 
hydrogen (ICMT4) was seen, as it decreases the affinity for caspase-3 several fold 
(199.5 nM affinity for caspase-3) compared to ICMT1 (59.9 nM affinity for caspase 
3).  Fluorine substituents on the phenyl ether (ICMT5 and ICMT6), increased affinity 
for caspase-3~ 2-fold; as compared with the nonfluorinated phenyl ether (ICMT1).  
The difluorinated substituents of the phenyl ether of the isatin analogues were even 
more potent (ICMT9 and ICMT10), and have an increase affinity for caspase-3.  
Introduction of 2′-fluoroethyl-1,2,3-triazole on either side of the molecule 
increased the potency further, with measured caspase-3 affinities of 12.6 and 16.7 
nM for the triazoles ICMT9 and ICMT12, respectively.  Of the compounds tested, the 
triazole ICMT11 was by far the most potent, with affinities of 0.5 and 2.5 nM for 
caspase-3/7, respectively.  All the compounds tested were poor substrates for 
caspases 1, 6, and 8 (EC50 > 5000 nM).  Please refer to Appendix, A3 for the 
nonlinear regression analysis of the inhibition profiles for caspase-3 for ICMT1-
ICMT14 at different times point. 
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Following this screening, ICMT11 isatin analogue (compound 15 in ref. [259], was 
chosen as a potential apoptosis imaging tracer radiolabelled with 18F for the in vivo 
studies. 
 
Table 9.  Caspase inhibition profile for synthesised compounds.  Each value is an 
average of two independent measurements each obtained from a fit to a 9-
concentration level data set (r2 > 0.9). 
 
 
 Isatin analogues               Caspase  EC50 (nM) 
         3         7    1/6/8 
           ICMT1        59.9        25.3     >5000 
           ICMT2        41.8        29.4     >5000 
           ICMT3        50.5        19.8     >5000 
           ICMT4      199.5        78.6     >5000 
           ICMT5        26.1          8.0     >5000 
           ICMT6        17        13.5     >5000 
           ICMT7        12.4        13     >5000 
           ICMT8        10.4        16.8     >5000 
           ICMT9        12.6        18.3     >5000 
           ICMT10        10.7        14.4     >5000 
           ICMT11          0.5          2.2     >5000 
           ICMT12        16.7        28.2     >5000 
           ICMT13        50.1        60.4     >5000 
           ICMT14          5.5          2.3     >5000 
 
 
 
Prior to synthesising the library of novel isatin analogues shown in Table 9 [259], 
ICMT1 (compound 4 in ref.[259] ) was radiolabelled with iodine-125 and assessed 
for the suitability of this class of compounds as apoptosis imaging agents [259] in 
term of its metabolic stability. 
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The cellular activity of [125I]ICMT1 was assessed in vitro in the isogenic pair by 
examining the binding to cleaved caspase 3 under conditions of drug induced 
apoptosis and conditions that mimicked necrosis.  The stability of [125I]ICMT1 over 
time was also assessed by looking at biodistribution in tissues over time in normal 
BALB/C mice.  These data are discussed below (Figures 47, 48 and 49). 
 
3.5.2 Binding studies of radiolabelled [125I]ICMT1 to apoptotic cells in vitro 
The biological properties of a radioiodinated analogue [125I]ICMT1 was initially 
determined  using the model of apoptosis described in the Methods section.  PEO1 
and PEO4 cells were treated singly either with cisplatin (25µM) or API-2 (20µM) or in 
combination where the cells were pretreated with API-2 for 1h followed by cisplatin 
over 24h.  The percentage binding to activated caspases was determined using the 
[125I] radiolabelled iodinated isatin tracer.  A significant percentage increase in 
binding was seen with combination treatment in both PEO1 and PEO4 cell lines 
compared to single treatment alone (Figure 38; A, B). 
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Figure 38.  Apoptosis was induced in vitro in the isogenic pairs for 24h and % 
binding of the [125I]ICMT1 was determined (A, B).  Data were expressed as % 
increase in bound radioactivity relative to control (count/dose solution).  Data are 
mean ± SEM of 4 independent experiments.  Significant differences are indicated 
by asterisks.  The data were statistically significant at p≤0.05 (**, p=0.0066(A); 
***p=0.0045 (B); versus cisplatin (CIS) alone).  
 
 
 
174 
 
3.5.3 Binding studies of radiolabelled [125I]ICMT1 to necrotic cells in vitro 
The binding of [125I]ICMT1 to activated caspase-3  was further characterised using 
the model  of necrosis.  Necrosis was induced in the PEO1and PEO4 cells following 
heating at 560 C for 30min and cold treatment in liquid nitrogen for 15 min.  
Necrosis is the term currently used for nonapoptotic, accidental cell death.  There is 
also the distinction between the structural and biochemical processes occurring in a 
dying cell and the endpoint of death itself [332].  Necrosis, therefore, refers to 
morphological stigmata seen after a cell has already died and reached equilibrium 
with its surroundings; in the absence of phagocytosis, apoptotic bodies may lose 
their integrity and proceed to secondary or apoptotic necrosis [333].  The binding of 
[125I]ICMT1 to necrotic cells was similar to control cells (Figure 39A, C), although a 
small increase of binding was seen with the PEO1 cells with heat treatment, this was 
not significant.  Similarly, in the luminescence assay for caspase-3/7, the levels of 
activated caspase-3 in both heat and cold-treated cells were much lower compare 
to control (Figure 39B, D).  Although ICMT1 is several fold less potent for activated 
caspase-3, it does not bind necrotic cells as shown here and thus compounds 
having an isatin sulphonamide scaffold as a base structure can be modified further 
to yield more potent isatin sulphonamides. 
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Figure 39.  The specificity of iodinated tracer [125I]ICMT1 for the detection of not 
only apoptotic but also necrotic cells following heat (560 C; 30min) and cold (liquid 
nitrogen, 15 min) -shock treatments.  (A, C) The binding characteristics of [125I] 
tracer in PEO1 and PEO4 cells following induction of necrosis.  A small increase in 
[125I] tracer was seen with heat shock treatment compare to control.  (B,D) This 
cellular model of necrosis also induces some apoptosis as detected by Luminescent 
caspase-3/7 activation assay in PEO1 and PEO4 cells. 
 
 
 
 
176 
 
3.5.4 Biodistribution of [125I] ICMT1 in nontumour-bearing mice 
The isatin sulfonamide ICMT1 was radiolabelled with iodine-125 (t1/2 = 59.9 days) 
using the method of Kopka [257].  [125I]ICMT1 was injected intravenously into mice, 
and its tissue distribution was measured in selected organs from 2 to 60 min after 
intravenous injection (Figure 40).  Tissues were removed, weighed, and counted for 
[125I] radioactivity.  Data were expressed as a percentage of injected dose per gram 
of tissue (% ID/g).  The radiotracer distributed rapidly to the major organs and was 
also rapidly eliminated (Figure 40). [125I]ICMT1 was completely eliminated from 
plasma within 10 min and there was rapid clearance in all tissues investigated and 
from 10 min onward, the majority of the injected radioactivity was excreted in the 
urine. 
Metobolic studies carried out by Smith et al. [259], following incubation of  ICMT1 
with murine liver S9 fraction [259], found that ICMT1 was almost completely  
degraded after 60 min incubation.  The HPLC metabolic profiles of ICMT1 isatins 
indicate that the isatin scaffold is relatively stable, whereas the phenyl ether group 
of ICMT1 undergoes rapid breakdown consistent with aromatic hydroxylation [259].  
It was also noted that radiotracer uptake in the stomach, which is known to 
accumulate radioiodide, was low, thus, this effect was not attributed to deiodination 
[259]. 
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Figure 40.  Biodistribution of [125I]ICMT1 in BALB/C mice at 2, 10, 30 and 60 min. 
Data are mean  SEM; n = 3 mice per time point. 
 
The results indicated poor biological stability and led to design a new series of 
isatins as mentioned above. 
 
3.5.5 Binding studies of radiolabelled [18F]ICMT11 to apoptotic cells in vitro 
The cellular activity of [18F]ICMT11 was assessed in the same in vitro model of 
drug-induced apoptosis as described for [125I]ICMT1 (Figure 41).  PEO1 and PEO4 
cells were treated singly either with cisplatin (25 µM) or API-2 (20 µM) or in 
combination where the cells were pre-treated with API-2 for 1h followed by 
cisplatin over 24h.  The percentage binding to activated caspases was determined 
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by gamma counting.  A greater significant cellular uptake of [18F]ICMT11 was seen 
(1.5-2~fold) with combination treatment in the isogenic pair compared to what was 
observed with [125I]ICMT1 in the same model (Figure 41A, C).   
 
3.5.6 Measurement of apoptosis with the Caspase-Glo 3/7 assay in vitro 
The amount of caspase-3 activation occurring in the in vitro apoptosis model was 
evaluated with the Caspase-Glo 3/7 assay (Figure 41 B, D).  The caspases (-3 and -
7) family play a key effector roles in apoptosis in mammalian cells [303].  Caspase-
3 activation has been shown previously to play an important role in cisplatin-
induced apoptosis and increase in caspase-3 activity was in line with the 
percentage of apoptosis occurring [334].  In this assay system, the luminogenic 
caspase-3/7 substrate containing the DEVD sequence is cleaved following caspase 
activation, measured as luminescence intensity.  Luminescence is proportional to 
the amount of caspase activity present in the in vitro system.  An increase in 
caspase-3 activity was seen with combination treatment which was statistically 
significant in both cells relative to cisplatin treatment alone (Figure 41B, D). 
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Figure 41.  Apoptosis as measured by both binding and caspase-3 activities in the 
isogenic pair.  Apoptosis was induced in vitro for 24h and % binding of the 
[18F]ICMT11 was determined (A, C); expressed as % increase in bound radioactivity 
relative to control (mg /protein).  This was compared with caspase-3 activity in the 
in-vitro model system (B, D); expressed as luminescence (RLU) and proportional to 
caspase-3 activity.  Data are mean ± SEM of 4 independent experiments.  
Significant differences are indicated by asterisks.  The data were statistically 
significant at p≤0.05 (***, p=0.0002 (A); ***, p <0.0001 (C); ***, p=0.0003 (B); 
***, p<0.0001 (D), versus vehicle-treated).  
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3.5.7  Specificity of binding of [18F]ICMT11 as determined by competitive inhibition 
with z-VAD-FMK in PEO4 cells 
z-VAD-FMK, a competitive and irreversible inhibitor of caspase-3/7 was added to 
PEO4 cells in a drug-induced model of apoptosis in vitro.  The pan caspase inhibitor 
was able to compete with [18F]ICMT11 for the active site of cleaved caspase-3, and 
reduced binding of [18F]ICMT11in PEO4 cells treated with both API-2 and cisplatin 
to level similar to vehicle treated cells (Figure 42A).  As shown previously, an 
increase in active caspase-3 was seen with combination treatment in the PEO4 cells, 
as measured with the Caspase-Glo 3/7assay.  This increase was attenuated with z-
VAD-FMK (Figure 42B).    
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Figure 42.  The effect of pan caspase inhibitor z-VAD-FMK (30 µM) on [18F]ICMT11   
binding and intracellular caspase activity in PEO4 cells.  Data are mean ± SEM of 3 
independent experiments (Cisplatin; CIS).  Significant differences are indicated by 
asterisks.  The data are statistically significant when p≤0.05 (**p=0.0085 versus 
combination treatment). 
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3.5.8 Binding of [18F]ICMT11 following depletion of intracellular GSH in cisplatin 
sensitive PEO1 cells 
Given the potential effect of GSH in the mechanism of localisation of [18F]ICTM11, 
the uptake of [18F]ICMT11 was assessed in both non-treated and cisplatin treated 
PEO1 cells, following  depletion of GSH with DEM.   
There was a ~1.5 fold increased binding of [18F]ICMT11 to apoptotic cells in 
cisplatin - treated cells following depletion of GSH compare to control cells treated 
with DEM which was significant (Mann-Whitney test) (Figure 43).  Thus, GSH 
depletion during apoptosis may contribute to the increased [18F]ICMT11 signal. 
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Figure 43.  Effect of DEM on [18F]ICMT11 binding to PEO1 cells treated with 
cisplatin (25μM).  Data are expressed as counts per milligram total cellular 
protein. 
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Following the screening of a small library of isatin-based caspase-3/7 inhibitors, 
ICMT11 was found to have subnanomolar affinity for caspase-3 and was of 
moderate lipophilicity [259].  Using the "click chemistry" approach, a 2'-fluoroethyl-
1,2,3-triazole was incorporated both in the N-1 position and on the left side ether 
position of the isatin 5-sulfonamide scaffolding producing a high affinity and 
metabolically stable apoptosis tracer to study caspase-3/7 activation in vivo [205, 
259, 313]. 
 
3.5.9 Uptake of [18F]ICMT11 in PEO4 tumour–bearing mice following treatment  
The identification of a isatin 5-sulfonamide, ICMT11 as a potential apoptosis 
imaging biomarker [259], has enable use of this tracer to evaluate drug–induced 
apoptosis in a xenograft model of ovarian cancer - PEO4 tumour. 
PEO4 tumour-bearing mice were randomised in 4 different groups, vehicle–, 
cisplatin (3mg/kg; i.p.,)-, API-2 (1mg/kg; i.p.,) and combination; mice were treated 
for 3 days using the same scheduling treatment as in Figure 13B (Materials and 
Methods) and were imaged 24h later with [18F]ICMT11 Figure 44A, shows a slight 
increase in tracer uptake in combination treatment compared to vehicle treated.  
The TAC curves were slightly increased with combination treatment (Figure 44B).  
The PET variables AUC, NUV60 were significantly higher in the combination 
treatment group compared to the vehicle-treated group (Figure 44C).  In the single 
treatment group, the PET variables (AUC, NUV , FRT) were not significantly different 
compared to that of the vehicle (Figure 44C).     
Given its central role, various nonpeptide small molecule inhibitors of the isatin 
sulfonamide class that bind selectively to the active site of caspase-3 (and -7), have 
been described, initially as potential inhibitors of apoptosis (8, 9). Furthermore, 
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recent reports described the utility of [18F]-radiolabelled isatins as probes for PET 
imaging of apoptosis (10–14), one of them using an experimental rat model of 
drug-induced liver apoptosis (15).  To date, no study (other than ours) has reported 
imaging of tumour models by this strategy.  Given that patient tumours typically 
show low levels of apoptosis at baseline and a relatively small increase after drug 
treatment (2- to 6-fold increase corresponding to 5–15% apoptosis) (16, 17), it is 
important to demonstrate the potential of new imaging agents in relevant tumour 
models.  
Thus using [18F]ICMT11 as a PET apoptosis tracer, PEO4 tumour-bearing mice were 
used to noninvasively image the drug-induced tumour apoptotic process in vivo 
(Figure 44). 
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Figure 44.  The effects of combination treatment (cisplatin (CIS) and API-2) on 
[18F]ICMT11 uptake.  (A) Typical transverse (0.5mm) [18F]ICMT11 PET images of 
PEO4 tumour-bearing mice after vehicle or combination treatment (API-2; 1mg/kg, 
CIS; 3mg/kg; i.p.,).  For visualisation, 30 to 60 min summed image data are 
displayed.  White arrowheads indicate the tumours.  Also note colour bar.  (B) 
[18F]ICMT11 PET time versus radioactivity curves for treatment groups in PEO4 
tumours.  The treatment groups were vehicle-treatment for 3 days; and API-2 given 
i.p., 1h before cisplatin over 3 days period.  (C) Semiquantitative imaging variables 
(FRT, AUC and NUV60) extracted from the TACs.  Significant differences are 
indicated by asterisks.  Data are mean ± SEM. 
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There was no significant difference in PET variables between singly treated- and 
vehicle mice (Table 10). 
 
 
 
 
 
Tumour    PET  variables                     Treatment group   
       API-2(1mg/kg)     Cisplatin (3mg/kg) 
PEO4 AUC          35.6 ± 1.77       41.62 ± 0.83 
 NUV60          0.65 ± 0.12       0.48 ± 0.07 
 FRT 60/1.5 min          0.69 ± 0.21       0.45 ± 0.11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: A summary of [18F]ICMT11 PET pharmacokinetics variables in API-2 and 
cisplatin treated PEO4 tumour-bearing mice.  Imaging studies were performed 24 
h after daily injection of the drug for 3 days.  API-2 was administered 1mg/kg; 
i.p.,/daily; and cisplatin was administered 3mg/kg; i.p.,/daily.  Data are mean ± 
SEM. 
 
Table 10.  Imaging studies of caspase 3/7 with [18F]ICMT11 following treatment of 
PEO4 tumour-bearing mice.  
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3.5.10 Double immunofluoresence staining for caspase -3 and TUNEL 
Apoptosis was detected in paraffin embedded tumour sections by using the 
terminal deoxynucleotidyltransferase-dUTP nick end labelling (TUNEL) assays that 
were originally introduced by the method of Gavrieli [335].  TUNEL is based on 
direct labelling of DNA breaks in nuclei in situ, and exploits specific binding of 
terminal deoxynucleotidyltransferase (TdT) to 3′-OH ends of fragmented DNA.  
After exposure of nuclear DNA on histological sections by proteolytic treatment, 
TdT was used to incorporate biotinylated deoxyuridine at sites of DNA breaks.  
Terminally modified nucleotide avidin-peroxidase amplifies the signal and allows 
for examination of labelled cells by fluorescent microscopy.  
With respect to apoptosis induction, the drug combination caused only a small 
induction of cleaved caspase-3 and DNA fragmentation (TUNEL) after 2 day of 
treatment (Please see Appendix,  A4) that increased after 3 days of treatment (day 
4) (Figure 45), compared with vehicle-treated tumours. 
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Figure 45.  In vivo effect of API-2 and cisplatin treatment on cell death as assessed by 
double-labelled immunofluoresence in PEO1 and PEO4 tumour sections.  Tumour 
tissues were removed after PET imaging, processed for histological analysis and 
stained for active caspase-3 (red) and DNA fragmentation (TUNEL assay; green 
staining) detection.  Sections (magnification, x400) are illustrated for vehicle-treated 
tumours and combination treatment whereby cisplatin (3mg/kg; i.p.,) and API-2 
(1mg/kg/day; i.p.,) were given for 3 days.  Insets, expanded views of tumour cells.  
Nuclei are stained blue (DAPI). 
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3.6 Preliminary studies to assess distribution of GSH levels, integrin 
expression and radiolabelled Inositols flux in tumour cell lines at baseline 
 
To further assess mechanisms underpinning sensitivity and resistance of paired cell 
lines used, a number of studies were initiated to establish baseline status of 
platinum resistant phenotype by both in vitro and in vivo work. 
 
3.6.1  Measuring intracellular GSH levels in vehicle and cisplatin-treated  PEO1 and 
PEO4 cells with or without GSH modulators 
One of the mechanisms proposed for the role of GSH in regulating cisplatin 
sensitivities, is as a cofactor via the ABC transporter that function as an efflux pump 
to eliminate cisplatin [57].  One of the platimun gene identified in the Gabra Lab 
code for the ABC transporter, which potentially might have an effect on platinum 
drug efflux.  Here, we have attempted to modulate GSH level in the paired cell line 
following treatment with CIS. 
Total GSH level in cisplatin and vehicle-treated PEO1 and PEO4 cells were measured 
by the DTNB-GSSG reductase recycling assay [336], using 5,5′-dithiobis(2-
nitrobenzoic acid) (DTNB) as described in Methods section (2.5).  The supernatant 
was assayed for GSH content by measuring the change in colour of DTNB at 412 nM 
in the presence of GSH reductase and NADPH (Figure 46).  Here, DEM was used to 
deplete GSH levels in PEO1 and PEO4 cells both in control and cisplatin treated cells 
and intracellular levels of GSH were measured following treatment.    
 
Cellular GSH level was slightly higher in PEO4 cells compared to PEO1 cells in 
vehicle- treated cells, which could be one factor responsible for the resistance 
mechanisms in the PEO4 cells.  The level of GSH was lower in both cisplatin-treated 
PEO1 and PEO4 cells.  Following treatment with cisplatin, the level of GSH decreased 
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further in the isogenic pair, even more in the sensitive cell line, which was not 
significant. Following exposure to DEM, there was as a marked decrease in GSH 
level compare to vehicle –treated in the isogenic pair.  When both cell lines were 
depleted with DEM and treated with cisplatin, the level of GSH was similar to 
treatment with DEM alone.  This reduction however is more significant in the 
resistant cell line, compare to the sensitive cell line.  This might suggests that GSH 
level might to some extent plays some part in mediating chemoresistance in PEO4 
cells.  However Cisplatin did not significantly alter GSH levels. 
 
                   
Ve
hi
cl
e 
D
EM C
IS
C
IS
 +
 D
EM
0
10
20
30
40
G
S
H
(n
m
o
l/
m
g
 p
ro
te
in
)
A
B
*
*
** **
PEO1
PEO4
Ve
hi
cl
e 
D
EM CI
S
CI
S 
+
 D
EM
0
10
20
30
40
G
S
H
(n
m
o
l/
m
g
 p
ro
te
in
)
 
 
191 
 
Figure 46.  Effect of DEM and cisplatin treatment on intracellular GSH concentration 
in (A) PEO1 and (B) PEO4 cell lines.  GSH levels were determined as stated in 
Materials and Methods.  Values are mean ± SEM of 3 independent experiments.  
Cellular GSH were significantly depleted with DEM treatment (CIS-cisplatin; DEM-di-
ethylmaleate).  Significant differences are indicated by asterisks. 
 
 
3.6.2 Initial assessment of integrin expression in ovarian cancer with assessment by 
PET imaging and IHC 
 
One key phenotype of PI3K/AKT modulation is angiogenesis.  One of the platinum 
resistance factors identified in the Gabra Lab is VEGF – a potent angiogenic factor.  
Expression of the αvβ3-integrin receptor on endothelial cells was assessed with an 
[18F]v3-ligand, [18F]fluciclatide, with which our group has conducted Phase I 
clinical trials.  Angiogenesis was only evaluated in part at baseline using this 
radiotracer, because of limited availability of the radiotracer.  Given the potential of 
αvβ3-integrin and αVβ5-integrin ligands for imaging of angiogenesis, we explored 
this as an endpoint of drug modulation in the resistant tumour line using 
[18F]fluciclatide-PET. 
 
[18F]Fluciclatide, was used to assess tracer uptake in the isogenic pair, PEO1 and 
PEO4 at baseline (Figure 47).  There was tracer localisation (white arrow) in both 
PEO1 and PEO4 tumours as seen in the coronal and transverse PET images slices 
(Figure 47A, B).  TACs showed good retention of the tracer in both tumours (Figure 
47C).  The semi-quantitative PET variables AUC, NUV60 and FRT were similar in both 
tumours following the dynamic scan (Figure 47D).  No significant differences of 
uptake were noted in PEO1 and PEO4 tumour cells.   
For tumour angiogenesis, most published prognostic studies have been based on 
the measurement of intratumoural vascularisation by counting of microvessels 
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identified by panendothelial or other angiogenesis-related markers and use of 
immunohistochemical techniques [337].  The steps of the method include the use 
of panendothelial markers such as monoclonal antibodies to CD31 to immunostain 
blood microvessels.  CD31 emerges as the panendothelial marker of choice for 
prognostic purposes [337]. 
For the IHC study, monoclonal antibodies to CD31 were used to stain paraffin-
embedded tumour sections for all treatments groups after 3 days treatment (Figure 
48).  Interestingly, all treatment groups displayed blood vessels; including 
proliferating blood vessels, stained yellow (merge).  There was not a reduction of 
blood vessels staining with either single or combination treatments.  There were 
also numerous yellow staining which indicate proliferating endothelial cells in the 
treatment groups (Figure 48B)  Treatment with API-2, cisplatin or combination did 
not seemingly affect tumour vascularity and thereby angiogenesis. 
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Figure 47.  Typical 0.5mm coronal and transverse [18F]-fluciclatide PET/CT slices 
showing tracer uptake at baseline in BALB/c mice bearing PEO1 and PEO4 tumour 
xenografts.  The white arrowheads point to tumour in coronal (A) and transverse (B) 
sections, respectively.  (C) Summary normalised time versus radioactivity curves in 
PEO1 and PEO4 tumour at baseline.  Tissue radiotracer uptake values are expressed 
as %ID/mL of tissue.  Data are mean ± SEM for four to six mice.  (D) Summary of 
kinetics parameters-NUV60, FRT, and AUC-determined as described in Materials and 
Methods. 
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Figure 48.  Proliferating endothelial cells in tumour section assessed by double 
immunofluorescence nuclear staining with DAPI and immunostaining with antibody 
against the proliferation marker, Ki67.  Green indicates Ki67-positive nuclei.  Red 
indicates staining of endothelial cells.  Yellow (merged section as indicated by 
yellow arrowheads), co-staining for Ki67 in the nuclei and CD31 on the cell 
membrane, indicating proliferating endothelial cells.  Representative images of 
histological tumour sections from PEO1 and PEO4 are shown. (A)  Vehicle-treated 
(Magnification x600); (B) Cisplatin (CIS); API-2 and CIS + API-2-treated sections 
(Magnification x400).  
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3.6.3 Assessing  distribution of radiolabelled Inositols analogues in tumour cell 
lines  
A number of studies were initiated to establish baseline status of platinum resistant 
phenotype by imaging.  Of these, imaging of inositols was the most advanced and 
is reported.  The uptake of [18F]-myo-inositol and [18F]-scyllo-inositol in both 
ovarian and other cell lines were compared.  This aspect of the work was the least 
developed a decision was made to include the data as this is an important and 
potentially exciting area for future research.  
 
3.6.3.1 Uptake of tritiated [3H] -myo-inostol  in IGROV-1 and SKOV3 cells in vitro 
[3H]–myo-inositol being of the same structure as myo-inositol, was used initially in 
the cell uptake assay, to define cellular responses in the ovarian cancer cell lines 
following treatment with both PI3K and transport inhibitors.  One hypothesis is that 
inositol fluxes across cell membranes can also be regulated by inositol transporters.  
To test this hypothesis we have used 2APB, which are modulators of the inositol 
transporters.  It was assumed that [3H]–myo-inositol would be taken up into cells by 
the same mechanism as that of myo-inositol and that it might be a substrate for 
the PtdIns synthase and therefore be incorporated into phospholipids. 
 
The cells uptake assay was not done in myo-inositol-deficient medium.  It would be 
expected that myo-inositol would compete with the myo-inositol analogues either 
for uptake into the cell and / or incorporated into PtdIns pathway. 
 
Uptake of [3H]–myo-inositol was assessed in SKOV3 and IGROV-1 tumour cells at 
different time points and at different concentrations in the presence of PI3-K 
inhibitors; LY294002 and wortmannin  and transport inhibitor; 2APB.  There was a 
decrease in uptake of [3H]–myo-inositol in IGROV-1 cells (Figure 49B), which was 
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both dose and time-dependent; the effect was more pronounced with LY294002.  
Similarly there was reduce uptake of [3H]–myo-inositol with 2APB in IGROV-1 cells 
(Figure 49B); the effect was more pronounced by increasing the time of exposure 
with the drug.  In SKOV-3 cells, a decreased uptake of [3H]–myo-inositol was seen 
at an earlier time point of exposure with both PI3-K and transport inhibitors, this 
effect is reversed with longer exposure time (Figure 49A).  
It is possible that the PI3K pathway might have an effect on the initial flux of 
inositols in the cells.  Further studies are warranted to evaluate the role of the PI3K 
pathway in mediating the inositols flux. 
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Figure 49  Uptake studies with [ 3H]–myo-inositol in (A) SKOV3 and (B) IGROV-1 
cell lines following time course experiments.  Cells were treated with PI3-K 
inhibitors LY294002 (2, 20 µM); wortmannin (10,100nM) and inositol transport 
inhibitor aminoethoxydiphenolborate (2APB; 5, 50 μM) at indicated time points. 
Uptake studies were performed for 1h using 2µCi activity/well, 370C.  The 
reaction was stopped by removing medium and washing with ice-cold PBS X3.  
Activity per well was counted by completely lysing the cell contents and oven 
drying. 200μl microscint 40 was added/well and the reading was taken on a 
Topcount.  Data are the average of 3 independent experiments (n=4 
well/treatment group).  Data are normalised to total cellular protein and is 
expressed as a % of control. 
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The cellular uptake of [18F]fluoro-scyllo-inositol and [18F]fluoro-myo- inositol in 
IGROV-1 tumour cells were compared under condition of normal and low serum.  
Lower serum content was used, to see whether tracer uptake was pathway related, 
as these cells have a constitutively activated PI3K pathway.  Cells were pre-treated 
with PI3K and transport inhibitors for 24h or transiently for 15min, and cellular 
uptake was performed for 60min.  Both PI3K and transport inhibitors were inactive 
towards the basal levels incorporation of [18F]fluoro–scyllo-inositol and [18F]fluoro-
myo-inositol in IGROV-cells in vitro, under both standard and low serum conditions 
(data not shown).  This is possibly due to the fact that [3H] myo-inositol is similar 
structure analogue to the naturally occurring myo-inositol isomer, thus make it 
more favorably substrate for the PI3K pathway, than the fluorinated inositol 
analogues which are partial structure inositol analogues.  Our in vitro data was 
inconclusive at this stage, we proposed to repeat these in vitro studies once the 
synthesis of the fluorinated inositol analogues have been improved.  
 
 
  
 
 
 
 
 
 
 
 
199 
 
3.6.3.2 [18F]FDG uptake in IGROV-1 and MDA-MB-231 tumour -bearing mice 
An [18F]FDG scan was performed in both IGROV-1 and MDA-MB-231 tumours  
(Figure 50A), to assess tumour viability.  There was good tracer uptake in both 
tumours.  Immunohistochemistry stainings for H&E and Ki67, showed  highly 
disorganised architectural characteristics of tumours with nuclear and cellular 
pleomorphisms (Figure 50B, top panels).  Both tumours were of high proliferative 
activity as assessed by Ki67 staining (Figure 50B, bottom panels). 
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Figure 50.  In vivo assessment of [18F]FDG uptake in size-matched IGROV-1 
and MDA-MB-231 xenografts- bearing mice (n=4-5), which were subjected 
to 60 min dynamic PET/CT scan.  (A) [18F]FDG PET images of two 
representative mice (arrows indicate the tumours; transverse sections).  (B) A 
typical histologic sections of MDA-MB-231 and IGROV-1 immunostained with 
Ki67 antibody and counterstained with haematoxylin.  Arrows, Ki67-positive 
nuclei (brown).  Corresponding haematoxylin and eosin (H&E) staining have 
also been included.  Magnification, x400.   
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3.6.3.3 Assessment of uptake of [18F] -fluoro-scyllo-inositol in IGROV-1 and 
MDA-MB-231 tumour-bearing mice 
[18F]fluoro-scyllo-inositol, a novel PET radiotracer, was developed recently by Neil 
vasdev et al. [291].  A dynamic scan revealed tracer uptake in athymic mice 
bearing human breast cancer xenografts, MDA-MB-231 and kidneys with very low 
brain uptake [291].  Scyllo-Inositol may also be a new marker for breast cancer, as 
it has been detected in human breast tumour extracts [338].  [18F]fluoro-scyllo-
inositol was initially developed as a radiotracer to image disease of the central 
nervous system, since scyllo–inositol inhibits cognitive deficits in TgCRND8 mice 
(mouse model of Alzheimer‘s disease; AD) and significantly ameliorates disease 
pathology, suggesting it might be effective in treating AD [339].  However, 
[18F]fluoro-scyllo-inositol does not readily pass the blood brain barrier. 
[18F]fluoro-scyllo-inositol uptake in IGROV-1 and MDA-MB-231 tumour-bearing 
mice at baseline were assessed (Figure 51).  A dynamic PET/CT scan showed that 
tracer uptake was slightly higher in MDA-MB-231 tumour–bearing mice compared 
to IGROV-1 xenografts mice (Figure 51A, B).  Semi-quantitative PET variables 
(Figure 51C) were higher in MDA-MB-231 compared to IGROV-1 tumours, 
however a Mann-Whitney test showed these increases to be non-significant (P 
=0.0571). 
 
 
 
 
 
 
 
201 
 
100%
0% 0 20 40 60
0
2
4
6
MDA-MB-231
IGROV-1
Time (min)
T
r
a
c
e
r
 u
p
ta
k
e
 (
%
ID
/
m
L
)
IG
RO
V-
1
M
D
A
-M
B-
23
1
0
100
200
300
A
U
C
IG
RO
V-
1
M
D
A
-M
B-
23
1
0
2
4
6
N
U
V
 (
%
ID
/
m
l)
IG
RO
V-
1
M
D
A
-M
B-
23
1
0
1
2
3
F
R
T
A B
C
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 51.  In vivo assessment of [18F]fluoro–scyllo- inositol uptake in sized-
matched IGROV-1 and MDA-MB-231 xenografts mice (n=4-5).  Tumour 
bearing mice were subjected to 60 min dynamic PET/CT imaging.  (A) 
[18F]fluoro –scyllo-inositol PET images of two representative mice (arrows 
indicate the tumours).  (B) The tumour time versus radioactivity curve 
normalised to heart (TAC).  (C) Semiquantitative imaging variables (AUC, NUV60, 
FRT) extracted from the TAC.  Data are mean ± SEM. 
202 
 
3.6.3.4 Assessment of uptake of [18F] fluoro-myo-inositol in IGROV-1, MDA-MB-
231, PEO1 and PEO4 (bilateral implants) tumour-bearing mice 
Based on work previously carried out on [18F]fluoro-scyllo-inositol [291], myo-
inositol was radiolabelled  in an analogous method in our lab., to develop [18F] 
fluoro-myo-inositol [309].  Myo-inositol is involved in insulin signalling, and 
signalling via the epidermal growth factor receptor is known to enhance myo-
inositol uptake in EGF responsive tumour cells [290, 340].  Besides having a 
constitutive active PI3K pathway, these tumours were selected because they are EGF 
responsive xenogratfs [340]. 
 
Uptake of [18F]fluoro-myo-inositol was compared in IGROV-1, MDA-MB-231, PEO1 
and PEO4 tumour-bearing mice at baseline (Figure 52A-D).  A 60 min dynamic 
PET/CT scan shows radiotracer uptake in all the tumours.  There was a significant 
increase in radiotracer uptake in MDA-MB-231 compared to IGROV-1 tumours 
(Figure 53A-C) as seen with the PET variables AUC and NUV60.  Radiotracer uptake 
profile was similar in mice-bearing PEO1 and PEO4 bilateral tumour implants. 
Radiotracer uptake in organs such as bladder and heart are also clearly visible. 
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Figure 52.  In vivo assessment of [18F]fluoro – myo-inositol uptake in size-
matched IGROV-1, MDA-MB-231, PEO1 and PEO4 (bilateral implants) 
xenografts mice (n=4-5).  Tumour-bearing mice were subjected to 60 min 
dynamic PET imaging.  (A, B) [18F]fluoro-myo-inositol PET images of three 
representative mice (arrows indicate the tumours).  (C, D)  The tumour time 
versus radioactivity curve, normalised to heart (TAC). 
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    3.6.3.5 Ex vivo biodistribution studies 
Comparison of tissues uptake of [18F]fluoro –scyllo-inositol in IGROV-1 and 
MDA-MB-231 tumour-bearing mice (Figure 54A, C) and [18F]fluoro-myo-inositol 
uptake in IGROV-1, MDA-MB-231, PEO1 and PEO4 tumour xenografts (Figure 54 
B, D and E) were carried out by counting pieces of tissue directly in a γ-counter 
soon after the imaging study. 
Both radiotracer analogues distributed rapidly in all the major tissues with good 
urinary clearance.  Uptake in brain was low with both [18F]fluoro –scyllo-inositol 
and [18F]fluoro-myo-inositol indicating that both tracers did not cross the blood-
brain barrier as previously demonstrated with [18F]fluoro –scyllo-inositol [291].  
High uptake of both inositol analogues were seen in kidneys.  High levels of 
myo-inositol  have been reported in the renal medullas of a variety of species, 
consistent with a role of inositol analogues in osmoregulation [341].  There were 
increases of both radiotracers analogues in the gall bladder and bone consistent 
of in vivo defluorination/uptake in bone marrow and metabolism of the 
radiotracers.  A greater bone uptake was seen in IGROV-1 tumour- bearing mice; 
this effect was lesser in MDA-MB-231 and PEO1 and PEO4 tumour-bearing mice.   
 
   
Figure 53.  (A-C)  Semiquantitative imaging variables (NUV60, AUC, FRT) 
extracted from the TAC.  Significant differences are indicated by asterisks 
(Mann- Whitney test).  Data are mean ± SEM.  
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Figure 54.  Comparison of tissue uptake of [18F]fluoro-inositol analogues in 
IGROV-1, MDA-MB-231, PEO1and PEO4 tumour xenografts.  (A, C) 
Biodistribution profile of [18F]fluoro-scyllo- inositol into IGROV-1 and MDA-MB-
231tumours respectively.  (B, D and E)  Biodistribution of [18F]fluoro-myo  
inositol into IGROV-1, MDA-MB-231, PEO1 and PEO4(bilateral implants)  
tumour-bearing mice as determined by ex vivo gamma counting.  Tissues were 
excised 60 min after radiotracer administration.  Tracer uptake was expressed as 
tumour to blood ratio; data are mean ±SEM (n=3-6 mice). 
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4.0 DISCUSSION 
 
We demonstrate that clinically acquired platinum-resistant ovarian cancer can be 
resensitised to platinum in vivo using an AKT inhibitor and that this effect is 
detectable by [18F]FLT-, [18F]FDG- and [18F]ICMT11-PET.  Ovarian cancer is the 
major cause of death from gynaecological malignancy, and there is an urgent need 
for new therapeutic targets.  The emergence of target-specific agents in cancer is 
expected to allow the definition of novel therapeutic strategies for tumours 
resistant to conventional cytotoxic agents [342].  Platinum therapy is the mainstay 
of ovarian cancer treatment, however, drug resistance remains a significant 
drawback, limiting its clinical utility [343].  The phosphatidylinositol 3-kinase 
(PI3K)/AKT pathway has been strongly implicated in the genesis of ovarian cancer 
and the potentiation of cytotoxicity by conventional chemotherapeutic agents 
following pathway inhibition has been previously demonstrated [344].  It has been 
postulated that inhibition of AKT alone or in combinations with standard 
chemotherapeutics will reduce the apoptotic threshold and preferentially kill cancer 
cells [345].  Biomarkers, and in particular, imaging biomarkers could play an 
important role in identifying and monitoring the early response to potential 
combination strategies for ovarian cancer. 
 
4.1 The clinically acquired platinum resistant cell line PEO4 was resensitised by API-
2 to platinum in vitro  
Aberrant activation of the AKT pathway occurs in almost 50% all the human 
malignancy [18, 346] and inhibition of AKT induces cell growth arrest and apoptosis 
[197].  Initially, we have shown that PEO4 cells expressed the active p-AKT at 
baseline although at a lesser level compared to OVCAR-3 (Figure 20).  It has been 
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previously shown that OVCAR-3 cells express hyperactivated AKT and this is 
inhibited by API-2 [197].  Given that API-2 induces apoptosis in tumour cell lines 
expressing high levels of endogenous activated AKT and was only modestly active 
in tumour cells expressing low levels of activated AKT, we demonstrated in the in 
vitro study that platinum-resistant ovarian cancer PEO4 cells can be resensitised to 
platinum using API-2.  BRCA2 proficient PEO4 cells that were insensitive to 
cisplatin, were resensitised to cisplatin by API-2 leading to a ~ 50% reduced cell 
growth compared to control.  Paired BRCA2 deficient PEO1 cells were sensitive to 
platinum.  A greater cell growth inhibition was also seen in the sensitive cell line 
with both cisplatin and combination treatment.  An increase in luminescence which 
indicates increasing caspase-3/7 activity and apoptosis was also seen with 
combination treatment in PEO4 cells but not with cisplatin treatment alone (Figure 
14).  API-2 treatment alone did not cause a significant growth inhibition in the 
resistant cell lines (Figure 15).  Washing the modulators (to simulate the in vivo 
situation) following pretreatment resulted in both cell growth inhibition and 
increased apoptosis with combination treatment in PEO4 cells.  Given that the 
schedules treatment used did not significantly had an impact on cell growth or 
caspase 3/7 activation, a greater level of caspase-3/7 activity was seen following 
1h pretreatment with API-2 in the PEO4 cells in the acute treatment (Figure 16D), 
thus this schedule treatment was chosen for our in vivo work.  
Although the mechanism underlying resensitisation was not elucidated, it was clear 
that the effect was not compound-specific.  The effect was not limited to API-2; 
both pathway-related (LY294002) and unrelated (decitabine) compounds also 
sensitised PEO4 cells.  The PI3K inhibitor, LY294002, also sensitised PEO4 cells to 
platinum.  This is consistent with previous studies showing that PI3K/AKT inhibition 
selectively induces apoptosis in ovarian cancer cell lines with constitutive AKT 
activity and augments cisplatin-induced apoptosis [319, 347].  Alternatively, 
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demethylation of DNA by decitabine reverses epigenetic silencing of a number of 
tumour suppressor genes leading to induction of differentiation or senescence, 
growth inhibition, and loss of clonogenicity [348].  Stronach et al. [296], have 
recently demonstrated resensitisation to platinum by AKT inhibition in vitro, in a 
broad spectrum of tumour types, including ovarian, lung and pancreatic cancer 
indicating generic utility of this approach.   
 
4.2 API-2 Inhibits constitutively active AKT and its immediate downstream target, 
p-PRAS40 in PEO4 cells  
After serum starvation overnight, PEO4 and PEO1 were treated with either API-2 or 
combination treatment at the indicated time points.  Level of p-AKT and the 
immediate downstream target of AKT, pPRAS40 and, decreased after treatment with 
API-2 and with combination treatment demonstrating target activity in paired cell 
lines.  This effect has been previously reported with API-2 which downregulates p-
AKT level in ovarian cancer cells that overexpress AKT [197, 349]. 
Treatment with cisplatin alone did not diminished the p-AKT signal as expected in 
the resistant cell line, but a reduction is seen with both API-2 and combination 
treatment which indicates reversal of platinum resistance.  This downregulation of 
both p-AKT and p-PRAS40 was also seen in the PEO4 cells, at both time points (1-
24h) to API-2 after removing the modulator by washing [Figures: 18 (B, D); 19 (F, 
H)].  Treatment with PI3K inhibitor LY294002 and combination with cisplatin was 
also effective at blocking both p-AKT and p-PRAS40 indicating this is a PI3K/AKT 
pathway effect, however this effect was reversed with washing.  Hence API-2 was 
more effective as a modulator in restoring platinum sensitivity in the PEO4 cells. 
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Cisplatin appears to induce p-AKT level in the sensitive cell line, which was quite 
unexpected, given that cisplatin alone induced high level of growth inhibition and 
apoptosis as measured by caspase 3/7 activity.  This effect has been previously 
reported in the sensitive cell line [350].  However this upregulation of p-AKT 
appears to be transient and goes down after 24h of treatment with cisplatin.    
Thus, we have demonstrated on our in vitro work, that pre-treatment with API-2 
followed by cisplatin inhibits both cell growth and induces apoptosis in the PEO4 
cells indicating resensitisation to cisplatin.  The basis of this sensitivity to cisplatin 
was further assessed, and was found to be a downregulation of p-AKT level in the 
PEO4 cells. 
 
4.3 The biological action of continuous administration of platinum and API-2 in 
modulating AKT activity as evaluated PET imaging in vivo 
We studied the value of two clinically useful imaging biomarkers, [18F]FLT-PET and 
[18F]FDG-PET and a novel apoptosis tracer [18F]ICMT11 as endpoints of biological 
activity in our resistant model of ovarian cancer. 
 
4.3.1 [18F]FDG-PET imaging  
The success of the tyrosine kinase inhibitor imatinib (Gleevec, STI571) in treating 
chronic myeloid leukemia, as well as other selected cancers has greatly increased 
optimism for the broader application of kinase inhibitor therapy in cancer [351].  
The beneficial effects were quickly apparent, because a large fraction of patients 
had complete or partial remissions [352]. 
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One particularly feature of these responses was the utility of PET scanning with the 
radiotracer [18F]FDG.  Prior to treatment, GIST tumours showed avid [18F]FDG uptake, 
which was substantially reduced after starting imatinib in patients, well in advance 
of tumour shrinkage based on CT scans [353].  Although the molecular basis for 
[18F]FDG update in GIST remains to be defined, these clinical findings serve as a 
dramatic illustration of the potential for molecular or ―functional‖ imaging.  
Molecular imaging approaches are evaluated in this thesis as potential methods for 
detecting early response to AKT inhibition alone and combined with chemotherapy 
combination approach in matched sensitive and resistant models of ovarian cancer. 
[18F]FDG is currently the most widely used radiotracer for imaging therapy response 
in oncology with PET [354].  It is metabolised to [18F]FDG-phosphate and provides 
information on the expression of glucose transporters and hexokinase activity 
[355].  However, [18F]FDG is not only trapped in tumour cells but also in 
macrophages, granulation tissues, and necrosis [356].  The PI3K/AKT pathway 
targets glucose uptake and metabolism [327], thus, [18F]FDG could be useful in 
functional imaging of the biological activity of inhibitors of the PI3K/AKT pathway 
[357-359].  
As expected, treatment of platinum-resistant PEO4 xenograft-bearing mice with 
cisplatin or API-2, given either singly or as multiple dosing did not lead to 
detectable changes in the [18F]FDG-PET imaging variables, NUV60 and AUC.  
However, API-2 induced significant changes in the immediate AKT downstream 
target pPRAS40 following continuous dosing, indicating that the pathway was 
inhibited.  In contrast, the combination of cisplatin and API-2 led to a reduction in 
[18F]FDG-PET variables consistent with resensitisation in this xenograft model in 
both treatment scheduling.  Compare to the single dose scheme, a more significant 
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reduction in [18F]FDG-PET variables were observed in the PEO4 xenograft model 
with continuous dosing. 
Thus, [18F]FDG-PET in this model reflects response rather than pathway activity. 
This assertion is supported by reduction in the [18F]FDG-PET imaging variables in 
the isogenic sensitive xenograft, PEO1, following treatment with cisplatin alone or 
API-2 following continuous dosing.  
 
Compared with the [18F]FDG-PET data, the ex vivo gamma counting data, was less 
efficient in discriminating between vehicle and treated tumours at 60 min.  A 
significant change was seen in radiotracer uptake between vehicle and combination 
treatment in the platinum-resistant PEO4 xenograft model.  No significant change 
was detected in the sensitive tumour with combination treatment; however a 
significant change was detected with cisplatin treatment.  This could be possibly 
attributed to tumour heterogeneity and also with the fact that only a small piece of 
the whole tumour is counted in the gamma-counter. 
 
4.3.2 [18F]FLT-PET imaging 
[18F]FLT-PET has been examined pre-clinically and in cancer patients as an imaging 
biomarker for cell proliferation since 1998 [360].  [18F]FLT undergoes 
monophosphorylation to [18F]FLT-phosphate catalysed by the cytosolic enzyme TK1, 
which, being cell cycle regulated [361-363], provides a surrogate measure of cells 
in S-phase of the cell cycle. 
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Like [18F]FDG-PET, [18F]FLT-PET selectively reported resensitisation of platinum 
resistant PEO4 tumours to cisplatin by API-2.  Again no significant changes in 
imaging variables were seen with cisplatin or API-2 alone, whereas the isogenic 
sensitive tumour, PEO1 xenografts showed significant reductions in the imaging 
variables.  Similarly the ex vivo gamma counting data, was less efficient in 
discriminating between vehicle and treated tumours at 60 min compared to the 
[18F]FLT-PET data. 
Here, we have shown that both [18F]FDG- and [18F]FLT-PET was sensitive for imaging 
changes in both glucose metabolism and proliferation associated with early 
response in this model of platinum-resistant of ovarian cancer.   
 
4.3.3 [18F]FDG- and [18F]FLT-PET biomarkers of response 
The reduction of [18F]FDG uptake was consistent with decrease in both GLUT-1 
expression/GLUT-1 membrane localisation and hexokinase activity.  A significantly 
higher expression of GLUT-1 has been reported for poorly differentiated epithelial 
ovarian compared to the more differentiated subtypes and borderline tumours [364] 
which may explain some of the biochemical changes observed.  Baseline hexokinase 
activity was significantly higher in PEO4 tumours compared to PEO1 tumours (Figure 
22).  This, however, did not translate to significantly higher [18F]FDG-PET uptake in 
the resistant line, ruling out the potential value of baseline [18F]FDG-PET as a 
predictor of resistance. 
 
Given that inhibition of proliferation exemplified by Ki67 immunostaining (Figure 
29) was more sensitive than induction of apoptosis or indeed tumour size 
reduction, studies in xenograft models and in human tumours have shown strong 
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associations between [18F]FLT-PET and LIki67 [234, 312, 365-366].  In keeping with 
the changes in imaging variables, LIki67 decreased with cisplatin and combination 
treatment in PEO1 tumours, but only in the combination treatment arm in PEO4 
tumours.  The reduction in [18F]FLT-PET variables was likely due to reductions in 
TK1 expression seen in the isogenic tumours.  TK1 expression was significantly 
reduced by both cisplatin and combination treatment in PEO1 tumours and by the 
combination treatment only in PEO4 tumours, in keeping with resensitisation of the 
platinum resistant phenotype.   Other than its role in predicting [18F]FLT-PET uptake 
in vivo [362, 367], TK1 may serve as an independent tissue biomarker of platinum 
resensitisation.  The retention of FLT within the cell, therefore, provides a measure 
of cellular TK1 activity, an enzyme which is closely tied to cellular proliferation.  
Thus, changes in [18F]FLT uptake can be correlated directly with cell proliferation.  
Hence, both [18F]FDG-PET and [18F]FLT-PET discriminated between the sensitive and 
resistant isogenic tumours, with reductions in radiotracer uptake following cisplatin 
treatment only in the former.  
In some tumours with high proliferative activity, as in human breast cancer, 
[18F]FDG uptake was compared in vivo with the proliferative activity assessed by 
Ki67 and GLUT-1 expression by IHC and a positive correlation was found between 
[368].  In ovarian cancer, it has been reported that MIB-1 immunostaining was 
significantly higher in malignant neoplasms than in borderline or benign lesions 
[369].  In a previous study [370], it was shown that cell proliferation assessed by the 
Ki67 index in the early stages of ovarian carcinomas is a prognostic marker 
outweighing other established parameters in the prediction of the disease-specific 
survival. 
Changes in LIKi67 did not, however, match the modest tumour growth inhibition seen 
in the PEO4 model.  LIKi67 preceded the changes in tumour size.  The lack of a direct 
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correlation between changes in LIKi67 and corresponding changes in tumour size is 
not dissimilar from previous observations in mice [312, 314, 324, 366] and humans 
[371], and supports the notion that changes in proliferation are more sensitive and 
precede tumour size changes. 
 
4.3.4 Correlating cellular proliferation marker Ki67 with [18F]FDG and [18F]FLT 
uptake 
Ki67 as a measure of cell proliferation strongly correlated with the imaging 
endpoints.  Following daily dosing (day 4)) there was a strong correlation between 
Ki67 and [18F]FDG uptake (r = 0.8266; p = 0.0017) in the PEO4 model.  A moderate 
correlation was seen when a similar comparison was made after a single dose of 
drug in the PEO4 model (r =0.7712; p =0.0012; day 2). 
Previous studies in xenograft models [312, 314, 324, 366] and in human tumours 
[372] have shown strong correlations between [18F]FLT uptake and LIKi67.   There was 
a moderate correlation between Ki67 and [18F]FLT in PEO4 tumour (compared with 
Ki67 and [18F]FDG), however there were a few outliers in this dataset.  This could be 
partly due to tumour heterogeneity.  Thus, both [18F]FLT and [18F]FDG predicted 
proliferative changes occurring with drug treatment. 
 
With respect to molecular biomarkers, the immediate downstream target of AKT, 
pPRAS40, decreased after treatment with API-2, alone and in combination with 
cisplatin, demonstrating target activity.  Other cognate biochemical pathway 
markers such as p-AKT, p-P70S6K (Thr389), and p-S6 ribosomal protein 
(Ser240/244) did not change consistently with cisplatin, API-2 or combination 
treatment (Figure 33), suggesting that at the drug concentration and schedule used, 
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AKT activity did not necessarily translate to activity on all downstream targets [373]. 
Consistent with previous studies, API-2 treatment resulted in a dose-dependent 
increase in p-AKT at S473, suggesting an AKT-specific feedback mechanism.  This 
increase in AKT phosphorylation at S473 is consistent with the feedback mechanism 
observed previously with GSK690693 and other AKT kinase inhibitors [1, 374].  
However, as shown by the reduction in pPRAS40, API-2 to some extent inhibited 
AKT kinase activity in cells, regardless of any feedback hyperphosphorylation of 
AKT.  Although the AKT substrates crucial for tumour development have not been 
clearly defined under all circumstances [375] the ‗critical substrates‘ can vary with 
cell type [376].  Furthermore, given the complex circuitry of the AKT pathway and 
cross-talk between other major cellular circuits, other targets might be more 
relevant in this model of ovarian cancer as pharmacodynamic markers of AKT 
inhibition.  
Hyperglycemia has often been reported as an on-target side effect of agents 
targeting IGF-IR, PI3K, AKT, and mTOR signalling [377].  At a dose of 1mg/kg/day 
given daily over 3 days, API-2 had no effects on blood glucose levels or body 
weight, and no obvious general toxicity was seen. 
4.3.5 Effect of inhibiting DNA-PK activity on glucose metabolism 
The development of AKT inhibitors for use in a clinical setting has been limited due 
to observed toxities relating to glucose metabolism.  Targeting DNA-PKcs, which 
phosphorylates AKT at S473, presents a novel strategy of reversing of platinum 
resistance and circumventing insulin-related toxicities [296]. 
In preliminary studies, using [18F]FDG PET, an imaging reponse was not seen 
following treatment with a DNAPK inhibitor, NU7741,combined with platinum in the 
PEO4 xenografts.  This is probably due to the fact that DNA-PKcs inhibition does 
not appear to affect insulin-activated AKT, as previously shown [296], which in turn 
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does not interfere with glucose metabolism.  However further studies are 
warranted, since a 3-days treatment schedule was used compared to a 5-days used 
by Zhao et al. [331].  Future work could examine effect of the DNA-PK inhibitor in 
combination with cisplatin on proliferative phenotype as measured using [18F]FLT-
PET. 
 
4.4 [18F]ICMT11 as an imaging biomarker of apoptosis 
 
Given the increase in apoptosis found in vitro with cisplatin and combination 
treatment, the role of apoptosis imaging was further assessed in the platinum-
resistant PEO4 ovarian cancer model using [18F]ICMT11 as a PET tracer. 
The IC50-values for caspase inhibition of the library of isatin-5 sulfonamides 
designed in our Lab, revealed that ICMT11 has subnanomolar affinity for activated 
capsase-3 with tremendous potential for radiofluorination [259].  It was reported 
earlier that isatin sulfonamides are highly potent and selective nonpeptide based 
inhibitors of the effector caspases-3 and -7 [253]. 
 
4.4.1 In Vitro  detection of apoptotic PEO1 and PEO4 cells with [18F]ICMT11 
We have demonstrated from the in vitro binding and PET imaging data that 
[18F]ICMT11 was able to detect tumour apoptosis in the PEO4 xenograft model after 
combination treatment with API-2 and cisplatin. 
The binding potencies of [18F]ICMT11 was evaluated in vitro and was found to 
exhibit good activity against caspases-3 and -7.  The cellular uptake of [18F]ICMT11 
in the PEO1 and PEO4 cell lines showed that radiotracer uptake was selectively 
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increased with combination treatment relative to cisplatin alone by up to 2- or 3-
fold respectively.  Increased cellular uptake of [18F]ICMT11 was also associated 
biochemically with higher cellular activity of caspase-3/7 activity in the same in 
vitro model (Figure 41).  The high binding affinity of [18F]ICMT11 for caspase3/ 7 
was further confirmed, when the binding potency of the low affinity caspase-3/7 
inhibitor, [125I]ICMT1, was compared in the same in vitro model of drug-induced 
apoptosis (Figure 38).  Furthermore some binding of [125I]ICMT1 was also observed 
in the heat-induced model of necrosis in the paired cell lines.  Caspase-3/7 activity 
as measured by Caspase-Glo assay was found to be several fold lower in the 
heat/cold-induced model of necrosis compared to our drug-induced apoptosis 
model.  
 
The extent of the specificity of binding observed with [18F]ICMT11 in this study for 
caspase-3, was further assessed is the same in vitro model, using the irreversible 
caspase 3 inhibitor, z-VAD-FMK.  z-VAD-FMK was able to reduce binding of 
[18F]ICMT11 to cleaved caspase-3 and this was associated with the luminescence 
quenching observed upon z-VAD-FMK binding to cleaved caspase-3 following 
combination treatment. 
Thus, we have demonstrated high specificity binding of [18F]ICMT11 to cleaved 
caspase-3, compared to [125I]ICMT1 in our in vitro model of ovarian cancer. 
 
4.4.2 [18F]ICMT11 PET imaging in the in vivo PEO4 xenograft model of ovarian 
cancer 
The in vivo potency of [18F]ICMT11 as an apoptosis PET imaging tracer was further 
evaluated using an experimental model of tumour apoptosis. 
221 
 
Although the levels of apoptosis appeared to be low in our in vivo model of drug-
induced apoptosis, as assessed by TUNEL, [18F]ICMT11 PET images showed  higher 
uptake of the radiotracer in PEO4 xenogratfs following combination treatment 
compared to vehicle treated (Figure 44A, B).   PET variables, AUC and NUV60, derived 
from the time activity curves were significant with combination treatment, however 
the slight increased seen in the FRT values with combination treatment was not 
significant.  
Gamma counting of tumour radioactivity after imaging, showed no significant 
increased tumour uptake of [18F]ICMT11 between combination and vehicle-treated 
PEO4 xenografts.  Direct radioactivity determination (γ-counting) of only a part of 
the tissue relative to sampling of the whole tumor in the case of imaging could also 
have led to this difference.  However uptake of [18F]ICMT11 was high in both liver 
and small intestine, as has previously shown (data not shown) [313]. 
Histological analysis of formalin-fixed tumour tissues showed an increased staining 
detectable by TUNEL or cleaved caspase-3, in the PEO4 tumours treated with both 
cisplatin and API-2 indicating resensitisation to platinum (day 4; Figure 45).  
However, no increased in active caspase-3 and fragmented DNA staining was seen 
with either cisplatin or API-2 treatment alone in the PEO4 tumour tissues (data not 
shown).  
The level of apoptosis was, however, distinctly low, indicating that apoptosis was 
not a major mechanism of tumour growth inhibition.  An important consideration 
for pharmacodynamic assessment of pathway-specific drugs is that the 
concentration of drug required to inhibit pathway activity may be insufficient to 
inhibit downstream signalling [373].  Previously in our Lab., it has been 
demonstrated that uptake of [18F]ICMT11 in the murine lymphoma xenografts in 
vivo, was 2-fold higher in drug-treatment tumours compared to vehicle treatment, 
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24h postreatment [313].  Factors such as tumour heterogeneity, GSH level, the drug 
concentration required to induced tumour apoptosis, together with the tumour 
models used, might all influence level of [18F]ICMT11 uptake in tumours.  We have 
also shown that when GSH level were depleted with DEM in PEO1 cells, prior to 
induce apoptosis, an increase in [18F]ICMT11 signal was also detected.  Thus, 
[18F]ICMT11 as a novel apoptosis tracer, looks promising in the evaluation of early 
tumour response in platinum-resistant ovarian cancer, however further studies are 
warranted. 
 
4.5 Preliminary study in measuring total GSH levels in the paired cell lines following 
pre-treatment with cisplatin 
Multiple mechanisms have been proposed in cisplatin resistance, including 
increased levels of GSH [378].  The role of GSH system in mediating cisplatin 
resistance has been well documented in literature [57, 379-381].  GSH limits the 
amount of drug available for binding to DNA [382].  An 8~fold enhancement in the 
amount of Pt-DNA adducts formed has been previously demonstrated, when 
cellular thiols were blocked with DEM [383].  In our study, both PEO1 and PEO4 cells 
were found to have high level of GSH at baseline.  The level of GSH was reduced 
following cisplatin treatment in the paired cell lines.  This is possibly due to the role 
of GSH, in mediating efflux of cisplatin, as has been previously shown [59].  
Following modulation with DEM, the level of GSH was further reduced, as expected 
in the cisplatin-treated paired cell lines.  This effect was more significant in the 
platinum-resistant cell lines.  Initially we wanted to study GSH modulation in the 
paired cell lines, because some of the platinum resistance genes identified in the 
paired cell lines, code for ATP binding cassette (ABC) transporters that function as 
efflux pumps for eliminating antitumour agents [58-59] and many studies have 
demonstrated direct interactions between GSH and ABC transporters, whereby some 
223 
 
of these transporters require GSH to mediate efflux of cisplatin [59].  Our Lab was in 
the process of radiolabelling fluoro-carboplatin with [18F] to image drug efflux and 
uptake but this was proving difficult at that time to make, thus for the rest of the 
thesis, we have focused mainly in modulating the PI3K/AKT pathway and using 
imaging biomarkers that are readily available to study these. 
 
4.6 preliminary study to assess integrin expression in ovarian cancer by 
[18F]fluciclatide PET imaging and IHC 
The importance of vascular studies in neoplasias has been intensively studied and 
angiogenesis are crucial for the understanding of tumour biology and for designing 
potential cancer preventive and therapeutic measures.  
 
One target structure is the αvb3 integrin receptor, which is highly expressed on 
activated endothelial cells during angiogenesis.  Various ligands based on the 
tripeptide RGD, which binds with high affinity to the αvb3 integrin receptor, have 
been developed for PET [269].  VEGF is one of the genes found to be upregulated in 
the platinum resistant phenotype and VEGF is a potent angiogenic factor.  We have 
examined the angiogenic phenotype characteristics of these isogenic paired cells 
using PET imaging of [18F]fluciclatide.  There was good tracer localisation in both 
PEO1 and PEO4 xenografts at baseline.  We have also observed similar radiotracer 
uptake kinetics in both platinum sensitive –and platinum-resistant xenografts, 
however all 3 parameters appeared to be higher, albeit not significant, in the 
resistant phenotype.  Given the role of AKT in tumour angiogenesis, it is possible 
that activation of AKT might confer a more aggressive phenotype in the platinum 
resistant tumour. 
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Tracer accumulation of [18F]fluciclatide appeared to correlate well with our IHC 
studies.  We have shown in our model system that representative pictures of 
tumours sections double-immunostained for both CD31 (staining of blood vessels) 
and Ki67 (staining of proliferating endothelial cells) were highly vascularised in all 
treatment groups.  Tumour tissue sections showed small vessels and vessels of 
variable sizes indicating defective vascular morphogenesis which is typical of 
tumours.  Some areas of microvascular proliferation were also observed in the 
tumour sections which might be interpreted as angiogenesis.  This appeared as 
yellow (merge) due to colocalisation of both Ki67 and CD31 staining.  
Treatment with either single or combination treatment, showed no significant 
reduction in the overall amount of vasculature in the paired tumours.  These results 
possibly indicate that API-2 is modulating the PI3K/AKT pathway by acting only on 
tumour cells and not necessarily on endothelial cells survival and proliferation. 
 
One strategy for cancer treatment is to target tumour vascularisation in order to 
inhibit angiogenesis.  Tumours employ diverse mechanisms for vessel formation, 
including sprouting from existing blood vessels [384], de novo recruitment of 
endothelial precursors and vessels remodelling [385] and these differ in different 
tumour types.  Each of these processes is regulated by diverse signalling pathways 
and the components of these signalling pathways therefore constitute potential 
targets for antiangiogenic therapy [386].   
Further studies are needed to elucidate the role of tumour angiogenesis in this 
tumour model.  Molecular imaging of angiogenesis using PET is an exciting field of 
research and may soon contribute significantly to individually targeted therapies in 
ovarian cancer. 
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4.7 Preliminary studies to assess distribution of radiolabelled Inositols analogues in 
tumour cell lines 
 
4.7.1 In vitro  tracer uptake 
There are several hypotheses that might explain inositol uptake and trapping into 
cells.  One of the hypotheses is that inositols are phosphorylated and this 
phosphorylation event is dominated by PI3K activity in cancer cells.  Thus, if the 
activity of the pathway goes down, one would expect that the bulk of inositol 
trapping would go down by inference.  To test this hypothesis, we have used PI3K 
inhibitors in our in vitro system.  Both LY294002 and wortmannin have been 
previously shown to inhibit cell growth in IGROV-1 and SKOV3 human cancer cell 
lines, that have a constitutive PI3K [276].  We have shown that both LY294002 and 
wortmannin were able to inhibit to some extent [3H]myo-inositol incorporation into 
cells.  In IGROV-1 cells, an inhibitory effect on [3H]myo-inositol uptake was more 
apparent at longer exposure time to the PI3K inhibitors, however this inhibitory 
effect was seen in the SKOV3 cells at the earlier 1h treatment time point.  This 
effect was attenuated following exposure to PI3K inhibitors at longer time points in 
the SKOV3 cells.  This is possibly due to the fact that SKOV3 cells has a much 
higher endogenous level of p-AKT compared to IGROV-1 (Figure 20) and were able 
to the reverse the inhibitory effects of the PI3K inhibitors rapidly.  
Although, [3H] myo-inositol does get incorporated to some extent into the PI3K 
pathway, uptake might vary within tumour cell lines, depending on how active if the 
PI3K/AKT pathway within that tumour cell line.  
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4.7.2 In Vivo  tracer uptake 
Given the role of the PI3K pathway in platinum resistance, and further, the report 
that tumours with higher deregulation of the pathway are more sensitive to AKT 
inhibitors, we evaluated a new set of inositol imaging agents to see if they could 
discriminate between sensitive and resistant tumours at baselines.  The tracers used 
were [18F]fluoro-scyllo-inositol and [18F]fluoro-myo-inositol.  Radiolabelled inositols 
are an interesting target due to their occurrence and importance within the cell 
cycle and messaging pathways, thus playing a crucial role in the development of 
certain cancers [279, 387].  
Vasdev et al [291] were first to radiolabelled [18F]fluoro-scyllo-inositol as a novel 
PET radiotracer; although this compound revealed low brain penetration, it showed 
promise in rodent tumour models for breast cancer imaging.  Our group has 
radiolabelled [18F]fluoro-myo-inositol in an analogous way and compared it with 
[18F]fluoro-scyllo-inositol [309]. 
We have seen similar uptake of tracer in vivo both in our ovarian and breast cancer 
models and similar biodistribution profiles in tissues when [18F]fluoro-myo-inositol 
was compared to [18F]fluoro-scyllo-inositol.  This might suggests that both 
radiotracers enter the cells in an analogous fashion, and that they undergo similar 
biological processes; however, at present we do not know the mechanism of tracer 
retention in tumours.  
Comparison of the PET kinetics of [18F]fluoro-scyllo-inositol in IGROV-1 and MDA-
MB-231 xenografts, showed better retention of [18F]fluoro-scyllo-inositol in the 
MDA-MB-231 xenografts, however this increased was not significant (Mann-
Whitney test).  Scyllo-Inositol has been previously detected in human breast tumour 
extracts and may also be a new marker for breast cancer [338].  A significant 
increased of [18F]fluoro-myo-inositol uptake was seen in MDA-MB-231 tumours  
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compared to IGROV-1 tumours.  Incorporation of [18F]fluoro-myo-inositol was 
highest in the isogenic paired tumour xenogratfs (~ 2 fold increased compared to 
IGROV-1 xenografts), however, [18F]fluoro-myo-inositol did not discriminate 
between platinum-sensitive and platinum-resistant ovarian tumours, as the uptake 
profile was similar in both tumours.  Overall, [18F]fluoro-myo-inositol was better 
retained in tumour xenogratfs compared to [18F]fluoro-scyllo-inositol, one possible  
reason could be because myo-inositol is the most abundant inositol in cells.  
With respect to normal tissues, there was high uptake of tracers activity in bone and 
elimination in gallbladder implicating defluorination of the radiotracers or specific 
uptake into the bone marrow.  The highest uptake of both radiotracers was seen in 
urine, in keeping with both the PET (high activity in the bladder) and the 
biodistribution data.  These were consistent with the predominance of renal 
elimination of both radiotracers.  Given also that [18F]fluoro-myo-inositol was 
higher in kidneys, bone and urine, this limit the utility of this radiotracer in tumours 
located in or adjacent to these tissues. 
New fluorine-substituted analogues of myo-inositol (fluorinated cyclitols) are being 
developed as antiproliferative therapeutics of the PtdIns pathway to target 
cancer[277] or as imaging probe [291].  So far these fluorinated cyclitols have not 
been very successful as an antiproliferative agents as the cells were able to 
overcome the effects of these fraudulent cyclitols by producing myo-inositol from 
D-glucose [277].  A further optimisation of the biological model may also be 
warranted. These studies were done in non-fasted mice, which could have 
confounded the results.  Future studies could consider using models of fasted mice 
to rule out the influence of de novo synthesis of inositols from glucose. 
Key to the success of any cyclitol being useful in intact cellular systems is that it 
must; 1) be lipophilic enough to cross cellular membranes and; 2) be a reasonably 
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good substrate for the first enzyme of the PtdIns cycle.  Several deoxyfluoro 
cylclitols have been synthesised where F replaces OH or H that would serve as 
substrates of the PtdIns.  These could be potential imaging probes of both transport 
and in some cases incorporation into the PtdIns pathway. 
There is also a possibility to improve the synthesis of [18F]fluoro-myo-inositol, by 
changing the position of the fluorine atom within the myo-inositol ring system,once 
the synthesis has been improved, we will be repeating these in vivo experiments. 
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5. CONCLUSION 
 
A bilateral xenograft model representing both platinum sensitivity and resistance 
has been developed and used to evaluate the role of imaging in predicting 
sensitivity not just to platinum but also to combine use of platinum and 
modulators.  Using this led to the following findings. 
 From our in vitro model, 1h pre-treatment with API-2 followed by    
cisplatin was found to be the optimal schedule treatment time point, in 
resensitising PEO4 cells to cisplatin as assessed both by cell-growth 
inhibition and apoptosis assays.  
 API-2 modulates the PI3K/AKT cascade in vivo in ovarian cancer.  API-2 
blocked the AKT phosphorylation measured as inhibition of downstream 
targets of the PI3K/AKT cascade, such as pPRAS40 and the proliferation 
marker Ki67. The combination of API-2 and platinum led to long term 
therapeutic benefit in mice that could be detected early by imaging.  Both 
[18F]FDG-and [18F]FLT-PET correlated well with cell proliferation (LIki67). 
However, [18F]FLT-PET was not found to be of superior specificity compared 
with [18F]FDG-PET for detecting proliferation in this tumour model. 
  [18F]FDG- and [18]FLT-PET are useful imaging biomarkers for detecting 
platinum resensitisation in vivo. 
 From screening a small library of isatin compounds, We have identified and 
radiolabelled a novel isatin 5-sulfonamide that has subnanomolar affinity 
for caspase-3 and has potential utility for imaging caspase-dependent cell 
death. 
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 In the resistant line, resensitisation could also be detected as an increase in 
apoptosis as measured by cleaved caspase activity in vitro and 
[18F]ICMT11-PET in vivo. 
 We have demonstrated in our in vivo xenogratfs model of ovarian cancer, 
accumulation and retention of [18F]fluciclatide at baseline, which might 
suggest that these tumours are of high angiogenic potential.  Treatment 
did not appear to have an effect of vessels density as seen both with single 
and combination treatment in the PEO1 and PEO4 tumour sections, as 
assessed by IHC. 
 Utility of other imaging biomarkers such as labelled inositols as predictors 
of platinum sensitivity remains to be fully elucidated. 
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A1.  Resensitisation of PEO1 and PEO4 ovarian cancer cells to platinum in vitro.  (A-B) 
Cells were pretreated with modulator decitabine (1μM) at indicated time points prior 
to adding cisplatin; control, equivalent amount of DMSO in media.  Cells were then 
exposed continuously to the modulator and cisplatin for 48h and then evaluated for 
growth inhibition (SRB assay) or apoptosis (caspase glo assay).  (C-D) To assess acute 
effects of the modulator, cells were pretreated with the modulator decitabine as above 
for indicated time points, after which modulator was removed by washing x2 with PBS.  
The cells were then incubated with cisplatin alone for 48h and assessed for growth 
inhibition and apoptosis.  Data are mean ± SE of independent experiments. 
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A3.  The nonlinear regression analysis of the inhibition profiles for Caspase 3 
with ICMT1-ICMT14 treatment at different compound concentrations and 
times point.  Fluorescence (arbitrary units) was measured using the Victor 3 
(Perkin Elmer) multi-plate reader. 
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A4.  In vivo effect of API-2 and cisplatin treatment on cell death.  Cisplatin (CIS; 
3mg/kg; i.p.,) and API-2 (1mg/kg/day;i.p.,) were injected in combination as a single 
dose and tumours were excised 48h later (day 2) and sections stained for cleaved-
caspase-3 (red staining) and DNA fragmentation (TUNEL assay; green staining).  
PEO1 PEO4 PEO1 PEO4 
CIS + API-2 (day 2) 
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